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CHAPTER I 
INTRODUCTION 
Septic shock, as a consequence of an invasive, nosocomial, Gram-negative 
bacterial infection often signals the end of a hospitalized patient's life. The entire 
spectrum of pathophysiological events that occur in the evolving septic state are 
now known to be orchestrated by a sequential, interacting cascade of endogenous 
mediators from both the endocrine and immune systems. The endogenous 
metabolic dyshomeostasis of sepsis initiated early in the host response to 
infection has long been related to the production of stress hormones such as 
catecholamines, insulin, glucagon and cortisol. In addition, immunological 
mediators such as tumor necrosis factor, (TN Fa), interleukin 1, (IL-1) and 
interleukin 6, (IL-6) have also been recently implicated to incite the sequence of 
pathophysiological steps characteristic of a fatal prognosis. Individually, the 
endocrine hormones and cytokines are able to disrupt cellular metabolism in the 
same tissue; however, the interaction between hormonal factors and the 
subsequent effects on the regulation of cytokine production have not been well 
established. 
The performance of many organs such as the lung, spleen and liver are 
severely impaired during septic shock by the production of cytokines from resident 
populations of macrophages. The liver is considered to be a biologically strategic 
2 
organ in the septic cascade. It is necessary metabolically for the maintenance of 
blood and tissue euglycemia by its unique ability to convert gluconeogenic 
precursors to glucose. As the first organ to "see" and to process endotoxin 
originating from the bowel, the liver may also be a front-line, primary producer of 
cytokines from its resident population of macrophages, the Kupffer cells. 
Endotoxin activation of second messenger pathways regulates the 
production of TNF and IL-6 by macrophages. The parallel increase in sepsis-
induced hormones may also stimulate two or more second messenger pathways 
that converge with the endotoxin-mediated signal to either up or down regulate 
the production of a gene product. One may postulate that the merging of the 
endocrine and immune signals may propagate the vicious cycles that can 
ultimately trigger lethal shock and tissue injury through a process of signal 
convergence conflict. 
The main focus of this thesis is to examine the interactive effects of insulin 
and glucocorticoids on TNF and IL-6 production during endotoxicosis. The specific 
aims include: 
1) to assess the effects and interactions of insulin and glucocorticoids on 
morbidity and mortality during sepsis. 
2) to evaluate the effects and interactions of insulin and glucocorticoids on 
metabolic parameters during sepsis. 
3) to examine specifically, the interactions between glucocorticoid and insulin 
and their effects on the production of TNF and IL-6. 
4) to examine possible mechanisms of glucocorticoid and insulin regulation of 
TNF and IL-6 production. 
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These aims will be accomplished by experiments at three biological levels 
of investigation. The effects of insulin and glucocorticoid during sepsis will initially 
be examined in an in vivo, endotoxic rat model in order that the response of the 
whole organism can be analyzed. The second model, the ex vivo isolated 
perfused rat liver will examine the contribution of the septic liver to the circulating 
levels of TNF and IL-6. The third level of examination investigates the endocrine 
regulation by the specific cells that produce TNF and IL-6 in vitro. Two isolated 
macrophage cell lines and two primary macrophage cultures will be tested as 
well as possible second messenger sites of regulation of glucocorticoid and 
insulin modulation of cytokine production. 
This dissertation aspires to reinforce the physiological importance of 
hormonal alterations during septic shock to the survival of the organism. Also, this 
research will contribute to the growing body of evidence that significant 
communication exists between the endocrine and the immune systems during 
situations of physiological stress such as septic shock. The notion of "classical" 
hormones, such as insulin, as only a metabolic regulator is challenged as insulin 
can be shown to propagate immunological activity during endotoxicosis. 
A. Introduction 
CHAPTER II 
LITERATURE REVIEW 
The pathophysiological mechanisms of septic shock are multifarious, 
involving the direct and indirect effects of microbial agents and the activation of 
host endogenous mediators. The inappropriate activation and regulation of the 
cells of the endocrine system, especially the sympathetic-adrenal axis, the 
pancreas, and the cells of the immune system, which acts collectively as a 
"pseudoendocrine" system, are responsible for the release of mediators into the 
circulation in high concentrations. This excess of circulating endogenous factors 
act as lethal autotoxins which work collectively against the host. Corticosteroids 
and insulin are two endocrine hormones produced early after endotoxin 
stimulation. The cytokines, TNF and IL-6 are also produced in the early phases 
of the septic cascade. 
This chapter is designed, to furnish the reader initially, with a basic 
understanding of the biology of endotoxin, TNFa and IL-6 and their roles during 
sepsis. Secondly, the literature pertaining to corticosteroids and insulin with 
respect to septic shock will be reviewed. The currently amassed literature 
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concerning these topics, especially TNFa and IL-6, is immense and grows 
exponentially on a monthly basis. Therefore, this review will be limited to those 
references which further the background and the rationale for the research 
described in this dissertation. This review cites literature up to and including 
references from February 1994. 
B. Endotoxin 
1. Structure 
Lipopolysaccharide (LPS) is one of the amphiphilic macromolecules that 
constitutes the outer wall of Gram negative bacteria and is necessary for bacterial 
viability (272). Endotoxin is a generic term which includes LPS from all species 
of Gram-negative bacteria. LPS consists of four covalently interlinked segments 
as illustrated in fig. 1. 
The 0-specific chain is a carbohydrate polymer consisting of up to 50 
oligosaccharide repeating units. LPS of wild type Salmonella or Escherichia coli 
exhibit a bimodal distribution of 0-specific chains. The bulk of the 0-specific 
chains are of high molecular weight and the remaining chains are of low 
molecular weight in 1-8 repeating units. The chemical composition of the sugar 
units and the degree of the polymerization gives heterogeneity to the molecule. 
The oligosaccharide units function confer the serological 0-specificity of the LPS 
and the bacteria containing them (as reviewed in 266, 267). 
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Fig. 1. Structure of Salmonella sp. lipopolysacharide. 
(adapted from C.R. Raetz, 1991 ) 
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The core region is divided into the outer core, which binds to the 0-specific 
chain and the inner core which binds to the Lipid A moiety. The structurally 
variability of the core region is limited. Salmonella sp. has only one core structure 
for all serotypes and E. coli has 5 core structures for over 100 serotypes. The 
outer core, is composed of common hexoses that form a branched 
pentasaccharide region. This region determines the outer core specificities and 
acts as a receptor site for bacteriophages. The inner core is the most conserved 
region of LPS and is characterized by uncommon heptose sugars arranged mainly 
in the L-glycero-0-manno configuration. Also present in the inner core is at least 
one a-linked pyranosidic or furanosidic, KOO, (2-keto-3-deoxyoctonic acid) region 
that occupies the lipid A proximal position. The inner core acts as a possible 
modulator of Lipid A biological activity and is essential for bacterial survival. 
bacteria with a defective inner core are not viable. KOO and LPS in general are 
essential for microbial growth and multiplication (as reviewed in 266, 267). 
The Lipid A region is composed of gluco-configurated and pyranosidic 0-
hexosamine residues present as P(1-6)-linked disaccharide . This structure has 
not been identified in other natural occurring compounds and is unique to Lipid 
A. The disaccharide is linked to both a glycosidic and a nonglycosidic phosphoryl 
group and in ester and amide linkages and to medium to long chain (R)-3-hydroxy 
fatty acids (C10 to C28), some of which are acylated at their 3-hydroxyl groups. 
The lipid A molecule usually carries four mole equivalents of fatty acids. Lipid A 
represents the least conserved region of LPS among bacterial species. The 
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resulting R-3-acyloxyacyl residues are found in distinct evolutionary groups of 
Gram negative bacteria and is characteristic of Lipid A. Lipid A is essential for 
bacterial viability and virulence and for the remarkable spectrum of endotoxic 
activities. This region is responsible for initiating the classical complement 
cascade as well as binding to receptors on monocytes/macrophages and other 
host cells (as reviewed in 266, 267, 323). 
2. LPS Stimulation of TNFa and IL-6 Production 
As the main surface antigen (0-antigen) of Gram-negative bacteria, LPS 
is a potent stimulator of immune cells : neutrophils (86), lymphocytes (352), 
monocytes and macrophages (3, 120). LPS is postulated to interact non-
cytotoxically with these cells and the consequences are the synthesis and 
secretion of a variety of cytokines and proinflammatory mediators (311). The 
macrophage appears to play a pivotal role in endotoxin induced lethality 
(96, 145,323,347). 
The cytokines secreted by macrophages in response to LPS include TNFa, 
IL-1 and IL-6 and are well documented; however, the receptor and signalling 
mechanisms by which LPS triggers cytokine production by macrophages remain 
unresolved (2, 120,363). Within the past 5 years evidence has accumulated which 
indicates that several pathways are employed by LPS for the activation of TNFa 
production by macrophages (145). 
As demonstrated with chemically synthesized constructs, Lipid A accounts 
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for the effects of endotoxin in animals and cultured cells (266). Several studies 
(96, 158, 319, 327, 352) suggest the existence of receptors for Lipid A on animal 
cells. The finding of acylated LDL or scavenger receptors which bind LPS on 
macrophages by Hampton et al., 1991 (146) suggested a possible site for 
macrophage activation. This binding facilitated the ability of cells to take up and 
dephosphorylate Lipid IVA at the 1 position thereby, greatly reducing the potency 
of endotoxin. However, Freeman et al., 1990, (119) found that although acylated 
LDL blocked the binding of LPS completely, it did not block the toxic effects of 
endotoxin and, therefore, may not be directly involved with the induction of 
cytokine synthesis. 
CD18, a heterodimeric complex found on the surface of macrophages, has 
been identified to bind particulate LPS on the surface of cells (as reviewed in 
352). The LPS-CD18 interaction results in the phagocytosis of particulate LPS. 
There is no strong evidence that CD18 participates in the LPS activation of TN Fa 
production by macrophages and monocytes. Patients with CD18 deficiency 
demonstrate a normal pattern ofTNFa production and a normal priming response 
to LPS. Also, antibodies directed against CD18 do not prevent monocyte 
synthesis of TNFa (352). 
Lipopolysaccharide binding protein, LBP, is a 60 kDa glycoprotein often 
referred to as an acute phase protein because it is synthesized by hepatocytes 
(127). LBP is found in normal serum and increases in response to endotoxin and 
acute phase protein synthesis. LBP binds specifically to the Lipid A moiety of 
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LPS. LBP functions to opsonize the LPS particles and activate neutrophils and 
macrophages(127) LBP-LPS particles have been shown to bind avidly to 
macrophages. LPS-LBP has been shown to be 1000 fold more active in the 
induction of the production of TNFa and IL-1 than LPS alone (352). This complex 
also raises the levels of mRNA transcribed and the TNFa protein released. 
The receptor for LBP-LPS has been demonstrated to be CD14 (352). CD14 
is a 55 kDa glycoprotein originally described as a myeloid differentiation antigen 
on monocytes and macrophages (13,352). CD14 has also been found free in 
human plasma. LPS upregulates CD14 production (192). Marchant et al., 1992, 
(208) demonstrated that LPS stimulated an increase in CD14 within 30 minutes 
after LPS stimulation. Surface antibodies against CD14 on macrophages 
efficiently block LBP-LPS binding. When normal rabbit serum was depleted of 
LBP, a substantial inhibition of TNFa production was observed. The blocking of 
CD14 by monoclonal antibodies also blocked TNFa synthesis (352). 
The results from these experiments support the model illustrated in fig. 2. 
The presence of endotoxin stimulates LBP synthesis. LPS can bind to CD18 or 
the scavenger receptor whereby the LPS can be phagocytosed by the 
macrophage and neutralized or processed for antigen presentation to T-cells. T-
cells respond to presented LPS by differentiating and synthesizing interferon y. 
Interferon r synergizes with endotoxin to enhance TNFa synthesis. LPS binds to 
LBP to form a complex that can bind to CD14. By an unknown second messenger 
pathway, CD14-LPS-LBP interaction stimulates TNFa synthesis and release. 
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Fig. 2. Proposed role of LBP and CD14 in the activation of TNF production by macrophages. 
( Raetz et al., 1990 ) 
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c. Tumor Necrosis Factor 
1. Background 
Over 100 years ago in separate clinical studies, Coley (67) and Chekhov 
(78) demonstrated that injections of endotoxin administered to cancer patients 
significantly reduced tumor growth. In 1943 Shear et al., (294) isolated the active 
component from Gram negative bacteria, a complex of lipid and sugar residues 
which they referred to as lipopolysaccharide. Shear believed that LPS directly 
induced the hemorrhagic necrosis of tumors observed in the Coley studies. 
O'Malley et al., 1962, (246) demonstrated that the serum from normal mice treated 
with Serratia marcescens LPS caused a dose dependent increase in the necrosis 
of tumors from tumor bearing mice. In 1975 Carswell et al. (62) using BCG 
stimulated murine serum, suggested that a serum factor produced by 
macrophages was responsible for the cytolytic activity towards tumors, and it was 
not LPS directly. In the mid 1980s research by both Beutler and Cerami described 
TNF and these authors are credited with pioneering cytokine biology. Agarwal et 
al., 1985, (5) succeeded in purifying and sequencing human TNFa and another 
tumorlytic protein produced by lymphocytes called lymphotoxin which is 30% 
homologous with TNF at the amino acid level and shares the same receptor. 
Several lines of evidence point to the macrophage as the principle source of TNF. 
Cerami and colleagues delineated the basic mechanism of cachexia associated 
with chronic disease states. Rouzer and Cerami, 1980, (277) demonstrated that 
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trypanosome-induced wasting in rabbits was accompanied by a paradoxical 
hypertriglyceridemia due to an endogenous mediator. Mice treated with LPS also 
demonstrated hyperlipidemia. These authors noted that endotoxin stimulated 
macrophages to produce a hormone capable of suppressing lipoprotein lipase 
essential for clearing plasma triglycerides. Beutler et al., (41) purified cachectin 
to homology and observed the murine cytokine had strong homology with reported 
human TNFa. 
2.Structure 
TNFa is the product of a single gene that resides within the major 
histocompatibility complex (short arm chromosome 6 human; chromosome 17 
mouse). The gene consists of four exons and spans 3 kilobases. The TNFP or 
lymphotoxin gene is present downstream on the same gene, separated by 1100 
base pairs. TNFP is subject to an entirely different form of regulation suggesting 
that TNF promoter/enhancer region lies downstream in this 1100 base pair region 
(5,322). 
The TNFa gene encodes a protein of 26 and 17 kDa molecular weight as 
determined by SDS PAGE (322). The cDNA and the genomic sequences are 
highly conserved among species. Table 1 summarizes the structural protein 
properties of TNF among different species. Human TNF is produced as a 
precursor molecule with a presequence region of approximately 79 amino acids 
(5). The precursor molecule also contains a conserved region 26 amino acids in 
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Table 1--TNF protein comparisons between species. 
Leader Mature 
peptide peptide 
Species Amino Acids lsoelectric Glycosylation Reference 
Point Sites 
Human 79 157 5.3 no 120 
Mouse 76 156 3.9 yes 135 
Rabbit 80 154 4.0 no 135 
Rat 78 156 n/d yes 161 
n/d = not determined 
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length and a hydrophobic region possibly important for secretion or processing. 
The very long leader sequence is thought to function as a transmembrane 
domain. The mature TNF consists of 157 amino acids. TNF has two cysteine 
residues conserved at positions 69 and 101. These residues are involved in a 
single intermolecular disulfide bond. This bond is important for biological activity 
as gene mutations that lack this disulfide bond have decreased cytotoxicity, 
macrophage activation and inhibition of lipogenesis without alterations in 
secondary or tertiary structure (5). Human TNF does not contain a glycosylation 
site which has been found at position 7-9 of murine TNF. The function of the 
glycosylation site is unknown as both peptides display equivalent biological 
activity. 
The active form of TNF consists of dimer, trimer or higher oligomer 
complexes. Variations in conformation have been attributed to the methods of 
analysis and species differences. Smith and Baglioni, 1987, (299) have 
demonstrated that the human and murine forms that bind to cellular receptors and 
evoke cell death in L929 cells exits as a trimer. Crystallographic analysis has 
revealed that each subunit an antiparallel p sandwich forms a trimeric molecule 
through edge to face packing (322). 
3.TNF Receptor 
Two distinct receptors, R1 and R2 have been found for TNF (227,276). 
They have a molecular mass of 55 and 75 kDa, respectively, and both bind 
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lymphotoxin. 
The amino acid sequence of the 55 kDa receptor contains 426 amino acids 
with a single membrane span. The extracellular domain contains 182 amino acids 
and the intracellular domain is 221 amino acids. N-linked glycosylation is 
responsible for the deviation of the predicted mass from the cDNA and the actual 
mass (276). 
The 75 kDa receptor is also a single membrane spanning protein 
comprised ofl 439 amino acids. The extracellular domain is 235 amino acids and 
the intracellular domain is 17 4 amino acids. Both N and 0 linked glycosylation 
sites have been found on the R2 receptor (276). 
Both R1 and R2 are considered distinct receptors as they share only 28% 
homology in the extracellular domain and no homology in the intracellular domain. 
This suggests that different signalling pathways exist for both receptors. The 
observation that the intracellular domains also do not share homology with any 
known protein further complicates the definition of TNF transduction pathways 
(276). 
Most tissues express both types of TNF receptors (17, 126). With the use 
of monoclonal antibodies, Tartaglia et al., 1993, (315) demonstrated that the 
binding of TNF to TNF-R1 results in the induction of NF-KB , MnSOD and 
cytotoxicity. The binding of TNF to TNF-R2 results in thymocyte proliferation and 
differentiation (322). As illustrated in fig. 3, TNF binding to receptors exerts 
multiple effects on many cell types. As has been demonstrated with other cytokine 
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receptors, the TNF-R1 and TNF-R2 are shed from the surface of cell.s and 
function as soluble TNF binding proteins in plasma (33,301,276). The release of 
these receptors has been postulated to bind excess TNF in plasma. Treatment 
with recombinant TNFRs partially protected mice from LPS induced lethality. The 
production of both receptors by cells is increased by trauma, TNF and LPS (312). 
Spinas et al., 1992, (301) demonstrated that three hours after E.coli administration 
to human volunteers, a four to five-fold increase in TNF-R1 and TNF-R2 
concentrations in plasma was observed. Pretreatment of the volunteers with 
ibuprofen slightly increased concentrations of TNF receptors. Bemelmans et al., 
1993 (33) have also suggested that the protective effect of LIF during endotoxic 
shock may occur via the ability of LIF to stimulate an increase in TNFR 
production. 
4. Regulation of TNF Production 
.fil Molecular Regulation 
TNFa is synthesized by many cell types including macrophages, 
monocytes, lymphocytes, NK cells, astrocytes, microglial cells, Kupffer cells, 
fibroblasts, endothelial cells ( as reviewed in 334) and eosinophils (72). A wide 
variety of infectious and inflammatory agents can trigger TNF synthesis including 
LPS, staphylococcus/streptococcus exotoxin, enterotoxin, toxic shock syndrome 
toxin, mycobacteria, viruses, CSa, fungal, parasitic infection, hemorrhage, IL-1 and 
TNF ( as reviewed in 334). With such a diverse group of stimulatants of TNF, 
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regulation of TNFa is under stringent regulation. Over the last 5 years, Beutler 
and coworkers, have contributed greatly to the current understanding of TNFa 
regulation at the gene level (41,42,43). 
The TNFa promoter region is responsive to LPS stimulation within primary 
macrophages. However, the intracellular journey from the membrane to the gene 
remains uncharted. Four NFKB regions have been identified within the promoter 
region that appear to be necessary for LPS enhancement of expression. 
Mutations that remove two or more of these sites abolish LPS stimulated TNFa 
production (42). However, several genes unresponsive to LPS contain the same 
NFKB region, suggesting that other factors or flanking regions on the gene are 
also required. A purine rich motif (PU box) that exits within the promoter region 
has the potential for determining tissue specific expression. SP-1 and TFllD 
regions confer "housekeeping" functions related to the initiation of transcription 
(41,42). 
TNFa is regulated at the level of transcription. Several studies 
(41,271,324,339) have demonstrated that TNFa mRNA is significantly increased 
after LPS stimulation up to 100 fold. The TN Fa protein, surprisingly is increased 
by 10,000 fold. Therefore, TNFa is also regulated at the level of translation (43). 
The identification of post transcriptional regulatory regions within the cDNA for the 
mouse TNF offered further explanation to the disparity between mRNA and 
protein levels. Caput et al., 1986, (59) noted repeated and intercleaved octomeric 
units of TT A TT AT in the 3' untranslated regions of the cDNA for both murine and 
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human TNF cDNAs. This region has also been found in the UTR 3' regions 
specifying other cytokines (IL-1, IFNy, several proto-oncogenes, GM-CSF) and 
more recently the inducible form of nitric oxide synthase (iNOS) (99). Shaw and 
Kamen, 1986, (293) identified this TTATT region as a pentameric unit and thus 
identified it to exist in a larger population of cytokine genes. From experiments in 
which this sequence was spliced into the UTR 3' region of the rabbit p globulin 
gene, Shaw and Kamen determined that the rate of transcription was not altered; 
however, the normal p globulin mRNA, which is extremely stable had a half-life 
of only 15 minutes (293). They postulated that the UA rich region confers 
message instability. This finding appears to be cell specific as transfected 
lymphocytes with modified message did not express mRNA instability (293). 
The observation of superinducibility may also be ascribed to the UA rich 
regions. Cells treated with an inhibitor of translation, such as cycloheximide, 
overexpress mRNA (65,247). The overexpression of mRNA thus results in the 
over production of the protein coded by the specific mRNA. This is also observed 
in modified 6 globulin mRNA (293). Superinduction has been accredited to 
unstable repressors of transcription which are destroyed and unreplenished in the 
presence of cycloheximide (43,65,247). Superinduction may also be ascribed to 
the existence of labile ribonucleases that specifically target such mRNA 
sequences. Beutler et al., 1992, have recently demonstrated that RNAase A found 
in macrophages selectively hydrolyses the UA dinucleotide linkages found in TNF 
mRNA (44). 
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Ql Regulators of TNFa Production 
Over the last 8 years, many researchers have investigated numerous 
pharmacological and physiological compounds that alter TN Fa production in many 
cell types. Table 2 is a compilation of the compounds and agents that have been 
examined as regulators of TNFa. As illustrated in table 2 the number of 
substances tested is extensive and, therefore, in the interest of brevity, two 
stimulatory compounds, IFN'Y and PMA as well as two inhibitors, PGE2 and IL-10 
will be discussed in the context of this review. Glucocorticoid inhibition of TNFa 
production will be discussed in detail in a later section of this chapter. 
Interferon 'Y also called macrophage activating factor is produced and 
secreted by T lymphocytes and large granular lymphocytes in response to 
antigens and T cell mitogens (212). IFN'Y stimulates macrophages to increase 
antimicrobial activity and secrete various inflammatory mediators. IFNysynergizes 
with LPS to produce augmented levels of TN Fa both in vivo and in vitro. Doherty 
et al.,1992, (85) demonstrated that TNFa and IFN-y, when administered to mice, 
were well tolerated individually; however, when given together, the combination 
caused a significant increase in mortality associated with increased plasma IL-6 
concentrations. The C3H/HeJ mouse carries the lpsd mutation which confers 
endotoxin resistance and the inability to produce TNFa in comparison with the 
wild type strain (309). Adi et al.,1992, (4) have shown that administration of IFN-y 
to C3H/HeJ mice restores TNFa production by both the liver and the spleen. Matic 
et al., 1992, (212) have also shown that IFN-y relieved the suppression of TNFa 
Table 2--Summary of pharmacological and biological modulators of TNF 
production. 
cycloheximide (247) LPS (334) 
PMA (66) interferon y (212) 
A23187 (345) growth hormone (91) 
okadaic acid (310) ACTH (292) 
INCREASES indomethacin (209) nitric oxide (99) 
TNF calcyclin A (310) pertussis toxin (361) 
calphostin (310) 
staurosporine (66) 
H-7 (66) 
FK565 (150) 
taxol (280) 
MDL201112 (250) adenosine (250) 
cyclosporin (238) TNF inhibitor (251) 
ibuprofen (196) PGE2 (209) 
cimetidine (196) glucocorticoids (339) 
diphenylhydramine (196) interleukin 6 (3) 
DECREASES taurine Cl (249) interleukin 1 ( 195) 
TNF N-acetylcysteine (255) TGF p (88) 
glutathione (255) interleukin 10 (113) 
E330 (228) G-CSF (138) 
puromycin (150) LIF (33) 
actinomycin D (365) arachidonic acid (174) 
polymyxin B (66) TNF receptor (301) 
pentoxyphylline ( 148) fatty acids (344) 
thalidomide (281) 
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synthesis induced by LPS induced tolerance in macrophages. They suggested 
that IFNy opposes endotoxin tolerance through its action on a PKC dependent 
pathway (212). 
Glucocorticoids are potent inhibitors of the synthesis of many cytokines. 
The inhibition of TNFa by glucocorticoids occurs both at the transcriptional and 
the posttranscriptional level (43). Interferon 'Y causes a reversal of 
dexamethasone-induced suppression of TNFa message and to a lesser extent 
TNF protein production (205). IFNy stimulation of TNFa synthesis and reversal 
of dexamethasone suppression also occurs at a transcriptional level. Dunham et 
al.,1990, (88) have also found that IFNy was able to relieve TGFP suppression 
of TNFa synthesis. 
Another potential mechanism of IFNy control is by regulation of TNFa 
receptor synthesis. Aggarwal et al., 1985, (5) have shown that IFNy increases 
TNFa receptor number in several cell lines without increasing TNFa receptor 
affinity. 
LPS has been shown to stimulate phospholipase C and to activate protein 
kinase C in macrophages (40,66,343). PMA is the most potent tumor promoter 
known and is a stimulant of PKC, which induces adherence and the synthesis of 
superoxide and peroxide radicals by monocytes (214). In murine Kupffer cells LPS 
stimulation of TNFa and IL-1 is attenuated by the PKC inhibitor, H-7 (345). PMA 
alone will not stimulate TNF production, however, in combination with LPS, PMA 
has been demonstrated to augment both TNFa and IL-1 production by 
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macrophages (129,259). Coffey et al.,1992, (66) observed a paradoxical 
stimulation and inhibition by PMA and H-7 based on the concentration used to 
treat human monocytes in vitro. Concentrations of PMA greater than 3nM 
inhibited TNFa production, whereas, concentrations between 0.3 and 3 nM 
augmented LPS induced TNFa production. H-7 addition (10-30 µM) augmented 
TNFa production, and higher concentrations of H-7 inhibited LPS induced TNFa 
production. The disparity in this report was suggested to be the result of activation 
of different PKC isozymes that may mediate stimulatory as compared to inhibitory 
effects of PKC on TNFa production (66). 
LPS stimulates the production of prostaglandin E2 and prostacyclin 12 (78). 
In vitro, PGE2 production occurs after TNFa production and once initiated TNFa 
production begins to plateau and decline, suggesting that PGE2 acts to inhibit 
TNFa synthesis. The addition of cycloxygenase inhibitors such as indomethacin, 
results in augmented TNFa production and results from several studies 
demonstrated that addition of PGE2 or prostacyclin to LPS stimulated 
macrophages results in a dose dependent reduction in TNFa production 
(180,345). PGE2 blocks TNFa production at the level of transcription (345). PGE2 
increases the intracellular cAMP concentration because its effects can be 
mimicked by the addition of dibutyrl cAMP, forskolin and phosphodiesterase 
inhibitors. Feedback control of TNF production is likely at a local level in in vitro 
studies as the role of PGE2 in vivo is not as clear (78). Administration of PGE2 
in vivo has been shown to have little effect on preformed TNFa and the addition 
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of PGE2 to LPS treated animals causes toxic responses (78). In fact, the use of 
cycloxygenase inhibitors has been shown to be beneficial in reducing the toxic 
effects of TNFa and LPS (78). Marcinkiewicz, 1991, (209) has shown that PGE2 
and PGl2 effectively inhibit TNFa and enhance IL-6 levels in peritoneal cells. 
Interleukin 10 was first described as a cytokine produced by subsets of T 
cells. IL-10 inhibits macrophage APC-dependent cytokine synthesis by Th1 Th 
cells. Ralph et al.,1992, (268) found that IL-10 is also produced by melanoma, 
epidermoid and fibroblast cell lines. IL-10 is also produced by LPS stimulated 
monocytes and inhibits IL-1, TNFa, IL-6, IL-8, G-CSF and class II MHC in purified 
monocytes (268). Gerad et al., 1993, (132) demonstrated in mice that IL-10 
pretreatment reduced TNF levels by 92%, reduced LPS hypothermia and 
significantly decreased mortality. Recently, Corradin et al., 1993, (71) 
demonstrated that IL-10 stimulated induction of NO synthase mRNA in LPS/IFN-y 
cells and increased NO synthesis. 
5. TNFa: Role in septic shock. 
TNFa has been implicated in the pathogenesis of many disease states 
such as ARDS, reperfusion injury, graft vs. host disease and rheumatoid arthritis. 
The contribution of TNFa to the pathology of these diseases is reviewed in 
several recent review articles (78, 126, 134,334 ). 
More literature exists on the role of TNFa in septic shock than any other 
cytokine. TNFawas implicated many years ago as causing many of the symptoms 
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of Gram-negative sepsis. 
Endotoxin administration to human volunteers results in a rapid and early 
increase in plasma TNFa concentrations as illustrated in fig. 4. The pattern and 
time course of cytokine appearance in vivo is remarkably consistent among 
species (116, 182, 271, 337). In comparison to the other cytokines, IL-1 and IL-6 
which appear 2 to 3 hours after endotoxin, TNFa is measurable in the circulation 
within the first 30 minutes (116). When injected into human volunteers, endotoxin 
stimulates increases in TN Fa within one hour which thereafter decline to baseline 
after 3 hours (116). The TNFa burst is an early event during endotoxemia as 
Galley et al., 1993 (128) have shown that the increase in TNFa message occurs 
within 5 minutes after stimulation of human monocytes with LPS. Remick et al. 
1989, (271) have also shown that the peak expression of message by peritoneal 
macrophages occurs one hour after LPS injection. 
Clinical studies have implicated TNFa as an important mediator in septic 
shock. Detectable levels of TNFa are found in the serum of patients with 
meningococcal disease and sepsis. Patients with serum levels greater than 0.1 
ng/ml subsequently died (as reviewed in 78). Recently, Casey et al. 1993. (60) 
observed that 45% of patients with sepsis syndrome exhibited increases in 
plasma TNFa concentrations. Increased plasma TNFa levels did not, however, 
correlate with death of these patients. This finding has been confirmed by several 
studies. The discrepancy may exist due to the inclusion criteria in the study or 
due to other injuries. Hemorrhagic shock and trauma dramatically alter the 
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Fig. 4. Time course of circulating cytokine production following endotoxin infusion in human volunteers. 
(Adapted from Fong et al., 1990 (116)) 
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cytokine profile as compared to that found in pure gram negative sepsis (60). 
The administration of highly purified recombinant TNFa causes shock and 
injury in every mammal studied. The list of species tested includes rat, mouse, 
rabbit, dog, pig, sheep, cow, monkey, baboon, and man. TNFa administration 
causes a syndrome almost indistinguishable from septic shock. Although other 
cytokine, IL-1 and IL-6 can induce some of the symptoms of septic shock, TN Fa 
administration is the best reproduces the septic state, not only because of its own 
pathological activities but also because of its ability to induce the production of 
other cytokines that are pathological. Hypotension, fever, hypoglycemia, increases 
in stress hormones and acidosis are only a few of the symptoms observed after 
TN Fa treatment. Sakurai et al., 1993, (278) recently demonstrated that high doses 
of TNFa injected into dogs caused a fall in arterial pressure, pulmonary artery 
pressure and cardiac index. They also concluded that TNFa caused a shift 
towards carbohydrate as an energy substrate by decreasing the availability of 
FFAs and decreasing lipid oxidation, while simultaneously increasing glucose 
production and clearance (278). Others have also shown that TNFa increases 
glucose oxidation especially in non-insulin dependent tissues such as Kupffer cells 
(223,224). 
TNFa has been implicated as the factor responsible for the lethal 
hypoglycemia observed during sepsis (337). Chajek-Saul et al., 1990, (63) 
demonstrated that rTNFa injected into adrenalectomized rats resulted in increased 
endotoxin sensitivity . Pretreatment with dexamethasone or glucose protected 
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these animals from death (63) A significant reduction in PEPCK activity was also 
observed (63). Satomi et al., 1985, (284) also found a strong negative correlation 
between plasma glucose concentration and plasma TNFa. 
Tumor necrosis factor has been shown to alter liver enzyme profiles. 
lntraperitoneal injections resulted in a 20-50% reduction in hepatic 
aminotransferases and a 50-200% increase in alkaline phosphatase (354). 
Yasmineh et al 1992. (355) demonstrated that TNFa administration in the rat had 
differential effects on the enzymes of gluconeogenesis. A significant reduction in 
kidney 1,6 diphosphatase, PEPCK and glucose-6-phosphatase was observed after 
TNFa administration (355). Hill and McCallum, 1992, (161) confirmed the findings 
of this group by demonstrating that PEPCK is transcriptionally negatively 
regulated by TNFa in mice and in H 4 II Reuber hepatoma cells. 
Protection against endotoxic or bacteremic shock has been achieved by 
passive immunization with anti-TNFa antibodies and anti-IL-6 antibodies. 
Controversy exists as to the efficacy of TNFa antibodies in septic therapy. 
Polyclonal antibodies administered to endotoxic mice and monoclonal antibody 
therapy in baboons have been shown to be efficacious in preventing endotoxic 
shock (as reviewed in 78). Recently Zanetti et al. 1992, (360) demonstrated that 
antibodies against TN Fa administered to a 100% mortality model in mice was 
extremely effective in reducing mortality as well as reducing the plasma 
concentrations of TNFa, IL-1 and IL-6. However, Eskarandi et al. 1992, (97) 
demonstrated that in a CLP sepsis model and during endotoxemia that anti-TNFa 
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Abs failed to prevent lethality. Results from clinical trials are currently ongoing, 
and anti-TNF Abs may possibly prove to be a useful clinical modality (89). As 
TNFa antibody therapy alone was shown to be ineffective in preventing death 
from sepsis syndrome, Mullen et al., 1993, (233) using a septic porcine model 
concluded that combination therapy with ibuprofen and antiTNFa antibody therapy 
provided greater protection from acute lung injury and hemodynamic failure. 
With the recent identification of soluble receptors for TNFa found in the 
plasma and urine of patients (312), another clincal modality is currently under 
review. Spinas et al., 1992 (301) have shown that partial protection against 
endotoxin induced lethality in mice can be achieved with TNFaR therapy. The 
TNFaR is thought to act like a "sponge" and neutralize the bioavailable TNFa 
present in the plasma. 
D. Interleukin 6 
1. Background 
Interleukin 6 is probably unique among cytokines because it was cloned 
inadvertently long before the discovery of its major biological activities (76). 
Weisenbach et al., 1980, (346) isolated two cDNA clones derived from 1.3 kb 
mRNA in a fibroblast cell line in search of the sequence for interferon p, calling 
this species interferon p2. Content et al., 1982 (68) cloned the same 1.3 kB 
mRNA species concluding that the protein synthesized which they named 26K 
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had no antiviral activity and was unrelated to interferon p. Simultaneously 
Teranishi et al., 1982, (316) observed that the activated T-cells produced a B cell 
differentiation factor called BSF-2. The cloned sequence was found to be identical 
for the sequence described for 26K (316). 
The existence of growth factors for plasmacytoma and hybridomas 
although unsuccessfully characterized, had been known since the 1970s. With the 
availability of stable growth factor dependent cell lines, these factors were easily 
characterized (76). Van Snick et al. (331) purified a factor from helper-T cells 
known as IL-HP1, and Nordan et al. 1986 (241) purified PCT-GF from the 
supernant of cultured macrophages. Van Damme et al., 1987, (328) purified a 
human hybridoma/plasmacytoma growth factor (HPGF) from the medium 
conditioned by IL-1 osteosarcoma cell line. It was eventually determined that 
these hybridoma growth factors all shared sequence homology with IFN-82 26K 
and BSF-2 and were collectively referred to as IL-6 (331). Later, Gauldie et al., 
(130) discovered that antibodies to IL-6 blocked the activity of a monocyte derived 
protein termed HepSgF which has been shown to activate acute phase synthesis 
by hepatocytes. As described in a review by Van Snick (331), IL-6 existed in the 
scientific world for many years by the following aliases: 
IFNP2 = 26K = BSF2 = PCT-GF = ILHP1 = HPGF = CDF = IL-6 
2. Structure 
The interleukin 6 gene has been cloned from human (10), mouse (314), rat 
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(48) and more recently from the pig (273). IL-6 is a single copy gene and in all 
species contains 5 exons and four introns with conservation among species of the 
intron exon borders. The interleukin 6 gene is located on chromosome 5 in the 
mouse and on chromosome 7 in man (10, 314). The cDNA share homology as 
illustrated in the table 3 with subsequent differences in the amino acid sequence 
of the protein. Messenger RNA transcripts are initiated from several cap sites on 
the human gene. The rat gene has 2 cap sites, however, only one site appears 
to be utilized during transcription (48). From the human gene, two species of 
mRNA are transcribed that are 1.3 kilobases long (10). Two polyadenylation 
signals which are 78 bases apart are utilized. In the mouse, however, only mRNA 
is produced from similar transcriptional signals (314). The rat gene codes for two 
species of mRNA, 1.2 and 1.35 kilobases in length (48). The transcript content 
of AUUUA regions which confer stability of the message, varies among the 
species (76). 
The IL-6 gene codes for a 211 amino acid protein in both the rat and the 
mouse and a 212 amino acid protein in human (10,48,314). The signal peptide 
is cleaved to yield a mature 183-185 amino acid protein. Human IL-6 has 2 N-
glycosylation sites and several 0-glycosylation sites. The mouse and rat IL-6 
proteins are not glycosylated. The absence of glycosylation sites in rodent IL-:-6 
may account for the inability of mouse IL-6 to bind to the human IL-6 receptor 
{6,7,28). All species studied to date have four cysteine residues at conserved 
sites on the protein. The rat has an additional free cysteine at position 103 whose 
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Table 3-- Comparison of species similarities with respect to the cDNA and the 
protein for IL-6 (76). 
Comparison cDNA homology Amino acid homology 
rat to mouse 92% 93 % 
rat to human 65% 58% 
mouse to human 68% 42% 
pig to human 83% 62% 
pig to mouse 61% 42% 
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function is yet to be determined (48). The N terminal region of the peptide is not 
necessary for bioactivity. Residues 1-28 can be removed without substantial 
alterations in action. The removal of as few as two amino acid residues from the 
carboxyl terminus of the protein results in significant loss of bioactivity (6,76). 
3. IL-6 Receptors 
An abundance of cell types express surface IL-6 receptors (6,300) . 
Petersen et al. 1990 (253) found that 1125 labelled IL-6 was quickly taken up from 
the circulation by the spleen. Approximately 60% of this binding was found to be 
by spleen macrophages. IL-6 was also shown to bind avidly to rat peritoneal 
macrophages in vitro (253). 
The IL-6 receptor has a molecular mass of 80 kDa and is highly 
glycosylated (6,28,313). It is structurally unique in comparison to other cytokine 
receptors. The extracellular portion consists of two domains. One domain is a 
member of the cytokine receptor family with a distinct region, and the other 
domain is a member of the immunoglobulin gene superfamily (28). The 
cytoplasmic domain is 82 amino acids in size and contains no known sequences 
that might mediate signal transduction (184). Taga et al. 1989, (313) determined 
that signal transduction by the IL-6 receptor occurs via the interaction with a 130 
KDa protein (gp130) at the extracellular domains. The structure of gp130 is similar 
to the G-CSF receptor, and IL-6R-gp130 association results in the transformation 
from a low to a high affinity receptor (184). Other cytokines such as IL-3, GM-CSF 
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and the IL-5 receptor also function in a similar manner. Signal transduction by the 
interaction with gp130 may explain the functional pleotrophy and redundancy of 
the many cytokines. The signal transduction mechanism for gp130 is unknown; 
however, evidence of tyrosine kinase autophosphorylation has been documented 
(184). 
4. Regulation of IL-6 Production 
fil Molecular Regulation 
The investigation of the molecular regulation of IL-6 production is a 
very recent area of study. Stimulation of IL-6 production has been demonstrated 
by at least three different intracellular pathways. The production of cAMP, 
diacylglycerol and an increase in intracellular of calcium are implicated in the 
upregulation of IL-6 synthesis (76) . Tanabe et al. 1988, (314) have described a 
highly conserved region in both the human and mouse IL-6 genes approximately 
350 base pairs upstream of the initiation site that acts as the IL-6 promoter 
region. The different regions of the IL-6 promoter region are illustrated in fig. 5. 
Within the promoter is the MRE region which contains several smaller segments 
that are responsible for activation by different substrates. The SRE is found in the 
-113 to -225 region and is necessary for oncogene activation by c-fos (7). The 
region at -145 to -158 is known as the NFIL-6 region. NFIL-6 is a nuclear factor 
whose synthesis is stimulated by LPS, IL-1, and IL-6. NFIL-6 belongs to the 
C/EBP family of nuclear binding proteins (7). This group of proteins includes 
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Fig. 5. Functional regulatory regions in the promoter of the IL-6 gene. ( Akira et al., 1990 (6)) 
(..) 
en 
37 
C/EBP, IL-6DBP, lg/EBP-1 and NF-IL6P. They recognize the same nucleotide 
sequence in a gene but exhibit distinct patterns of expression among different 
cells (7). The CRE is also found in the MRE region. The NFKB region is found 
between the -63 to -73 positions and is necessary for induction of transcription 
(7). Matsusaka et al., 1993, (213) recently described the synergistic activation by 
NF-IL6 and NFKB of the IL-6 promoter. 
Negative regulation of IL-6 synthesis by glucocorticoids has been described 
by Ray et al., 1990, (269). DNase footprinting demonstrated that the glucocorticoid 
receptor bound across the MRE, TATA box and the INr. At least two GRE regions 
have been described in the IL-6 promoter (7). Two AP1 sites have also been 
described on the promoter, however, the function of these sites remains 
unresolved (7). 
Ql Regulators of IL-6 Production 
Most nucleated cells studied, including transformed cells, are capable of 
producing IL-6 (76,154). Since IL-6 has not yet achieved the same degree of 
research notoriety as TNF, the substances tested to date as possible regulators 
of IL-6 synthesis are limited. Also, activation of IL-6 synthesis by endotoxin, 
growth factors and pharmacological compounds is dependent on the cell type 
examined (76,288). In fibroblasts the most potent stimulator of IL-6 production is 
IL-1 and TNFa. In macrophages the most potent stimulator of IL-6 is LPS and the 
phorbol ester, PMA (76). 
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IL-6 production in vivo is significantly augmented by LPS induced TNF 
production (290, 326, 338). Many studies in vitro have also concluded that the 
production of TNF is closely followed by the production of IL-6 (95, 116, 290). 
Therefore, substances which alter TNF production also alter IL-6 production in the 
same direction. Shalaby et al., 1989, (290) demonstrated in vivo that injections of 
both TNF and IL-1 could stimulate IL-6 production by mice. The administration of 
both TNF and IL-1 resulted in a synergistic increase in IL-6 production. 
Administration of TNF antibodies also partially attenuated IL-6 production in LPS 
stimulated mice (290). However, reports from in vitro studies with transformed cell 
lines (211) and isolated primary liver endothelial cells (101) indicate that IL-6 
production is not coupled to the presynthesis of TNF. 
The activation of protein kinase C by PMA results in IL-6 production by 
macrophages (76,283). Mengozzi et al. 1991, (220) have also demonstrated that 
PMA could reverse LPS tolerant suppression of IL-6 production, but not TNF 
production in mice. They also observed that IFN-y could also partially restore IL-6 
production in this model (220). Recently, Sironi et al.,1993 (296) found that PMA 
could also reverse LPS tolerance in a mouse glioma cell line. The restoration of 
cytokine production by PMA was also specific for IL-6 as TNF production was not 
restored by PMA treatment. From this study the authors concluded that down 
regulation of IL-6 production during LPS tolerance occurred at the level of 
transcription by down regulation of PKC or another PMA-induced signalling 
pathway (296). 
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5. IL-6 Function and Regulation during Sepsis 
As illustrated in fig. 6, IL-6 is a polyfunctional cytokine that plays a central 
role in many host defense mechanisms. The impact of IL-6 on the cell types 
illustrated can be found in a recent comprehensive report by Van Snick (331). 
IL-6 has been implicated in vivo to be one of the mediators of the host 
response to trauma, infection and sepsis, as several authors have demonstrated 
that LPS administration stimulates the production of IL-6 ( 15, 16,24, 46, 81, 94, 
115, 116, 168, 181, 185). Fong et al., (116) demonstrated that E.coli administration 
to human volunteers stimulated IL-6 production. Moreover, recent clinical studies 
(80,244,359) have described a strong correlation between elevated plasma IL-6 
concentrations and both postoperative complications and increased mortality of 
septic patients. Patients with Pseudomonas pseudomallei sepsis, whose serum 
IL-6 levels were greater than 1 ng/ml had a 75% increased mortality rate (123). 
Casey et al. 1993, (60) demonstrated similar results. Septic syndrome patients 
who died had significantly elevated plasma IL-6 concentrations. Plasma tumor 
necrosis factor and IL-1 concentrations did not correlate with an increased 
mortality rate (60). 
IL-6 administration to animals results in the physiological sequelae 
observed during sepsis, such as acute phase protein synthesis, fever, 
hypoglycemia and hypotension (27). 
IL-6 is the cytokine predominately responsible for the production of acute 
phase proteins (APP) by the liver (27,53,155). LPS stimulates Kupffer cells and 
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the hepatic endothelial cells to produce IL-6, and a paracrine activation of APP 
synthesis by hepatocytes is initiated (76). The proteins specifically induced by IL-6 
include cysteine proteinase inhibitor, a2-macroglobulin, fibrinogen, a 1-
antiproteinase inhibitor, haptoglobin, a1-antichymotrypsin, ceruloplasmin and C1 
esterase. In combination with IL-1, IL-6 also stimulates the synthesis of other 
acute phase proteins such as C3 and C-reactive protein (103,210). Maximal 
production of APP by hepatocytes requires the presence of glucocorticoids. 
Glucocorticoids enhance the production of APP by stimulating the upregulation of 
IL-6 receptors on hepatocytes. IL-6 also inhibits the production of corticosteroid-
binding protein, CBG, thus increasing the availability of the glucocorticoid to the 
hepatocyte (23). Regulation of APP by IL-6 is via increased transcriptional activity 
(76,131). An IL-6RE has been described by Baumann et al.,1990 (26) in the 5' 
promoter region of the a2 macroglobulin gene. This region contains nucleotide 
sequences similar to that described to bind NFIL-6 (6,7). Perlstein et al., 1991, 
(256) reported that interleukin 6 administration directly into the CNS of conscious 
rats stimulated the production of ACTH. The stimulation of ACTH production 
occurred through increased CRF secretion by the hypothalamus (235, 256). 
ACTH secretion would subsequently stimulate cortisol production by the adrenals 
and augment APP production by the liver. 
The cells of the central nervous system, primarily astrocytes and microglial 
cells produce interleukin 6 (58,296) . Elevated IL-6 concentrations in the cerebral 
spinal fluid of patients with meningitis and sepsis have been documented (80). 
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The ability of IL-6 to cross the blood brain barrier has not been described. The 
production of IL-6 within CNS has been postulated to be responsible for the 
induction of LPS induced fever and anorexia. Damas et al., 1992 ,(80) found a 
strong correlation between increased body temperature and plasma IL-6 levels. 
LeMay et al., 1990 ( 197, 198) have shown that intracerebroventricular injections 
of IL-6 to rats stimulated a dose-dependent increase in body temperature. 
Identical doses administered either i.p. or i.v. did no cause fever. Prostaglandin 
synthesis mediated the fever observed as indomethacin completely blocked IL-6 
induced fever. A direct link between IL-6 and neural degeneration was recently 
described by Campbell et al., 1993 (58). Transgenic mice that overexpressed IL.:.6 
in the central nervous system, exhibited severe neurodegenerative disease, 
tremors, ataxia and seizures (58). 
Alterations in carbohydrate and protein metabolism are characteristic 
observations in patients with sepsis (122). TNF and IL-1 have been implicated as 
mediators of hypoglycemia and weight loss in these patients (93). Gershewald 
et al. 1990. (133) observed that immunization against IL-1 type I receptor 
attenuated not only cachexia and anorexia but also significantly reduced plasma 
IL-6 concentrations. The reduction of plasma IL-6 concentrations could also have 
been responsible for the reduction of symptoms observed. Oldenburg et al., 1993, 
(245) found that IL-6 receptor blockade prevented weight loss and anorexia to the 
same extent as that observed with IL-1 blockade. They concluded that the 
influence of IL-1 on cachexia is in part mediated by IL-6. Recently, Strassmann 
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et al. 1993, (308) illustrated that the administration of anti-IL-6 antibodies in vivo 
significantly decreased LPS induced hypoglycemia and weight loss. However, the 
administration of TNF antibodies reduced LPS induced hypertriglyceridemia and 
had a lesser effect on LPS induced hypoglycemia. 
E. Glucorticoids and Insulin Physiology during Sepsis 
Whether endotoxin directly stimulates endocrine cells or the stimulation of 
cytokine production and inflammatory mediators indirectly initiates the 
endocrinological stress responses, remains unknown (318). The hypothalamic-
pituitary-adrenal axis responds primarily to endotoxin induced hypotension by 
increasing plasma concentrations of ACTH, catecholamines, cortisol and 
aldosterone (295,318). The pancreas responds to increased plasma cortisol and 
glucose concentrations by increasing plasma insulin and glucagon concentrations 
(31,295,318). 
1. Glucocorticoids and Sepsis 
Glucocorticoids are important to the natural host defense against endotoxin. 
Sepsis increases plasma glucocorticoids, such as corticosterone and cortisol (167, 
295) A measurable increase in plasma corticosteroids occurs within the first one 
half hour after an endotoxin challenge (116, 248, 257). At the level of the pituitary 
gland, ACTH also increases in response to endotoxin. This increase ultimately 
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results in an increase in plasma cortisol. During physiological stress, such as 
sepsis, glucocorticoids are important for providing amino acids as substrates for 
gluconeogenesis in the liver and for the up regulation of enzymes necessary for 
gluconeogenesis (36,37). Cortisol also acts to maintain blood pressure and 
cardiac output as well as modulating an activated immune system. 
Several aspects of glucocorticoid physiology are impaired by endotoxin and 
sepsis. Under normal conditions, the increases in plasma glucocorticoids 
observed during stress initiate feedback inhibition at the level of the hypothalamus 
and the pituitary by inhibiting CRF and ACTH (167). However, recently, Perrot et 
al. 1993., (257) demonstrated in a group of septic patients in which elevated 
cortisol and p lipotrophin concentrations were refractory to the suppressive effects 
of dexamethasone infusion. This finding suggests that other factors are interfering 
with the normal feedback mechanisms (257). 
Corticosteroids exert their activity by binding to cytoplasmic glucocorticoid 
receptors (22,25). The binding of cortisol and corticosterone results in a structural 
and conformational change in the receptor converting it from the inactive to the 
active form (22, 25). The activated receptor then translocates to the nucleus 
where it binds to the GRE of a particular gene to either upregulate or inhibit 
transcription. The positive or negative modulation of transcription is determined 
by the interaction of the glucocorticoid-GRE complex with other nuclear regulatory 
proteins such as AP1 or NFKB (25). 
Endotoxin wields a dichotomous impact on glucocorticoid receptors 
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depending on the cell type influenced. During an endotoxin challenge, several 
authors (8, 159,304,305,332) have shown that glucocorticoid receptors in liver and 
cultured hepatocytes decrease. McCall um et al., 1983 (215) hypothesized that the 
hypoglycemia observed during sepsis occurs because of the inhibition of 
glucocorticoid mediated enzyme induction. This is due to the down regulation of 
cytosolic glucocorticoid receptors (215). Ali et al., 1990, (8) found that 24 hours 
after subcutaneous E.coli injection glucocorticoid receptor binding declined by 
40%. The glucocorticoid receptor mRNA declined by 30%. Transformation of the 
receptor from the inactive to the active form was unaffected during sepsis (8). 
In other cell types, for example, macrophages, glucocorticoid receptors are 
increased. Salkowski et al. 1992. (280) demonstrated that in RAW 264.7 and 
primary macrophages, endotoxin stimulated an increase in glucocorticoid receptor 
number without altering receptor affinity. The observed increase was present as 
early as 4 hours after stimulation and was maximal at 12 hours after stimulation 
(280). These findings suggest that LPS sensitizes the macrophage for both the 
positive and negative regulation of cytokine production. 
In spite of increased plasma glucocorticoid concentrations during septic 
shock, the induction of hepatic gluconeogenic enzymes, glucose-6-phosphatase, 
fructose 1,6-bisphosphatase and phosphoenolpyruvate carboxykinase (PEPCK) 
are decreased during endotoxicosis (11, 12,83, 160). The pharmacological 
administration of synthetic glucocorticoids such as dexamethasone has proven 
effective in restoring gluconeogenesis and euglycemia when administered prior 
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or concurrently with endotoxin (37,38, 167,358). The benefits of glucocorticoid 
treatment are negated when endotoxin is administered. Berry and Smythe 
observed that glucocorticoid mediated protection could be removed by the 
administration of actinomycin D and other inhibitors of protein synthesis (295). 
They proposed that protection was related to the ability of corticosteroids to 
induce the synthesis of certain liver enzymes (38). PEPCK converts oxaloacetate 
to PEP, is considered to be the rate limiting step in gluconeogenesis (140), and 
is subject to regulation by several hormones including insulin, glucocorticoids, 
thyroxine and glucagon (140). Granner et al., 1990 (141) have confirmed that 
distinct regulatory sites exist on the PEPCK gene for the positive modulation by 
corticosteroids (176, 254) and the negative modulation by insulin (242,243). 
Therefore, the effect of glucorticoids may act to increase PEPCK transcription in 
normal and in stress situations such that euglycemia may be maintained in the 
organism. 
PEPCK activity is significantly altered by endotoxin. Berry introduced the 
concept that LPS induced mediators released from immune cells, primarily 
macrophages, were culpable for antagonizing the positive effects of 
glucocorticoids (229, 295). The inhibitory activity derived from LPS-stimulated 
macrophages was termed , GAF, glucocorticoid antagonizing factor (230). Berry 
further investigated the properties of the antagonizing factor of endotoxin. He 
determined that GAF possessed protein-like properties and was derived from 
macrophages with a molecular weight of 150,000 (230,295). Berry also 
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postulated that glucocorticoids may act to control GAF production by 
macrophages (295). Although GAF was never identified specifically as one of the 
many cytokines known today, some scientists have postulated that GAF could 
have been a oligomeric complex of TNFa (295). Recently, Hill and Mccallum, 
1991 (160) demonstrated that rats treated with endotoxin exhibited lower rates of 
PEPCK transcription. They also found that both TNFa and IL-6 altered PEPCK 
transcription rates (160). 
2. Glucocorticoid Regulation of Immune Function 
For many years physicians have known that clinically, glucocorticoids 
posses the ability to reduce inflammation in conditions such as arthritis, trauma 
and injury (142). The reduction in inflammatory activity is attributed to the ability 
of corticosteroids to influence the activity of almost every immune cell type (142). 
Glucocorticoids in pharmacological doses suppress hematopoiesis, induce 
apoptosis in T cells and reduce neutrophil chemotaxis and phagocytosis 
(22,31, 142). Glucocorticoids also have a potent effect on monocyte and 
macrophage activity. Increases in plasma cortisol cause decreased differentiation, 
margination, emigration/ and phagocytosis by macrophages (151, 171, 
236,297,335). 
The research conducted over the last ten years has uncovered the 
fundamental rationale of corticosteroid's powerful anti-inflammatory activity. 
Glucocorticoids block the production of many cytokines including, IL-1, IL-2, G-
48 
CSF, INFy, IL-6 and TNFa(39,75,175,189,205,219,234,239,252). Glucocorticoids 
have the ability to alter cytokine production by binding directly to the regulatory 
elements of the cytokine gene and altering transcription or by altering the rate of 
translation (22). Indirectly, glucocorticoids alter cytokine production by regulating 
the production of other biological modifiers of cytokines such as prostaglandins 
(236). 
TNFa stimulates the production of other cytokines such as IL-1P, IL-2, INFy 
and IL-6 by macrophages and other immune cells. Glucocorticoids have been 
shown to significantly suppress TNFa production both in vitro (252) and in vivo 
(21,39, 248,271,339). Remick et al. 1989, (271) investigated the in vivo dynamics 
of TNFa mRNA production and the effects of dexamethasone suppression in 
mice. They determined that TNFa protein and mRNA are rapidly induced following 
an endotoxic challenge. Time course studies indicated that 4 hours pretreatment 
with dexamethasone (4 mg/kg) significantly suppressed TNFa; however, post 
treatment as short as 20 minutes after endotoxin administration did not alter TN Fa 
production in comparison with endotoxic control mice. Pretreatment with 
dexamethasone did not entirely suppress mRNA, indicating only partial inhibitory 
effects at the level of transcription (271 ). 
Dexamethasone can also abolish TNFa synthesis without entirely 
eliminating TNFa mRNA accumulation (44, 365) . At the level of transcription, 
glucocorticoids exert strong inhibitory influence by reducing mRNA by 80% 
(42,44). However, the effect appears to be more effective at the level of 
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translation. Greater than 99% inhibition can be achieved at the protein level in 
peritoneal macrophages (44). Using nuclear runoff assays which measure the rate 
of message degradation, Remick et al., 1989, (271) determined that the slope of 
message degradation over time was sharply increased in the presence of 
dexamethasone. TNFa, other cytokines and fast inducible genes such as NO 
synthase contain UA rich regions in the 3' untranslated region of the gene. This 
region is believed to confer message instability. Using TNFa promoter:CAT 
constructs as well as CAT-TNFa 3' UTR constructs in transfected cells, Han et al. 
1991 (147, 148) demonstrated that dexamethasone treatment hinders the 
expression of TNF. Both regulation in the promoter and in the 3' untranslated 
region of the TNF gene was observed. 
Glucocorticoids significantly depresses IL-6 production in macrophages, 
fibroblasts and endothelial cells (144,340). Waage et al., 1990, (340) showed that 
dexamethasone completely abolished IL-6 production in isolated human 
monocytes and RAW 264.7 macrophages. Dexamethasone substantially reduced 
IL-6 mRNA levels, indicating that the suppressive effect occurred primarily at the 
level of transcription (340). Akira et al. 1992. (7) have found GRE responsive 
elements in the promoter region of the IL-6 gene. Dexamethasone binding to its 
receptor occludes the inducible elements of the MRE enhancer region and the 
TATA box (start site) of the IL-6 gene (269). The presence of unstable UAUA 
regions on IL-6 mRNA is currently controversial. From experiments involving 
translational inhibitors of cytokine synthesis such as cycloheximide, IL-6 does not 
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appear to be regulated at the level of translation (65). Therefore, the inhibitory 
action of dexamethasone with respect to IL-6 production is currently limited to the 
transcriptional level (65). 
3. Glucocorticoids and Clinical Sepsis 
Controversy still exists in clinical studies as to the efficacy of glucocorticoid 
in the prevention of septic shock induced mortality (289, 298,). Authors have 
demonstrated in animal models (18,39,164) that pretreatment with glucocorticoid 
significantly reduces endotoxin-mediated mortality. Also, the adminstration of a 
glucocorticoid receptor antagonist, RU3486, has been shown to increase mortality 
during experimental endotoxicosis (50, 153,216). Hinshaw and coworkers, in a 
series of papers, examined the protective effects of corticosteroid administration 
in LD100 canine and baboon models septic shock (77, 162, 163, 164, 165,348). They 
concluded that high dose corticosteroid administration prior or early in the septic 
trial protected the animals from hypotension, hypoglycemia, tissue necrosis and 
mortality. The prognosis for survival was especially good when the steroids were 
administered early and in conjunction with antibiotics (167). 
Although these and numerous other authors have demonstrated the 
protective effect of corticosteroid therapy in animal models, the efficacy of 
corticosteroid use in clinical sepsis remains unproven (298). Early studies by 
Schumer et al., 1976, (289) found that the administration of corticosteroids 
provided protection to septic patients. However, in two later and rather 
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significantly cited clinical trials (47, 166), the use of high dose methylprednisolone 
was shown to be ineffective and partially detrimental to septic patients. The 
factors that have been ascribed to the differences observed between the human 
and the animal studies include species differences, health and immune status of 
the clinical patients, preshock complications, the choice of the steroid and the 
dosage, inotropic and metabolic support, and primarily the failure of early 
recognition of sepsis (21,167,298). One of the distinct conclusions of all animal 
research was the early administration of corticosteroids, primarily for the reduction 
of TNFa synthesis. One of the inclusion criterion for clinical trials by both Bone 
and Hinshaw was the appearance of fever. The clinical appearance of fever is 
preceded by cytokine production (117, 197) and therefore, corticosteroid therapy 
would be ineffective. Unfortunately, the early and possibly corticosteroid 
modifiable stages of clinical sepsis cannot be detected with present clinical 
techniques (167). 
4. Insulin and Sepsis 
A marked disturbance in substrate metabolism is one of the classic 
characteristics of Gram negative septic shock (107). Changes in plasma energy 
substrates such as glucose and amino acids have been reported to occur after 
lethal doses of endotoxin in several mammalian species used as experimental 
models of septic shock (4, 116, 122,350,353). The alterations in plasma 
metabolites have been attributed to the presence of endogenous mediators and 
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elevated circulating hormones. 
Several authors have reported that endotoxin administration alters plasma 
concentrations of glucagon and insulin (11,12,83, 104, 105, 187, 270, 306). The 
in vivo response to endotoxin is associated with a profound hyperglycemia and 
hyperinsulinemia which is often followed by a lethal hypoglycemic phase (107). 
Buchanan and Filkins, 1976, (52) found that serum insulin levels were significantly 
elevated 90 minutes post intravenous endotoxin. In response to a glucose 
challenge, insulin values were inappropriately elevated when compared to the 
control values (180 vs. 55 µU/ml). Although insulin levels return to pre-endotoxin 
values by eight hours, the values are significantly elevated above control values 
between two and six hours post endotoxin (52). Knowles et al. 1986, (187) 
observed that rats administered S. typhimurium endotoxin exhibited increases in 
plasma insulin and glucose concentrations. In rats made septic by cecal ligation 
and puncture Ardawi et al. 1989, (11) 1990, (12) also measured significantly 
elevated plasma insulin and glucagon concentrations. 
As stated above, within the first two hours after endotoxin administration, 
a hyperglycemic, hyperinsulinemic phase has been observed in several species 
(11, 104, 107). Even in the presence of significantly elevated plasma insulin, 
peripheral tissues such as muscle and adipose are unresponsive to insulin-
stimulated glucose uptake and thus, plasma glucose remains elevated 
(122, 187,221,222). This observation has been classically cited as "sepsis-induced 
insulin resistance" (193,221). Both sepsis and burn injury produce clinical states 
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characterized by a poor response to insulin and a glucose intolerance. Shangraw 
et al. 1989. (291) investigated the difference between septic and postburn insulin 
resistance. They concluded that septic and postburn insulin resistance differ in 
that peripheral tissue glucose uptake in sepsis is refractory to pharmacological 
insulin stimulation. Nonseptic burn injury patients exhibited a normal response to 
insulin administration and insulin-induced potassium uptake is unchanged in both 
conditions (291). 
The role of endotoxin as the direct stimulator of insulin secretion remains 
controversial. The hyperglycemia and possibly other endogenous factors have 
been suggested as key factors responsible for glucose dyshomeostasis (4,82, 104, 
110, 111, 112) . The hyperinsulinemia observed during sepsis is not always related 
to the increase in plasma glucose concentrations. Cornell, 1989, (70) 
demonstrated that low dose endotoxin stimulated hyperinsulinemia and 
glucagonemia without hyperglycemia. Rayfield et al.,1977, (270) observed fever 
and subsequent increases in plasma insulin and glucagon with little change in 
plasma glucose concentrations during acute nonlethal endotoxicosis in fasted 
human subjects. Yelich and Filkins, 1980, (356) demonstrated that the liver's 
capability of removing endotoxin from the circulation was unimpaired during 
endotoxicosis and that the mechanism for increased plasma insulin was due to 
hypersecretion by the endotoxic pancreas. In subsequent studies, these authors 
also observed that the media from inflammatory exudate cells stimulated insulin 
release from the isolated perfused pancreas (111,357). The acronym, MIRA, 
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(macrophage insulin releasing activity) was attributed to the monokine producing 
this response (108). MIRA eventually was purified and found to be interleukin 1 
(108) . Cornell 1989 (70) demonstrated that the cytokine IL-1 was the mediator 
of the hyperinsulinemia observed during endotoxicosis. Hyperinsulinemia was 
observed 30 minutes after injection of recombinant human IL-1 into rats (70). 
The lethal phase of hypoglycemia observed in the study by Buchanan and 
Filkins and other authors, occurs two to six hours after endotoxin administration 
when insulin levels are not markedly elevated (52). The hypoglycemia is the result 
of a negative balance between the production of glucose by gluconeogenesis and 
the disposal of glucose by the peripheral tissues (107). The prior hyperinsulinemic 
phase may have altered both the tissue sensitivity to insulin and the liver enzymes 
responsible for gluconeogenesis (107). Filkins and Figlewicz 1979, (109) 
demonstrated that the epididymal fat pads from endotoxic rats manifested 
increased basal glucose oxidation. Moreover, an enhanced increase in glucose 
oxidation of the endotoxic tissues was observed to several insulin doses (109). 
Lang and Dobrescu, 1991 (193) observed that injections of live E.coli into rats 
increased whole body disposal of glucose by 53% in comparison to controls. 
Sepsis induced glucose uptake by the liver, spleen, lung, ileum and skin under 
hypoglycemic-insulinopenic conditions was augmented (193). This observation 
suggests that the non-insulin dependent tissues (ie. macrophages and Kupffer 
cells) requirement for glucose is enhanced during sepsis (55, 73,74). Insulin may 
not directly alter glucose uptake in these tissues; however, insulin may alter other 
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factors related to the enhanced septic glucose utilization (73,74,333). 
During sepsis hepatic gluconeogenesis is severely impaired in the liver and 
in the kidney (9,106,173,187,188). Ardawi et al., 1990, (12) observed that the 
maximal activities of glucose-6-phosphatase, fructose-1,6-bisphosphatase, 
pyruvate carboxylase and phosphoenolpyruvate carboxykinase (PEPCK) were 
markedly decreased in kidneys obtained from septic rats. PEPCK activity in the 
liver is severely depressed during sepsis. McCallum et al. 1983 (215) observed 
that following endotoxin challenge hepatic PEPCK activity dropped rapidly and 
was consistent with the overall hypoglycemia which subsequently appeared. The 
upregulation of PEPCK activity by glucocorticoid therapy was negated by 
endotoxin pretreatment (215). Recently, Hill and McCallum, 1991, (160) have 
shown that the PEPCK transcription rate was significantly reduced by endotoxin 
pretreatment. Insulin is a negative modulator of the PEPCK gene by affecting a 
15 base pair sequence (242,243). This group has also shown that insulin and 
phorbol esters exert dominant regulation, since both prevent stimulation of PEPCK 
transcription in the presence of the inducers cAMP or glucocorticoid. Although 
phorbol esters and insulin de-induce PEPCK gene transcription through distinct 
signal pathways, the final target of both substances is the same DNA element 
(243). The hyperinsulinemia observed during sepsis may exert dominant 
suppression of PEPCK activity, thus causing hypoglycemia. Recently, Hill and 
Mccallum 1992, (161) challenged the role of insulin as a modulator of PEPCK 
activity during sepsis. Using diabetic rats, they found no alterations in PEPCK 
56 
activity suggesting that a cytokine mediator was responsible for the alterations in 
PEPCK transcription observed. 
Insulin can exacerbate endotoxin lethality. Buchanan and Filkins, 1976, (51) 
have shown that an exogenous dose of insulin given at the same time as 
endotoxin can increase mortality from 20 to 97%. Tolbutamide, a stimulator of 
endogenous insulin secretion can also increase mortality (51). Endotoxin in 
combination with phorbol esters (PMA) also results in an increase in mortality 
(177). The animals in the above studies are hypoglycemic and have elevated 
lactates prior to death (178). Satomi et al., 1985, (284) have observed that 
glucose administered to correct the endotoxin-induced hypoglycemia is ineffective 
and death is quickened. Insulin may produce or affect other mediators that initiate 
hypoglycemia and are unresponsive to restoring euglycemia. 
5. Insulin Regulation of Immune Function 
Does insulin regulate immune function and cytokine production ? Cornell, 
1989, has documented that cytokines, primarily IL-1 stimulate insulin secretion 
(70). However, whether insulin can modulate cytokine secretion normally or during 
sepsis remains unknown. Several pieces of indirect evidence and a few in vitro 
studies suggest a possible role for insulin as a cytokine modulator. 
Insulin receptors have been classically associated with metabolically active 
cells such as hepatocytes, myocytes and adipocytes (362). With the use of 
radiolabelled insulin as a ligand, insulin receptors have been identified on 
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erythrocytes, platelets and lymphocytes (321). Several authors (20,29,30,321,364) 
have demonstrated that insulin receptors are present on monocytes. Tsibris et 
al., 1980, (321) found that human monocytes contain approximately 50,000 insulin 
receptors per cell, suggesting that insulin may be important for the metabolism 
and function of this cell class. Bautista et al.,1987 (29), 1989 (30) also found 
insulin receptors on the surface of peritoneal macrophages and demonstrated 
down regulation of insulin receptors in Propionibacterium acnes activated 
macrophages. Bierger et al., 1980, (45) demonstrated that insulin binding to 
monocyte receptors can initiate a specific reaction increasing hexose 
monophosphate enzyme activity and antimicrobial activity . 
Certain hormone receptors associate with MHC Class I antigens (201). The 
insulin receptor and MHC Class I appear to be situated in close proximity in the 
cell membrane as evidenced by coimmunoprecipitation the presence of insulin in 
the media also increases MHC I and insulin receptor association on monocytes 
(201). Insulin receptor affinity appears to correspond with MHC class I alleles. 
Helderman et al., 1992, (156) have discovered a monocyte insulin regulatory 
protein (MIRRF), a small molecular weight peptide that stimulates the upregulation 
of insulin receptors on lymphocytes and is derived from monocytes stimulated with 
insulin. Insulin is necessary for lymphocyte proliferation and activation (201) .. 
Insulin has been shown to act as a growth factor, as some cell lines require 
it for growth and survival in vitro (69,100,122). Freund et al., 1993 (122) 
demonstrated that insulin and IGF-1 can increase mitogenesis and glucose 
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metabolism in the multiple myeloma cell line RPMI 8226. The regulation of 
mitogenesis and glucose metabolism by insulin was postulated to potentiate 
malignancy (122). 
The immunologic activities of peripheral leukocytes is altered by insulin 
(264). The polymorphonuclear cell functions such as adherence, chemotaxis, 
phagocytosis and superoxide production are impaired in diabetic patients (135). 
The in vivo administration of insulin to diabetic patients improves immunological 
activity. Cavot et al. 1992 (61) demonstrated in vitro that increasing 
concentrations of insulin from 40 to 320 nM increased PMN chemotaxis. 
Insulin increases PGE2 binding to P388D1 macrophages (265). PGE2 is a 
potent inhibitor of macrophage TNF production. However, Doherty et al., 1992, 
(84) observed that murine peritoneal macrophages in the presence of LPS (10 
µg/ml) and insulin concentrations from 0.2 µU/ml to 400 µU/ml increased TNFa 
production as assessed by L929 bioassay and ELISA above that of controls. IL-6 
bioactivity was increased by insulin and LPS. Insulin had no effect on IL-1 
production. The transcription of TNFa was slightly reduced in the insulin treated 
cells suggesting the site of regulation is post-translational. IL-6 gene transcription 
was unaltered from the control (84). Recently, Halan and Minowada, 1992, (172) 
reported that insulin, IGF-1 and IGF-11 stimulated IL-1P production in LPS 
stimulated monomyelocytic cell lines, although none of the hormones stimulated 
IL-1 production alone. This affect appears to specific to monocytic cell lines as T-
cell lines tested were unresponsive to LPS and insulin treatment (172). 
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The effects of insulin on cytokine production may be due to its ability to 
cross react with the IGF-1 receptor, which has been found on macrophages (179, 
275, 364). Rom and Paako, 1991, (275), have demonstrated that human alveolar 
macrophages express IGF-1 receptors only when activated with LPS or asbestos. 
The structural similarity between the IGF-1 and the insulin receptor indicates that 
insulin can cross react weakly with the IGF-1 receptor (124, 179, 364). Insulin-like 
growth factors (IGF-1) and (IGF-2) are peptide hormone homologous to insulin 
that have rapid insulin-like and slow-growth promoting actions in vivo 
(232,240,282). The circulating plasma pool of IGF-1 is derived primarily from 
hepatocytes under the influence of pituitary growth hormone (282); however, other 
cells such as macrophages, endothelial cells and fibroblasts can produce IGF-1 
under the influence of growth hormone and other currently unknown stimuli 
(14,91, 170,275). 
Currently the role of IGF-1 as a mediator of cytokine production or the role 
of IGF-1 in sepsis remains sparsely documented. Edwards et al., 1991 (90,91) 
have demonstrated that GH serves a protective action against the lethal effects 
of Salmonella typhimurium in vivo . In the above studies plasma IGF-1 was not 
measured, and it could not be concluded whether the protective action of GH was 
direct or indirectly modulated by IGF-1. They also demonstrated that 
hypophysectomy in rats altered TNFa production (90). GH treatment of endotoxic 
macrophages in vitro has been shown to enhance TNFa production (92). One 
preliminary report has shown that plasma IGF-1 is not increased in septic patients 
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in response to a 48 hour infusion of GH (79). Fu et al., 1990, (125) have 
demonstrated in vitro that GH and IGF-1 are both potent signals in 
polymorphonuclear cells (PMNs) superoxide generation. PMNs have also been 
shown to synthesize GH and IGF-1 and may be able to activate superoxide 
generation in an autocrine fashion (125). 
6. Insulin and Clinical Sepsis 
The hyperinsulinemia characteristic of experimental septic shock is not 
always detected in the hospitalized septic patient (64, 116, 122, 183). The 
observation of hyperinsulinemia appears to depend on several factors such as 
severeity and stage of sepsis, the plasma glucose concentrations, the 
administration of dextrose or total parenteral nutrition (203) and the timing of the 
blood samplings (336). However, most clinicians agree that the septic patient 
does have an altered sensitivity to insulin (237,291). In spite of plasma insulin 
concentrations that should theoretically prevent lipolysis, stimulate peripheral 
glucose uptake and prevent protein breakdown, the opposite scenario of 
hypertriglygeridemia, hyperglycemia and protein catabolism is often documented 
(64, 122, 270). Freund et al. 1978 (122) found in a group of 15 septic patients a 
significant elevation in plasma aromatic amino acids, phenylalanine and tyrosine 
concentrations at an insulin/glucagon ratio of 3.6. Sauerwein et al. 1991 (285) 
concluded as well that significantly higher insulin concentrations were necessary 
to obtain equal values for endogenous glucose production and glucose tissue 
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uptake in septic patients compared to control subjects. The cellular mechanisms 
for the sepsis-induced altered sensitivity to insulin remain unknown; however, 
from these and other clinical studies the authors have determined that muscle 
tissue exhibits a greater degree of insulin resistance in comparison to adipose 
tissue (284,285,286). 
Insulin administered therapeutically has profound systemic effects, 
especially with respect to plasma potassium concentrations (291). Therefore, in 
contrast to glucocorticoids, insulin has not been routinely used as a 
pharmacological modality in patients with shock. Insulin administration is indicated 
only if the patient exhibits significant hyperglycemia. Bronsveld et al. 1985 (49) 
observed that an infusion of the combination of glucose-insulin-potassium (GIK) 
to septic patients in cardiac failure significantly improved survival. They concluded 
that because GIK increased cardiac output and decreased systemic vascular 
resistance, and improved 02 consumption, its administration may be considered 
when conventional volume loading and vasoactive medication have failed (49). 
Insulin administration to septic patients may reduced muscle catabolism. Mitchell 
and Norton, 1990, (226) demonstrated in an in vitro system that insulin could 
protect against the muscle proteolysis induced by plasma from septic patients. 
The clinical use of insulin as an anabolic agent has not been seriously explored 
in comparison to other anabolic hormones such as IGF-1 (87,232) and growth 
hormone. 
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E. Summary 
Insulin and glucocorticoids circulate within the organism in a precarious 
balance regulating metabolic activity. The fundamental determinant of 
homeostasis is the appropriate "ying and yang" of these hormones. Under the 
influence of physiologic stress, such as sepsis, the balance between these two 
hormones is significantly disturbed, thus inducing an ominous metabolic 
dyshomeostasis. The ability of elevated circulating glucocorticoids to induce 
gluconeogenesis and restore euglycemia as well as to modulate and supress 
immune activity is profoundly impaired during septic shock. 
The findings of Granner (242,243) are important to the research proposed 
in this dissertation for two reasons: 
1) since insulin is a dominant regulator of PEPCK activity, one could 
hypothesize that the elevated insulin concentration observed during sepsis may 
overide the stimulatory activity of glucocorticoids, thereby inducing hypoglycemia 
and death. 
2) the control of PEPCK gene expression is modulated in opposite 
directions by two hormones, and this glucocorticoid-insulin regulation of gene 
expression is not limited to PEPCK (204). Glucocorticoids suppress TNF and IL".'6 
production. Sepsis-induced insulin production may also modulate the production 
of TNF and IL-6 in a manner similar to PEPCK. 
Therefore, the purpose of the following studies is to examine the ability of 
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insulin to alter the metabolic status of the animal as well as the production of TNF 
and IL-6 in endotoxic and dexamethasone-protected models of septic shock. 
A. Animals 
CHAPTER Ill 
MATERIALS AND METHODS 
Male Holtzman viral antibody free rats were used for all experiments. The 
body weight range for the initial in vivo studies was 400 to 450 g. The liver 
perfusion studies used rats of 500 to 600 g in order to facilitate the surgical 
procedures. The rats were obtained from Harlan (Madison.WI) or Sasco (St. 
Louis, Mo). They were housed in pairs in plastic containers covered with filtered 
hoods in order to minimized airborne infections. Environmental conditions were 
a temperature of 24°C, a humidity of 45-50% and a 12 hour light and dark cycle 
(7:00 am to 7:00 pm CDT). The rats had ad libitum access to Purina rat chow and 
fresh water. Prior to the initiation of experiments, the rats were acclimatized to the 
facility for at least 7 days. The rats were moved to the laboratory from the animal 
facility the evening before the experimental procedures in order to reduce stress-
induced alterations in plasma hormones that would result during transportation. 
All experiments were initiated between 10:00 am and 2:00 pm. When fasting was 
required, food, but not water was removed at 4:00 pm on the day prior to the 
experiment. 
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1. Cell Lines 
The cell lines used for experimentation were obtained from the laboratory 
of Elizabeth Kovacs. PhD, Dept. of Cell Biology, Neurobiology and Anatomy, 
LUMC. The ANA 1 cell line (75) is a murine macrophage cell line obtained from 
the bone marrow of the C57 /BL mouse which was transformed with a J2 retrovirus 
expressing v-myc/v-raf oncogene (L. Varesio, Laboratory of Molecular 
lmmunoregulation, National Cancer Institute, Fredrick, MD). RAW 264.7 cells are 
macrophages from the BALB/c mouse, which were transformed with Abelson 
leukemia virus and supplied by American Type Culture Collection, Rockville, MD. 
Two cell lines were used to bioassay the cytokines TNF and IL-6 in 
plasma, media and perfusate samples of rat origin. IL-6 was measured using the 
89 cells, obtained from Dr. Jack Gauldie, Department of Pathology, McMaster 
University, Hamilton, Ontario, Canada. 89 cells are a murine B-cell hybridoma cell 
line dependent on IL-6 for growth (1,194). TNF was measured using the L929 
cytotoxicity bioassay. L929 mouse myeloma cells are an adherent fibroblast cell 
line, obtained from the American Type Culture Collection, Rockville, MD. The 
cytokine bioassays are described in detail in the assay section of this dissertation. 
2. Primary Cells 
Primary macrophage cultures were also used for several experiments. 
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Peritoneal macrophages and Kupffer cells were obtained from male, fed Holtzman 
rats which had body weights of 400 to 450 g. The procedures required for the 
isolation of these cells are described in detail later in this dissertation. 
C. Agents 
1. Endotoxin 
Lyophilized Salmonella enteritidis lipopolysaccharide Boivin, lot # 764190, 
was utilized for all experiments and was purchased from Difeo, Detroit, Ml. The 
endotoxin was suspended in 0.9 % sodium chloride prior to injection. For cell 
culture studies, the endotoxin was serially diluted to the desired concentrations 
in sterile calcium and magnesium free phosphate buffered saline (PBS)(Gibco, 
Grand Island, NY). 
2. Dexamethasone 
For the in vivo and liver perfusion experiments, dexamethasone 21-acetate 
(Sigma, St. Louis, Mo.) was suspended in 0.9% sterile sodium chloride and 
sonicated for 5 minutes using a Bransonic 12 sonicator (VWR Scientific, USA). 
For cell culture studies, sterile dexamethasone sodium phosphate 
( Sigma, St. Louis, Mo) at an initial concentration 4 mg/ml, was then diluted to 
the required concentrations using sterile phosphate buffered saline without 
calcium or magnesium (Gibco, Grand Island, NY). 
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3. Insulin 
Humulin R (Lilly, Indianapolis, IN), human insulin of recombinant origin was 
used in all experiments. For in vivo experiments, insulin was diluted in 0.9% 
sodium chloride and 0.5% bovine serum albumin (BSA) (Sigma, St. Louis, Mo.). 
For cell culture experiments, insulin was initially diluted in 0.5% BSA and further 
diluted in sterile PBS . The endotoxin content of the insulin was determined to be 
below the detectible limits (< 0.001 ng/ml) of the Limulus Amoebocyte Lysate 
Assay (see assay section). 
4. Tolbutamide 
Tolbutamide, (Upjohn, Kalamazoo, Ml), tolbutamide sodium, was used as 
a stimulator of endogenous insulin secretion. The tolbutamide was diluted for 
injection in sterile 0.9% sodium chloride. 
5. Tumor Necrosis Factor 
Recombinant murine tumor necrosis factor (Genzyme, Cambridge, MA) was 
used as the TNF standard in both the L929 cytotoxicity assay and the ELISA. 
The TNF was reconstituted with endotoxin free water and diluted further with 
sterile PBS. 
Recombinant murine TNF was also used to test the stability of TNF in the 
perfusion apparatus. TNF was reconstituted with endotoxin free water (Sigma, St. 
Louis, Mo) and added to 100 ml of KRB with 5% albumin for this procedure. 
68 
Endotoxin content of the reconstituted TNF was determined to be less than 0.01 
ng/ml by the Limulus Amoebocyte Lysate test (Whittaker, Walkersville, MD). 
6. Interleukin 6 
Recombinant human interleukin 6 (Endogen, Boston, MA) was added to the 
B9 cells culture media in order to maintain growth. Recombinant rat IL-6, ( Dr. J. 
Gauldie, McMaster University, Hamilton, Ont., Canada) was utilized to generate 
the standard curve in the B9 proliferation bioassay. The IL-6 was diluted in 
lscove's Minimal Essential Media with 5% fetal bovine serum (FBS). Endotoxin 
content was determined to be less than 0.01 ng/ml by LAL testing. 
7. Phorbol myristate acetate (PMA) 
PMA (Sigma, St. Louis, Mo) was utilized as a stimulator of protein kinase 
C (PKC) in tissue culture experiments involving the ANA1 and RAW 264.7 
macrophages. PMA was initially dissolved in dimethyl sulfoxide (DMSO) and 
diluted further in PBS. 
8. 1-(5-isoquinolinyl sulfonyl)-2-methyl-piperazine (H-7) 
H-7, (Calbiochem, San Diego, CA), an inhibitor of protein kinase C and 
other kinases was utilized in tissue culture experiments involving ANA 1 cells, 
RAW 264 cells and peritoneal macrophages. H-7 was dissolved in DMSO at a 
concentration of 1 mg/ml. Further dilutions were performed using sterile PBS. 
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9. lndomethacin 
lndomethacin (Sigma, St. Louis, Mo), an inhibitor of cycloxygenase and 
thus, prostaglandin synthesis, was utilized in cell culture experiments involving the 
ANA1, RAW 264.7 and peritoneal macrophages. lndomethacin was dissolved in 
70% ethanol at a concentration of 1 mg/ml. Further dilutions were performed with 
sterile PBS. 
10. Insulin-like Growth Factor 1 (IGF-1) 
IGF-1 was used in cell culture experiments to determine if insulin was 
acting similar to this growth factor. Lyophilized recombinant human IGF-1 
(Gropep, Adelaide, Australia) was reconstituted to 1 mg /ml with sterile saline 
containing 3% BSA. Further dilutions were performed with sterile PBS. 
11. Okadaic Acid 
Okadaic acid, an inhibitor of serine phosphatase activity and, hence, a 
promoter of PKC actions, was used in cell culture experiments to determine its 
effect on cytokine production. One hundred micrograms of okadaic acid was 
reconstituted in 10 ml of 70% ethanol and further diluted with sterile PBS. 
12. Cycloheximide 
Cycloheximide, a non-specific inhibitor of protein synthesis, was utilized in 
tissue culture experiments involving the ANA 1, RAW and peritoneal macrophages. 
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Cycloheximide was reconstituted and diluted to the required concentrations in 
PBS. 
D. In Vivo Projects 
1. The Effect of Exogenous Insulin Administration on Lethality and Glucose 
Homeostasis. 
To investigate if insulin could alter dexamethasone protection against the 
lethal effects of endotoxicosis in vivo, the following experiments were designed. 
Overnight, fasted male Holtzman rats were assigned to control and 
treatment groups as illustrated in table 4. The rats initially received either 
dexamethasone (DEX) at a dose of 0.33 mg/kg dexamethasone acetate, i.p., or 
an equal volume of saline. Three hours later, endotoxin (EXT) or saline, was 
administered at a dose of 20 mg/kg , i.p. One hour post-endotoxin, the rats were 
given either insulin or saline at 1.0 U, s.c. The animals were followed over a 12 
hour time period and time of death was recorded. Prior to death, which was 
assessed to be the time the righting reflex was lost, a blood sample of 1 ml was 
taken and analyzed for glucose, lactate and insulin concentrations. 
2. The Effect of Insulin Dose on Mortality 
To determine the minimum effective dose of insulin needed to alter 
dexamethasone action in the endotoxic rat, male Holtzman rats were assigned to 
71 
Table 4-- Treatment groups for exogenous insulin experiments. 
GROUP DEXAMETHASONE ENDOTOXIN INSULIN 
1. - - -
2. - + -
3. - + + 
4. - - + 
5. + - -
6. + + -
7. + + + 
8. + - + 
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treatment groups illustrated above. The treatment protocol was identical to that 
used in the first experiment except three doses of insulin were tested, 1 U, 0.5 U 
and 0.25 U in order to determine the minimum effective dose. The animals were 
followed over a 12 hour time period and time of death was recorded. 
3. The Effect of Endogenous Insulin Secretion on Lethality and Glucose 
Metabolism 
The ability of endogenous insulin to alter dexamethasone protection 
against endotoxicosis was tested by administering sodium tolbutamide, (Orinase, 
Upjohn, Kalamazoo, Ml), a sulfonyl urea stimulator of insulin secretion. Male 
Holtzman rats were assigned to treatment groups as illustrated in table 5. The 
same treatment protocol as that illustrated in fig. 7 and discussed previously was 
followed, however instead of insulin, 66 mg/kg tolbutamide was administered s.c. 
1 hour post-endotoxin. The animals were then followed over a 12 hour time 
period, and time of death was recorded. Prior to death, a blood sample was taken 
by cardiac puncture and analyzed for glucose, lactate and insulin concentrations. 
4. The Effect of Restoring Euglycemia on Mortality 
In order to determine if the hypoglycemia resulting from the treatment 
protocol was responsible for the mortality in these animals, 5% dextrose solution 
was administered i.p. to a each treatment group after insulin administration to 
determine if mortality could be altered. Plasma glucose was monitored initially 
73 
Table 5-- Treatment groups for endogenous insulin experiments. 
GROUP DEXAMETHASONE ENDOTOXIN TOLBUTAMIDE 
1. - - -
2. - + -
3. - + + 
4. - - + 
5. + - -
6. + + -
7. + + + 
8. + - + 
DEXAMETHASONE ACETATE 
( 0.33 mg/kg ) 
3 hr. 
ENDOTOXIN ( S. enteriditis) 
( 20 ng/ kg) 
INSULIN 
( 46 ug/kg) 
-
-
-
• - mortality 
- plasma for: 
glucose 
lactate 
insulin 
TNF 
IL-6 
analyses 
TOLBUTAMI DE 
( 66 mg/kg) 
-
-
-
• 
- mortality 
- plasma for: 
glucose 
lactate 
insulin 
Fig. 7. Basic treatment protocol for the in vivo experiments. 
.. 
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every 15 minutes for two hour and then at 1 hour intervals during the treatment 
period. One ml of dextrose was administered if plasma glucose concentrations fell 
below 70 mg/dl . Mortality was assessed at the end of 12 hours. 
E. In Vivo Cytokine Measurements 
1. The Effect of Insulin on Cytokine Production in the Endotoxic Rat 
In order to evaluate the effects of insulin on TNF and IL-6 production in a 
dexamethasone-protected endotoxic rat model, fasted male Holtzman rats (n=8/ 
group) were weighed and administered either DEX or saline 3 hours prior to 
endotoxin administration. At the end of the 3 hours, the rats were anesthetized 
with 50 mg/kg pentobarbital i.p. and placed supine on a warming pad heated to 
37°C. A baseline tail-snip blood sample was obtained, and then 20 mg/kg 
endotoxin or an equal volume of 0.9% saline was injected, i.p. Blood samples 
were then taken every 15 minutes for a period of 2 hours. After 1 hour 1 U of 
either insulin, s.c., or saline was given. Blood samples were collected every 15 
minutes for 2 hours post insulin. Blood was collected in heparinized microtubes 
and placed on ice until samples were centrifuged and the plasma was removed. 
Plasma was analyzed for glucose, lactate, TNF and IL-6. 
2. The Effect of Insulin- Induced Hypoglycemia on Cytokine Production 
To observe the effect of insulin-induced hypoglycemia on TNF and IL-6 
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production, one group of male Holtzman rats was anesthetized and given SU of 
insulin s.c. Blood samples were taken every 15 minutes for 2 hours. Plasma was 
analyzed for TNF and IL-6. 
F. Ex Vivo Liver Perfusion Studies 
The liver is a biologically strategic organ in sepsis. The liver is necessary 
metabolically for the maintenance of euglycemia and the location as the first 
organ to process endotoxin from the bowel, may also make it a primary producer 
of cytokines from its resident population of macrophages, the Kupffer cells. The 
following experiment was designed to determine if the endotoxic liver was able to 
produce TNF and IL-6 and also to observe if the production of these cytokines 
could be modulated by dexamethasone and insulin. 
1. Animal Preparation 
Male Holtzman rats (500-600 g) were fasted overnight, but had ad libitum 
access to water prior to experimentation. The rat was injected with either 0.33 
mg/kg dexamethasone acetate or saline, i.p .. Three hours post dexamethasone, 
the rat was injected with Salmonella enteritidis endotoxin (20 mg/kg) or saline, 
i.p .. Insulin (1 U) or saline was administered, s.c. one hour post endotoxin. The 
animal was anesthetized with 50 mg/kg sodium pentobarbital i.v. in preparation 
for excision of the liver. 
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2. Liver Perfusion Apparatus 
Liver perfusion experiments were performed in a specially designed 
perfusion-aeration apparatus (Medical Research Apparatus; Clearwater FL) (fig. 
8) as originally described by Miller et al., 1951 (225). Prior to the perfusions, all 
glassware was disinfected and autoclaved and all tubing was gas sterilized. Krebs 
bicarbonate buffer ( KRB; 118 mM NaCl, 4.7 mM KCI, 2.5 mM CaCl2-2H20, 1.2 
mM KH2P04, 1.2 mM MgS04-7H20 and 25 mM NaHC03; pH 7.4) containing 5 
mg/ml bovine albumin (BSA) (RIA Grade; Sigma) was continuously recirculated 
through the system using a Masterflex peristaltic pump (Cole-Palmer Instruments 
Co., Chicago, IL). The KRB used in all experiments was filter- sterilized through 
a 0.2 µM filter and stored in sterilized 500 ml glass bottles at 4 °C. The endotoxin 
content of the buffer was determined to be < 0.01 ng/ml by Limulus Amoebocyte 
Lysate Assay (Whittaker, MA). For each experiment 100 ml of KRB was 
recirculated through the system. Temperature was maintained at 36-37 °C by a 
system of heating coils. The perfusate was oxygenated continuously with 95% 0/ 
5% C02 by passing over a gas exchange lung. To remove particulate or fibrous 
material produced during the perfusion, a sterile lucite filter lined with silk mesh 
was placed in the system. Between perfusions the apparatus was dismantled and 
washed with Micro disinfectant, rinsed and dried in a 300 °F oven. The apparatus 
was reassembled and rinsed twice with 150 ml of sterile irrigation normal saline. 
Prior to initiation of experiments, the empirical determination of TNF and 
IL-6 stability during the perfusion period was required. Recombinant murine TNF 
Pump 
Gas exchange 
tube I 
"lung" 
Humidifier 
Manometer 
Perfusion 
Fig. 8. Diagram of the liver perfusion apparatus 
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or recombinant murine IL-6 was added to KRB + 5% BSA at a concentration of 
1 ng/ml was recirculated through the system under the normal perfusion 
conditions without the presence of a liver for one hour. 100 µI of perfusate was 
removed every 5 minutes and immediately frozen. The perfusate was then 
analyzed for TNF and IL-6. 
3. Liver Removal 
Removal of the liver was performed under sterile conditions. All 
instruments, gauze sponges, suture and cannulas were previously gas sterilized 
or autoclaved to reduce contamination. 
Fasted, treated rats were injected i.p. with sodium pentobarbital to induce 
pain insensivitity. The level of anesthetic was assessed by unresponsiveness to 
a tail pinch. The rat was placed supine on a prewarmed metal tray and the 
abdomen was swabbed with betaine and 70% ethanol. A midline incision was 
made from the level of the pubic symphysis caudally to the xiphoid process just 
below the diaphragm. Two lateral incisions were made below the diaphragm left 
along the ribcage to the distal edge of the spleen and right along the ribcage to 
the distal edge of the liver. The intestines and mesentery were reflected to the 
animal's left and placed on sterile gauze soaked in sterile normal saline. This 
procedure exposed the portal vein. The connective tissue ligature attaching the 
posterior lobule of the right lobe of the liver to the fascia surrounding the 
abdominal vena cava was cut, and a 5 cm 3-0 suture was placed around the vena 
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cava above the renal veins but not tied. Another 5 cm suture was placed around 
the distal end of the portal vein but not tied. A final 5 cm suture was placed 
around the proximal end of the portal vein above the termination of the lineal vein. 
Heparin (Upjohn, Kalamazoo, Ml) (500 U/rat) was injected into the dorsal penile 
vein and allowed to circulate for 6 minutes prior to continuation of the surgery. 
During this time period the anterior lobule of the right lobe and the Spigelian lobe 
were freed from the surrounding connective tissue. At the end of 6 minutes, the 
sutures surrounding the vena cava and the distal end of the portal vein were 
securely tied. A small incision was made in the portal vein, and a cannula (PE 
260 tubing) was inserted into the portal vein and securely tied. The cannula was 
immediately flushed with warm KRB. The chest cavity was opened to expose the 
heart, and a suture was placed around the thoracic inferior vena cava. A 1 cm 
cannula (PE 280 tubing) was inserted through the right atrium into the inferior 
vena cava and tied with a suture. The liver was quickly excised from the 
abdominal cavity and continuously flushed with warm, KRB until the fluid from the 
liver was free of red blood cells. The liver was then placed into the perfusion-
aeration apparatus chamber within 4 minutes of the tying of the first suture 
surrounding the vena cava. 
4. Liver Perfusion 
Prior to the introduction of the liver into the perfusion-aeration apparatus, 
the perfusion reservoir was filled with 100 ml of KRB + 5% BSA which circulated 
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through the system until the buffer reached a temperature of 37 °C. The excised 
liver was placed on moistened sterile gauze on a glass platform. The inflow 
cannula was connected to the perfusion tubing, and flow was established. The 
outflow was adjusted such that all lobes of the liver were perfused without undue 
distension. The temperature of the liver was maintained at 37 °C as measured by 
a thermistor placed between the lobes of the liver. Perfusion flow was kept 
constant between 30 - 35 ml/min. Flow did not fluctuate during the one hour 
perfusion period. 
Once flow had been stabilized(< 2 minutes), a 200 µI sample of perfusate 
was removed from the reservoir at 0, 5, 10, 15, 20, 25, 30, 40, 50, and 60 
minutes after the initiation of flow. Flow was measured at 10 minute intervals 
during the perfusion. The perfusate samples were kept on ice and frozen at -20 
°C until analysis. At the conclusion of the experiment, the liver was removed and 
gently dried with absorbent paper and weighed. Perfusate samples were 
analyzed for glucose, lactate, TNF and IL-6. 
G. In Vitro Studies 
The in vivo response to endotoxicosis is a complicated progression of 
metabolic, cardiovascular, neural and immunological events that blend into an 
infinite number of combinations and permutations. To determine the contribution 
of a particular cell population to the response and to study the cellular 
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mechanisms of these interactions in vivo often represents an insurmountable task. 
In an effort to elucidate the mechanisms of action of insulin and dexamethasone 
on TNF and IL-6 production by macrophages, the following series of experiments 
was designed and tested initially in two cell lines as well as in two primary 
macrophage populations. 
1. Cell Preparation and Cell Lines 
ANA1 or RAW 264.7 cells were maintained in 75 ml tissue culture stock 
flasks in RPMI 1640 with 5% fetal calf serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin (1X antibiotics) and 2 mM glutamine. The cells were split at a 1 :30 
dilution upon reaching confluence, approximately once a week. For experiments, 
a stock flask was pipetted into a 50 ml conical centrifuge tube and centrifuged for 
10 minutes at 3000 rpm. The medium was removed, and fresh medium was 
added to the cells. A 200 µI sample of cells was taken and diluted to 1 ml with 
400 µI of RPMI 1640 and 400 µI 10% trypan blue and vortexed. A sample was 
placed on a hemocytometer, and viable cells were microscopically counted. 
The cells were then diluted in medium to 106 cells per ml and plated in 24 
well cell culture plates at 1 ml total volume /well. The cells were "rested" for 24 
hours, the old media was aspirated, and new medium was added. 
2. Experimental Design 
The basic experimental design is illustrated in fig. 9. Cells were initially 
DEXAMETHASONE ACETATE 
( 100 nM ) 
' 3hr. 
ENDOTOXIN ( S. enteriditis) 
( 1 or 100 ng/ml) 
) ~hr. 
PMA ( 1 nM) 
INSULIN ( 100 uU/ml) 
• 
saline or diluent 
H-7 ( 1 ug/ml) 
indomethacin ( 1 O ug/ml ) 
cycloheximide ( 1 0 ug/ml ) 
okadaic acid ( 1 O ng/ml ) 
IGF-1 ( 1 Ong/ml) 
• 16hra. 
Harvest Media .. 
IGF-1 (10 ng/ml) 
TNF and 
IL-6 Assays 
Fig. 9. Basic treatment protocol for the cell culture experiments. 
•. 
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treated with 100 nM dexamethasone phosphate or an equal volume of PBS. At 
3 hours post-dexamethasone, 1 or 10 ng/ml S. enteritidis endotoxin or saline was 
administered to the cells. Finally, at one hour post-endotoxin, insulin (100 µU/ml) 
or saline was added to the cells. The medium in each well was then harvested at 
16 hours after endotoxin addition. In the time course experiments, media was 
harvested at 2, 4, 8, 12, 16 and 24 hours post endotoxin. The medium samples 
were frozen at -20 °C until analysis for TNF, IL-6, glucose and lactate. 
In a separate set of experiments, designed to elucidate the mechanisms 
of insulin action in these cells, several agents were employed in combination with 
the basic protocol illustrated in fig. 9. To examine the role of PGE2 in this system, 
indomethacin (1 µM) was added with insulin. H-7 (1 µM) an inhibitor of protein 
kinase C was added with insulin. PMA was added to examine if insulin was acting 
as a phorbol-mimetic. Cycloheximide ( 1 µM) was added to examine if insulin 
was acting via synthesis of RNases. Okadaic acid was added to establish if the 
blocking of a phosphatase, which regulates PKC actions, was involved. IGF-1 was 
added to examine if insulin was acting like IGF-1 as a stimulator of cytokine 
production. 
3. Primary Cultures 
.fil Peritoneal Macrophages 
Peritoneal macrophages were obtained using a modified method described 
by Doherty et al., 1992, (84). Male Holtzman rats were injected i.p. with 10 ml of 
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10% thioglycollate broth (Difeo, Detroit, Ml). Four days post injection, the animals 
were killed by C02 narcosis and the abdomens were lavaged with 60 ml of sterile 
PBS. The lavage fluid was centrifuged for 10 minutes at 3000 rpm, and the fluid 
was aspirated leaving a cell pellet. To remove contaminant red blood cells, the 
pellet was washed with 2 ml of ACK Lysing Buffer ( Quality Biological, Inc. 
Gaithersburg, MD) and resuspended in 20 ml RPMI 1640. Ten ml of Lymphocyte 
Separation Media (LSM) (Organon Teknika, Durham, NC) was carefully added to 
the cell suspension as an under layer. This mixture was then centrifuged at 3000 
rpm for 30 minutes to remove dead cells and contaminating debris. The cells were 
aspirated from the interface between the LSM and the RPMI and resuspended in 
RPMI with 3 times normal concentration of antibiotics (3X), washed and 
centrifuged 3 times in RPMI with 3X antibiotics. After the third centrifugation the 
medium was aspirated and the cells were resuspended in RPMI with antibiotics. 
An aliquot of the cells was removed to determine total number of cells and also 
to determine cell types present in the peritoneal lavage fluid. The cells were 
diluted to 106 cells/ml, and 1 ml of cell suspension was added to each well of 24 
well tissue culture plates. Two hours later, the medium was aspirated from each 
well to remove nonadherent cells and 1 ml of fresh RPMI was added to each well. 
Twenty-four hours later, the media was again removed from the wells and fresh 
medium was added. The cells were then allowed to incubate for 24 hours prior 
to experimentation. 
The treatment protocol illustrated in figure 9 was utilized for experiments 
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on the peritoneal macrophages cells. To examine the roles of second messenger 
systems in these cells the compounds described above were utilized. 
Q}. Kupffer Cells 
Kupffer cells were obtained according to the procedure described by Pilaro 
et al., 1989, (261). Male Holtzman rats were anesthetized and the liver was 
isolated and excised according to the procedure described in the liver perfusion 
experiments. The liver was initially perfused for 5 minutes at 20 ml/min with 100 
ml of Hanks Balanced saline (HBSS) (Ca2+/Mg2+ free) buffered with 25mM HEPES 
and contained 0.5mM EGTA at pH 7.2. The pump was then stopped; the tubing 
was attached to a second reservoir containing 100 ml of Leibovitz's (L-15) 
medium buffered with 25 mM HEPES, pH 7 .2, which contained 300 mg pronase 
E, 20,000 U collagenase type IV, 10,000 IU penicillin and 10,000 µg streptomycin. 
The pump was restarted and perfusion of the liver was continued for 10 minutes 
or until the parenchymal cell mass separated away from the liver capsule. The 
perfusion was stopped, and the liver was transferred to a sterile petri dish 
containing 20 ml of L-15 media. 
The liver capsule was cut with sterile scissors, and a sterile wide toothed 
metal comb was dragged through the liver to obtain a uniform cell suspension. 
The cell suspension was transferred to a sterile Erlenmeyer flask containing 20 
ml L-15, pronase E and a small stir bar. The volume was brought to 100 ml with 
L-15 and incubated for 15 minutes in a 37 °C water bath. Five ml of 1 mg/ml 
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DNase (Sigma, St. Louis Mo) was added to the mixture and digestion continued 
until no visible tissue remained (45 minutes). The suspension was filtered through 
60-70 µm nylon mesh into two 50 ml sterile centrifuge tubes and centrifuged at 
50 x g for 1 minute at 4 °C to remove the hepatocytes. The supernant was 
transferred to sterile 50 ml centrifuge tubes and centrifuged at 300 x g for 5 
minutes at 4 °C to pellet the nonparenchymal cells. The hepatocyte pellets were 
resuspended in 1 O ml of L-15 and centrifuged at 50 x g for 1 minute. The 
supernant was removed and centrifuged to pellet the nonparenchymal cells. Each 
nonparenchymal pellet was resuspended in 10 ml of L-15 and combined. The 
suspension was centrifuged for 10 minutes to pellet the nonparenchymal cells. 
The cells were washed 4 times in total. After the last wash, the pellet was 
resuspended in 5 ml of L-15 in preparation for gradient centrifugation. 
A two step gradient was used to separate the Kupffer cells from other 
nonparenchymal cells. A 30% metrizamide solution, pH 7.5, was made by adding 
30 g metrizamide to 100 ml of NaCl-free Gey's balanced salt solution. In a 15 ml 
sterile tube, 3 ml of 30% metrizamide and 2 ml of L-15 was added to form the 
18% bottom layer. The 13% top layer was formed by adding 5 ml of cells to 4 ml 
of 30% metrizamide and mixed well. This layer was gently layered on top of the 
18% layer. The gradients were centrifuged at 1400 x g, 16 °C for 20 minutes. The 
Kupffer cells were collected from bands in the interface between the two gradients 
and reconstituted to 50 ml with L-15. The cells were centrifuged at 500 x g for 5 
minutes to pellet the cells. 
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The cells were resupended in 10 ml and an aliquot was taken for 
differential staining and counting. The remaining suspension was diluted to 106 
cells per ml in DMEM, 10% FBS, 4mM glutamine and 1 % penicillin/streptomycin 
and plated into 96 well tissue culture plates. This isolation procedure resulted in 
a 83% yield of Kupffer cells as assessed by peroxidase staining. 
The cells were allowed to attach for 4 hours, and the medium was removed 
and new medium was added. The cells incubated for 48 hours prior to 
experimentation. The cells were treated with the basic treatment protocol used for 
the ANA1 cells described previously in fig. 9. 
H. Assays 
1. Glucose and Lactate Measurements 
A YSI model 2300A glucose/lactate monitor was utilized to analyze plasma, 
perfusate and cell culture media samples. The sensor technology is based on the 
principles conceived by Dr. Leland Clark, Children's Hospital Foundation, 
Cincinnati, OH. The instrument contains two probes fitted with a three layer 
membrane containing immobilized glucose oxidase or L-lactate oxidase in the 
middle layer. The sample (25 µI) is injected into a buffer filled chamber (600 µI) 
where the tip of the probe is situated. The substrate diffuses through the 
membrane and on contact with the enzymes is oxidized producing hydrogen 
peroxide (H20 2). 
D-glucose + 0 2 -------- > glucono-k-lactone + H20 2 
glucose oxidase 
L-lactate + 0 2 ---------.> pyruvate + H20 2 
L-lactate oxidase 
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The hydrogen peroxide is in turn oxidized at a platinum electrode producing 
electrons. 
------> 2H+ + 0 2 + 2e· 
platinum electrode 
The electron flow is linearly proportional to the steady state H20 2 concentration 
and, therefore, proportional to the concentration of glucose or lactate. To prevent 
the oxidation of substances other than hydrogen peroxide from adding to the 
sensor current, the membrane contains an inner layer consisting of a very fine 
film of cellulose acetate. However, this film passes H20 2 readily, and excludes 
compounds with molecular weights greater than 200. 
Prior to analysis of the samples, the instrument is calibrated with two 
standards. One standard contains 500 mg/dl glucose, lactate free; the other 
standard contains 15 mmol/L lactate, glucose free. 
2. Insulin 
Insulin was measured in plasma for the in vivo experiments. This procedure 
involved the use of a double antibody radioimmunoassay ( Binax, South Portland, 
Maine) This assay had a sensitivity level of 2.0 µU/ml and an interassay 
coefficient of variability of less than 5%. 
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3. Tumor Necrosis Factor 
fil Enzyme-Linked lmmunoadsorbent Assay (ELISA) 
Tumor necrosis factor was measured in plasma, perfusate and cell culture 
medium using a specific test kit for murine TNFa. The Factor-Test mTNF-a ELISA 
( Genzyme, Cambridge, MA) is a solid-phase enzyme immunoassay employing 
the multiple antibody sandwich principle. A hamster monoclonal antibody specific 
for murine TNFa is coated on microtiter wells in a 96-well plate. TNF present in 
standard samples and unknown specimens is captured by the solid-phase 
monoclonal antibody. A goat anti-murine TNF antibody, which binds to multiple 
epitopes on the TNF contained on the solid-phase is added. A third antibody, 
horseradish peroxidase-conjugated donkey anti-goat lg is used to bind to the anti-
murine TNF:murine TNF immune complexes. The peroxide enzyme reacts with 
peroxide substrate and a chromagen (OPD) to produce a yellow color proportional 
in intensity to the amount of TNF present. Color intensity is quantitated by 
measuring absorbance at 492 nm using an ELISA plate reader (Titertek, ICN, 
Irvine, CA). A reference standard curve is plotted using the mean absorbance of 
several concentrations of TNF ranging from 0.05 ng/ml to 3.2 ng/ml (fig. 10). The 
TNF levels in the experimental samples were determined from the linear 
regression equation generated from the standard curve. 
At the time of these experiments, rat TNFa was unavailable for complete 
validation of the TNF ELISA. Since the monoclonal antibody against murine TNF 
is of hamster and not rat origin, and Estler et al.,1992, (98) have recently 
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demonstrated that a 92 % homology exists between the biologically active forms 
of mouse and rat TNF , we feel confident that rat TNF can be measured in this 
system. 
Ql Bioassay 
Selected samples of rat perfusate, plasma and cell culture medium were 
analyzed using the L929 cytotoxicity assay (114, 258) and compared to the 
results obtained in the ELISA. The cytotoxicity assay measures the effect of TN Fa 
on the L929 mouse myeloma cells as described previously by Flick et al., 1984, 
(114). Briefly, L929 cells are cultured in 96 well microtiter plates at a 
concentration of 150,000 cells/ml in DME + 5% FBS for 24 hours. 100 pl of 
medium is added to the first three wells. The rest of the plate received 50 pl of 
4 pg/ml actinomycin D (Calbiochem, San Diego CA) to inhibit DNA synthesis. 50 
pl of murine TNF standard protein was added at several dilutions to generate a 
standard curve, and 50 pl of test sample was added in triplicate to the rest of the 
wells. A typical standard curve is illustrated in fig. 11. The plate was incubated 
for 18 hours at 37 °C. The wells were washed twice with PBS and 100 pl of 0.2% 
crystal violet in 2% ethanol and stained for 1 O minutes. The plate was rinsed with 
tap water and then air dried. The stained cells were solubilized with 200 pl 1 % 
sodium dodecyl sulfate (SOS). Absorbance was determined at 550 nm using an 
ELISA plate reader (Titertek, ICN, Irvine, CA). The TNF concentration was 
determined from the standard curve from each assay. 
. 
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4. Interleukin 6 
fil ELISA 
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The interleukin 6 content of media from experiments involving ANA 1 and 
RAW 264.7 cells was measured using an ELISA specific for murine interleukin 6 
(Endogen, Boston, MA). The principle of this assay is similar to that described for 
the ELISA for murine TNFa. A representative standard curve for this assay is 
illustrated in fig. 12. 
Ql Bioassay 
Samples of rat plasma, perfusate and cell culture medium from the 
peritoneal and Kupffer cells were analyzed for IL-6 using the 89 proliferation 
assay as described by Aarden et al., 1987 (1). 89 cells are murine hybridoma 
cells dependent on IL-6 for growth (194). 89 cells were cultured in lscove's 
Modified Dulbecco's Medium (IMDM) with 5% FBS, 5x10-5 M 2-mercaptoethanol 
and 1 % penicillin-streptomycin. The medium was supplemented with IL-6 at 10-
100 U/ml for maintaining the cells. For the assay, cells were washed 3 times to 
remove all residual IL-6 and 2500 cells in 50µ1 of IMDM were added to each well 
of 96 well microtiter plates. Samples and standards were diluted to a minimum 
dilution of 1: 1 O and 50 µI is added to each well. Rat interleukin 6 (courtesy of Dr. 
J. Gauldie) and recombinant human interleukin 6 were used to generate standard 
curves for this assay. (fig. 13). The plates were incubated for 72 hours at 37 °C 
in 5% C02• After 72 hours 10 µI of 3-[4, 5-dimethylthiazol-2-yl] -2,5-
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diphenyltetrazolium bromide (MTT) were added to each well and incubated for 4 
hours. 50 µI Triton X was added to each well until color has fully developed 
(overnight). Absorbance was measured at 550 nm. 
5. Endotoxin 
Endotoxin content of perfusates and pharmacological reagents used in the 
experiments was determined using the Limulus Amebocyte Lysate Assay (LAL) 
(Whittaker, Walkersville.MD). The chromogenic LAL assay is a quantitative 
measure for gram-negative bacterial endotoxin. This assay is based on the 
principle developed by Levin and Bang,(1964), that endotoxin catalyses the 
activation of the proenzyme of LAL to the active form. The initial rate of activation 
is determined by the concentration of endotoxin present. The activated enzyme 
catalyzes the formation of p-nitroaniline (a yellow colored compound) from a 
colorless peptide substrate, Ac-lle-Ala-Arg-pNA. The p-nitroanaline is measured 
photometrically at 405 nM. The assay is linear between the 0.02-0.10 ng/ml 
range. The concentration of endotoxin in the samples was calculated from the 
standard curve (fig.14). 
1. Statistics 
Results are reported as mean ± standard error of the mean. Chi squared 
analysis was performed on the lethality data. A one way Anova followed by a 
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Tukey's post hoc test was performed on plasma glucose, lactate and insulin data 
from the in vivo experiments and on the data from the cell culture studies. A 
multiple variate analysis (treatment, time) with repeated measures was performed 
on the in vivo measurements and on the data from the liver perfusion 
experiments. In each case significance was accepted at p<0.05. 
A. In Vivo Projects 
CHAPTER IV 
RESULTS 
1. The Effect of Exogenous Insulin Administration and Endogenous Insulin 
Secretion on Lethality and Glucose Homeostasis. 
The graphs used to illustrate the effects of exogenous and endogenous 
insulin on mortality and metabolic homeostasis are depicted in figs. 15, 16, 17 
and 18. Each treatment group contained 8 to 15 animals. Mortality was 
determined after 12 hours, and the metabolic parameters, plasma glucose, lactate 
and insulin were measured approximately two hours after insulin administration 
as two of the treatment groups survival time was only within the two hour window 
after insulin. Dexamethasone, DEX, or saline was administered at 0.33 mg/kg, 
i.p., 3 hours prior to an injection of 20 mg/kg S. enteritidis endotoxin, ETX, or 
saline, i.p. One hour after ETX, insulin, INS, (1 U) or saline was injected, s.c. To 
determine the effect of endogenously produced insulin in this system, tolbutamide, 
TOL, was administered (66 mg/kg) in substitution for insulin. Insulin, 
dexamethasone and tolbutamide were tested for endotoxin contamination using 
LAL tests. The endotoxin contamination for these substances was ~ 0.1 ng/ml. 
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Fig. 15 depicts the mortality observed among the treatment groups. 
In this particular study 20 mg/kg of S. enteritidis endotoxin administered 
intraperitoneally resulted in a 66% mortality over 12 hours. Insulin ( 1 U) 
administered one hour after endotoxin increased mortality to 100 %. All rats died 
within two hours after insulin administration. Laparotomy revealed that both the 
upper and lower intestinal tracts were dark purple and congested with petechiae 
and hemorrhages for both the ETX and the ETX/INS treatment groups. 
Tolbutamide treatment alone had no lethal effects on the rats. However , 
ETX/TOL treatment resulted in 100% mortality after 12 hours. These animals died 
within the 12 hours, however, later than the two hour period observed in the 
ETX/INS group. The examination of the intestinal tract in these animals revealed 
large regions of hemorrhage similar in degree to that observed in the ETX/INS 
group. 
The administration of 0.33 mg/kg dexamethasone 3 hours prior to 
endotoxin administration significantly reduced mortality to 6.25%. When insulin 
was administered to a dexamethasone protected group, DEX/ETX/INS, mortality 
was significantly reversed and increased to 75%. The appearance of the bowel 
on autopsy also exhibited increased areas of petechiae and hemorrhaging in 
comparison to the DEX/ETX group which demonstrated only minimal and isolated 
areas of petechiae. However, the bowel pathology observed in the DEX/ETX/INS 
group was not of a comparable degree of intensity as that observed in the 
ETX/INS group. Administration of tolbutamide to dexamethasone protected rats, 
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DEX/ETX/TOL, significantly increased mortality from 6.25% to 58%. These 
animals exhibited only limited areas of petechiae on pathological examination of 
the intestinal tract. The control groups illustrated in fig.15, insulin, INS, 
dexamethasone, DEX, and the combination, DEX/INS did not die as a result of 
the treatments. These groups did not have any gross evidence of bowel 
pathology upon autopsy. 
The plasma glucose concentration of the saline control group was 101. 7 
± 6.2 mg/dl. As illustrated in fig. 16 insulin treatment alone caused a mild 
hypoglycemia and resulted in a plasma glucose of 77.8 ± 6.5 mg/dl. This value 
was not significantly different from the plasma glucose concentration (81.8 ± 6.9 
mg/dl) in the ETX treated animals. Endotoxin and insulin in combination 
significantly decreased plasma glucose concentrations (8.1 ± 3.3 mg/dl) and a 
profound hypoglycemia was observed . TOL administration caused a decrease in 
glucose (83.8 ± 5.8 dl) that was not significantly different from ETX or INS 
alone. Plasma glucose concentration of the ETX/TOL group was significantly 
reduced to 5.9 ± 2.2 mg/dl. 
The DEX/ETX animals exhibited a mild hyperglycemia (135.6 ± 8.1 mg/dl) 
which was not significantly different from the DEX alone treatment group (129.2 
± 5.1 mg/dl). Insulin treatment resulted in a significantly reduced the plasma 
glucose level in the DEX/ETX/INS group (16.7 ± 6.6 mg/dl). Tolbutamide 
substituted for insulin resulted in a similar decline in plasma glucose in the 
DEX/ETX/TOL group (31.4 ± 3.8 mg/dl) however, not to the same intensity as 
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Fig. 16. The effect of exogenous and tolbutamide stimulated insulin secretion on plasma glucose in endotoxic 
and dexamethasone protected endotoxic rats. Plasma was collected at 3 hours post endotoxin administration. 
DEX= dexamethasone (0.33 mg/kg); ETX = endotoxin ( 20 mg/kg); INS= insulin (1 U); TOL = tolbutamide 
(66 mg/kg). The bars represent the means + SEM for each group. The solid line indicates plasma glucose 
concentration of saline treated rats. * p < 0.05 compares ETX to ETX/INS and ETXITOL. 
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that observed in the DEX/ETX/INS group. 
The mean plasma lactate concentration of the saline treated animals was 
1.8 ± 0.06 mmol/L. Endotoxin treatment significantly increased plasma lactate 
values to 2.75 ± 0.35 mmol/L as depicted in fig. 17. ETX/INS treatment and 
ETX/TOL treatments profoundly elevated plasma lactate concentrations to 7.9 ± 
1.19 mmol/L and 6.8 ± 1.34 mmol/L respectively. Insulin or tolbutamide without 
endotoxin did not alter plasma lactate concentrations. 
Dexamethasone pretreatment of the endotoxic group did not significantly 
alter lactate values above those of ETX alone (2.5 ± 0.28 mmol/L). Insulin 
posttreatment of the DEX/ETX group significantly increased plasma lactates to 7.4 
± 1.5 mmol/L. However, TOL, posttreatment did not alter plasma lactates (2.28 
± .41 mmol/L ) above those of the ETX group. 
Plasma insulin concentrations illustrated in fig. 18 indicated that saline 
treated animals had a fasting insulin level of 18.5 ± 8.1 µU. Endotoxin elevated 
plasma insulin concentrations to 40.2 ± 5.4 µU. All treatment groups administered 
insulin exogenously had significantly elevated levels of plasma insulin. INS alone 
increased plasma insulin to 85 µU. Plasma insulin concentration of the ETX/INS 
group was 165 ± 27.6 µU. Tolbutamide did increase plasma insulin in the 
ETX/TOL group ,(68.3 ± 7.0 µU) however, not statistically above that of endotoxin 
alone. 
The DEX/ETX group had elevated plasma insulin concentrations (65.8 ± 
5.6 µU) however, these were not different from the ETX group. DEX/ETX/INS 
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Fig. 17. The effect of exogenous and tolbutamide stimulated insulin secretion on plasma lactate in endotoxic and 
dexamethasone protected endotoxic rats. Plasma was collected at 3 hours post endotoxin administration. DEX 
= dexamethasone (0.33 mg/kg); ETX = endotoxin ( 20 mg/kg); INS= insulin (1 U); TOL = tolbutamide 
· (66 mg/kg). The bars represent the means + SEM for each group. The solid line indicates plasma lactate 
concentration of saline treated rats. * p < 0.05 compares ETX to ETX/INS and ETX/TOL. 
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treatment elevated plasma insulin to 136 ± 27.7 µU. DEX/ETXITOL treatment 
however, only mildly increased plasma insulin (54.8 ± 4.3 µU). DEX alone 
suppressed insulin secretion and DEXITOL treatment caused plasma insulin 
concentrations to equal that observed by ETX treatment (44.4 ± 4.4 µU vs. 40.2 
± 5.4 µU). 
2. The Effect of Insulin Dose on Mortality 
Table 6 summarizes the results of administering three different doses of 
insulin, 1 U, 0.5 U or 0.25 U of insulin on mortality 12 hours after insulin injection. 
Insulin administered without endotoxin was not lethal to the rats at any of 
the three doses. Dexamethasone and insulin in combination was also obsereved 
to be not lethal. Endotoxin mortality as shown in figure 15 was 61 %. With the 
addition of 1 U or 0.5 U of insulin to endotoxic rats mortality was increased to 
100%. The addition of 0.25 U resulted in mortality that was not different from 
endotoxin treatment alone. Dexamethasone pretreatment of endotoxic rats 
reduced mortality from 61 % to 6.25%. The addition of 1 U of insulin to the 
dexamethasone protected group increased mortality to 75%. This increase in 
mortality (75%) was also observed with the addition of 0.5 U of insulin to the 
dexamethasone-protected group. However, the mortality observed when 0.25 U 
of insulin was administered to dexamethasone-protected rats was not significantly 
altered from that observed with endotoxin treatment alone. 
Table 6 --The effect of insulin dose on mortality in endotoxic 
and control rats 
Insulin dose 1 u 0.5 u 0.25 u 
INS 0 % ( 0/15) 0% ( 0/8) 0% ( 0/8) 
ETX/INS 100%15/15) 100 %( 8/8) 63% ( 5/8) 
DEXIETX/INS 75% (11/15) 75 % (6/8) 63% (5/8) 
D/INS 0 % ( 0/15) 0% ( 0/8) 0% ( 0/8) 
ETX = endotoxin; INS = insulin; DEX = dexamethasone. 
( ) = mortality per group 
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3. The Effect of Restoring Euglycemia on Mortality 
Profound hypoglycemia was observed in the ETX/INS and the 
DEX/ETX/INS treatment groups. To determine if restoring euglycemia would be 
effective in countering the lethal effects of these treatment regimes, 5% dextrose 
solution was injected intraperitoneally and plasma glucose was monitored for 2 
hours post insulin treatment. 
Table 7 compares mortality rates in the treatments administered dextrose 
during the experiment and the plasma glucose concentrations immediately prior 
to death. It was almost impossible to maintain euglycemia over the two hour 
period and plasma glucose concentrations fluctuated dramatically in the ETX/INS 
and the DEX/ETX/INS groups. As shown in table 7 administration of dextrose did 
not alter mortality in the E/I treated and DIE/I treated groups even though plasma 
glucose concentrations were 71.8 ± 9.4 mg/dL and 86.5 ± 5.3 mg/dL respectively. 
Dextrose treatment also significantly increased plasma glucose (122.6 ± 8.2 
mg/dL) and mortality in the ETX treatment group. 
4. The Effect of PMA and H-7 on Mortality 
To determine if the effect of insulin on mortality was via the activation of 
the protein kinase C pathway, two experiments were designed. First, phorbol 
myristate acetate, PMA, a PKC activator, was substituted for insulin in the 
protocol described above. Secondly, H-7, a blocker of protein kinase C activity, 
was coadministered with insulin to examine if insulin action could be altered.' 
111 
Table 7-- Effect of dextrose (05) treatment on plasma glucose concentrations 
and mortality . 
Plasma Glucose (mg/dl) Mortality 
Treatment - 05 + 05 - 05 
ETX 81.8 ± 12.9 122.6 ± 8.2 * 11/15 
ETX/INS 8.1 ± 3.2 71.8 ± 9.4 * 15/15 
DEX/ETX/INS 16.6 ± 6.5 86.5 ± 5.3 * 12/15 
ETX = endotoxin; INS = insulin; DEX = dexamethasone. 
* p < 0.05 compares no dextrose (-05) to dextrose ( + 05). 
ns no significant difference. 
Mortality 
+ 05 
616 .. 
616 .. 
5/6 1111 
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Table 8 depicts the effect of this treatment regime on mortality over 12 hours. 
PMA treatment did not cause mortality nor did the DMSO based diluent used to 
dissolve the PMA. ETX/PMA treatment produced 100% mortality. DEX/ETX/PMA 
treatment increased mortality from 6.25% in the DEX/ETX group to 80 %. 
When H-7 was administered with insulin, H-7 was unable to reduce or alter 
mortality in any of the test groups. H-7 also had no effect on the survival of the 
groups that did not receive insulin. 
8. In Vivo Cytokine Measurements 
1. The Effect of Insulin on Cytokine Production in the Endotoxic Rat. 
In this study the effect of insulin on TNF and IL-6 production in an in vivo 
setting was evaluated. Initially, however, plasma glucose and lactate 
concentrations were obtained. Fig. 19 illustrates the plasma glucose responses 
of the various treatments groups over 180 minutes. Endotoxin treatment 
stimulated a rapid increase in plasma glucose to a maximum value of 161 ± 5.8 
mg/dl, approximately 90 minutes post endotoxin. This hyperglycemia was then 
observed to decrease over time to within normal range by the end of the 180 
minute sampling period. Insulin post-treatment (ETX/INS) incited a profound 
hypoglycemia (10.3 ± 3.79 mg/LI at 120 minutes) such that the rats died prior 
to the 150 minute sampling point. Dexamethasone pretreatment of endotoxic rats 
Table 8--The effect of PMA and H-7 on mortality in endotoxic and 
dexamethasone protected endotoxic rats. 
Treatment Mortality 
PMA 0% (0/6) 
ETX/PMA 93% (13/14) 
DEX/PMA 0% (0/6) 
DEX/ETX/PMA 80% (12/15) 
ETX/H-7 63% (5/8) 
ETX/1NS/H-7 100% (8/8) 
DEX/ETX/H-7 12.5% (1/8) 
DEX/ETX/I NS/H-7 75% (6/8) 
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(DEX/ETX) did not alter glucose above that of endotoxin treatment (169.5 ± 16.3 
mg/dl), however, the dexamethasone induced hyperglycemia persisted until 180 
minutes even though the plasma glucose concentration of the ETX group was 
declining. Insulin post-treatment of dexamethasone-protected endotoxic rats 
(DEX/ETX/INS) markedly decreased plasma glucose concentrations over time. 
The decline in plasma glucose was less dramatic than without dexamethasone 
pretreatment and the rats in this group survived to the end of the 180 minute 
sampling period. Insulin ,INS, alone initiated a mild hypoglycemia (76.9 ± 3.71 
mg/dl) that remained constant over the time course. Dexamethasone, DEX, and 
in combination with insulin, DEX/INS treatments did not alter plasma glucose 
significantly from saline controls over the experimental time course. 
Plasma lactate values as illustrated in fig. 20 were significantly increased 
by endotoxin over time. The maximum lactate concentrations were observed at 
105 minutes after endotoxin to be 4. 75 ± 0. 75 mmol/L. Although not statistically 
different, increased plasma lactate concentrations above that of endotoxin 
treatment were observed in the ETX/INS group. The maximum plasma lactate 
value observed was 5.1 ± 1.8 mmol/L at 120 minutes post endotoxin. DEX/ETX 
treatment reduced plasma lactate concentrations significantly below those of ETX 
and ETX/INS over the entire time course. The maximum plasma lactate values 
observed were 3.2 ± 0.48 mmol/L at 180 minutes. DEX/ETX/INS treatment did 
not significantly alter plasma lactate concentrations from those in the DEX/ETX 
treatment group. 
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Fig. 20. Plasma lactate response to an insulin challenge in endotoxic and dexamethasone protected 
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Administration of endotoxin resulted in an almost typical response in 
plasma TNF as illustrated in fig. 21 . TNF appeared in the plasma 60 minutes 
post -endotoxin, peaked maximally (3. 72 ± 0.845 ng/ml) at 90 minutes and was 
almost absent from the plasma (0.375 ± 0. 412 ng/ml) at 180 minutes. ETX/INS 
treatment did not alter TNF concentrations significantly from the ETX group until 
120 minutes post endotoxin. The plasma TNF in this group at this time point was 
sustained at 3.32 ± 1.0 ng/ml and appeared to be increasing whereas the ETX 
group TNF response (2.2 ± 0.768 ng/ml) was in the initial phase of decline. 
Dexamethasone pretreatment had a significant effect on the production of TNF 
in the DEX/ETX group. TNF was completely suppressed and did not appear until 
90 minutes post endotoxin. Peak values were significantly reduced in comparison 
to the ETX group (0.558 ng/ml vs. 3. 72 ng/ml). Insulin post treatment of the 
DEX/ETX/INS group elevated TNF at 75 minutes post endotoxin and maximum 
levels were observed at 90 minutes post endotoxin (1.35 ± 0.986 ng/ml). This 
elevation in TNF was significantly different, p < 0.05, from the DEX/ETX group. 
INS, DEX or DEX/INS without endotoxin did not ellicit a response in plasma TNF. 
Plasma IL-6 was not observed to be present in significant amounts until 
120 minutes post endotoxin (table 9). Endotoxin treatment caused a significant 
increase in IL-6. This increase was maximal at 180 minutes (2.964 ± 0.369 
ng/ml). ETX/INS treatment resulted in a significant increase in IL-6 at 120 minutes 
(638.1 ± 187.3 pg/ml). Values at 150 and 180 minutes were not obtained due to 
the death of the animals. Dexamethasone pretreatment suppressed IL-6 until 150 
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Table 9-- Plasma IL-6 production by endotoxic and dexamethasone 
protected endotoxic rats in response to an insulin injection. 
0 minutes 120 minutes 150 minutes 180 minutes 
119 
E 20.9 ± 2.1 152.1 ± 43.1 1621.3 ± 59.1 2964.5 ± 369.5 
E/I 23.2 ± 3.3 638.1 ± 87.3* N/D N/D 
DIE 18.9 ± 1.4* 23.9 ± 4.3* 322.0 ± 159.3* 77.1 ± 46.04* 
DIE/I 19.1 ± 1.3 22.0 ± 1.2 142.1 ± 91.4 295.2 ± 70.1 
Values represent the mean ± SEM for each treatment group ( n = 6/group) in 
pg/ml at 0, 120, 150 and 180 minutes post endotoxin. 
E = endotoxin; I =insulin; and D = dexamethasone. 
N/D = not determined due to lethality. 
* p < 0.05 compares E to E/I and E to DIE at the same time point. 
120 
minutes post endotoxin although maximal values were significantly below those 
of endotoxin alone. DEX/ETX/INS treatment increased IL-6 above that of 
DEX/ETX treatment alone at 180 minutes, although not statistically significant. 
Fig. 22 compares plasma glucose and TNF concentrations in a model of 
insulin induced hypoglycemia. Plasma glucose concentrations fell dramatically in 
response to a 5 U challenge of insulin, s.c., plasma TNF concentrations over the 
time period of the experiment did not change. Plasma IL-6 levels were not 
detected in this experiment. 
C. Ex Vivo Liver Perfusion Studies 
1. Cytokine Stability 
Prior to examining the production of TNF or IL-6 by the isolated perfused 
liver in the endotoxic rat, the ability to measure TNF and IL-6 concentrations in 
the perfusate and the stability of both peptides in the perfusion apparatus under 
normal perfusio.n conditions had to be determined. 
Fig. 23 demonstrates the stability of TNF in the perfusion apparatus over 
a 120 minute perfusion without a liver present in the circuit. 75 ng and 20 ng of 
murine TNF were added to 100 ml of perfusate. As illustrated, both amounts 
remained stable over the 120 minute perfusion period. 
Fifty nanograms of murine IL-6 was also tested in order to establish IL-6 
stability in the perfusion. Fig. 24 depicts the IL-6 concentration in the perfusate 
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Fig. 22. The effect of insulin induced hypoglycemia on plasma glucose concentrations and plasma TNF 
over 180 minutes in anathetised normal rats. Insulin, I, ( 5 U) was injected s.c. immediately after the 
t=O blood sample and blood samples were taken at the indicated time points. Values represent the 
means + SEM for the group ( n = 6 ) at each time point. 
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samples over 120 minutes of a "liverless" perfusion. Interleukin 6 concentrations 
remained constant over the 120 minute perfusion period. The maximal fluctuation 
was 12%. 
The concentration of endotoxin in the perfusate prior to the introduction of 
a liver into the circuit was determined. Perfusate endotoxin concentrations were 
found to be less than 0.1 ng/ml initially. 
2. The Effect of Dexamethasone and Insulin on Cytokine Production in the 
Isolated Perfused Liver. 
The perfusion studies were performed with livers from rats treated in vivo 
with the experimental protocol described above in section A. Fig. 25 illustrates the 
TNF concentration in the perfusate over a 60 minute perfusion period. In the 
control, saline treated group TNF was not present in the perfusate until 50 
minutes after the initiation of the perfusion. At 60 minutes TNF was also increased 
(0.233 ± 0.04 ng/ml) and appeared to be further increasing. DEX alone in the 
perfusion was able to significantly suppress this increase in TNF observed at the 
50 and 60 minute time points. There was no measurable TNF in the perfusate of 
INS treated livers until 60 minutes at which time TNF was determined to be (0.18 
± 0.06 ng/ml). DEX/INS treatment completely suppressed TNF production at all 
time points. 
ETX treatment significantly increased perfusate TNF concentration above 
the saline treated rats. TNF increased in the perfusate at a steady rate over the 
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Fig. 25. TNF production by the isolated perfused liver over 60 minutes. The rats were injected with 
dexamethasone, D, ( 0.33 mg/kg) 3 hours prior to the administration of endotoxin, E, ( 20 mg/kg) or saline, S, . 
The liver was then removed and perfused for 1 hour. Values represent the mean + SEM for each group. 
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60 minute perfusion period. Maximal TNF production was observed at the end of 
the perfusion period (1.08 ± 0.22 ng/ml). DEX/ETX pretreatment in vivo 
significantly suppressed TNF production by the perfused liver . The maximum 
concentration of TNF observed was 85.8 ± 36.4 pg/ml. 
Fig. 26 examines the effect of insulin addition on TNF production by the 
perfused liver over 60 minutes. ETX/INS treatment resulted in a significantly 
increased initial TNF concentration in the perfusate (0.429 ± 0.062 ng/ml) in 
comparison to ETX treatment (0.25 ± 0.05 ng/ml). The initial increase in TNF 
production continued until approximately 40 minutes after the initiation of the 
perfusion, when TNF production almost ceased. DEX/ETX treatment significantly 
decreased TNF production in comparison with ETX and ETX/INS. Insulin post-
treatment in vivo in the DEX/ETX/INS group could not restore TNF production. 
TNF perfusate concentrations of the DEX/ETX group and the DEX/ETX/INS group 
were not significantly different over the entire time course of the experiment. 
Fig. 27 graphically illustrates the IL-6 levels in the perfusate of the 
treatment groups during the 60 minute perfusion period. The saline treated group 
had undetectable levels of IL-6 until 40 minutes of the perfusion. IL-6 
concentration in the perfusate was 53.1 ± 3.9 pg/ml. This amount did not 
significantly change at the 50 and 60 minute sampling periods (54.1 ± 4.0 pg/ml 
and 52.8 ± 3.7 pg/ml). INS treatment initiated a similar response as measurable 
concentrations of IL-6 were detected to be 26. 7 ± 2.87 and 41.3 ± 3.1 pg/ml at 
50 and 60 minutes respectively. DEX and DEX/INS treatment were found to 
Fig. 26. TNF production by the isolated perfused liver over 60 minutes. The rats were injected with 
dexamethasone, D, ( 0.33 mg/kg) 3 hours prior to the administration of endotoxin, E, ( 20 mg/kg) or saline, S, . 
Insulin, I, ( 1 U) or saline was administered 1 hour post-endotoxin. The liver was then removed and perfused 
for 1 hour. Values represent the mean+ SEM for each group.* p< 0.05 compares E with Ell. 
** p < 0.001 compares E and Ell with DIE and DIE/I. 
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represent the mean+ SEM for each group.* p< 0.05 compares E with Ell, DIE and D/Ell at 10 and 20 minutes. 
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suppress the increases in IL-6 at the 50 and 60 time points as no detectable 
levels of IL-6 were found in these groups at all time points. 
Initial IL-6 production by the ETX perfused liver was approximately 77.8 ± 
5.72 pg/ml. The peak concentration (93.1 ± 5.2 pg/ml) was observed at 20 
minutes. The IL-6 concentration in this group then declined over the remaining 
perfusion time period such that at 40 minutes it appeared that IL-6 production by 
the perfused liver had ceased. DEX/ETX treatment significantly suppressed IL-6 
production (60.4 ± 4.8 pg/ml) below that of the ETX treatment group. There was 
no change in IL-6 production observed over the time course of the perfusion. The 
ETX/INS treatment group had a significantly lower initial IL-6 concentration ( 55.7 
± 7 .08 pg/ml) than the ETX group. This concentration did increase slowly until a 
peak concentration of 73.1 ± 1.48 ng/ml was observed at 60 minutes. 
DEX/ETX/INS treatment caused no significant change in IL-6 over time until 50 
minutes, where IL-6 concentrations began to decline. The concentration (0.45 ± 
6.3 pg/ml) was significantly different from all the other experimental groups at 60 
minutes. 
D. In Vitro Studies 
1. Cell Lines 
In order to investigate the effects of hormonal modulation on TNF and IL-6 
production in isolated cell systems, two macrophage cell lines, ANA 1 and RAW 
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264.7 cell lines were initially examined. The experimental design employed was 
similar to that used in the in vivo and ex vivo studies. 
The cells were cultured at density of 1x106 cells/ml. Dexamethasone 
phosphate ( 100 nM) was added to the cells three hours prior to treatment with S. 
enteritidis endotoxin (1 ng/ml or 100 ng/ml). Insulin (100 µU) was added 1 hour 
post endotoxin. The medium was harvested 16 hours post endotoxin and 
analyzed for TNF and IL..:.6 concentrations. These treatments did not alter cell 
viability or the rate of growth over the test period. Endotoxin concentrations of the 
dexamethasone and insulin was determined to be less than 0.1 ng/ml. 
Fig. 28 and Fig. 29 illustrate the TNF and IL-6 levels in the medium of 
ANA1 macrophages 16 hours after endotoxin. In response to 1 ng/ml endotoxin, 
ANA1 cells produced 3.4 ± 0.42 ng/ml of TNF and 6.5 ± 0.81 ng/ml of IL-6. 
Contrary to the response observed in the in vivo experiments, insulin post-
treatment of endotoxic macrophages significantly suppressed TNF (1.7 ± 0.036 
ng/ml) and IL-6 production (2.5 ± 0.91 ng/ml). Dexamethasone pretreatment of 
endotoxin-stimulated ANA 1 cells (DEX/ETX) did not significantly suppress TNF 
production, however, the IL-6 concentration in the media was completely 
abolished (< 1 pg/ml). The addition of insulin to the DEX/ETX/INS group did not 
statistically increase TNF concentrations. The addition of insulin did, however, 
restore IL-6 production ( 5.0 ± 0.85 ng/ml ). 
The macrophage cell line, RAW 264. 7, was also tested using the same 
protocol. The response of these cells to hormonal modulation is graphically 
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Fig. 28. TNF production by ANA 1 macrophages . ANA 1 macrophages were pretreated with dexamethasone, 
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Fig. 29. IL-6 production by ANA 1 macrophages . ANA 1 macrophages were pretreated with dexamethasone, 
DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) administration. One hour after ETX, 
insulin, INS, ( 100 uU) was added to the cells. Media was harvested 16 hours after ETX and analysed for IL-6 
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illustrated in Figs. 30 and 31. In response to 1 ng/ml of endotoxin, these cells 
produced impressive quantities of TNF (9.3 ± 0.59 ng/ml) and IL-6 (3.6 ± 0.26 
ng/ml). Insulin post- treatment of the endotoxin-treated group, ETX/INS, did not 
significantly alter the TNF or IL-6 concentrations in the medium. 
DEX did not stimulate TNF or IL-6 production. DEX/ETX treatment 
significantly diminished TNF concentrations in comparison to ETX treatment (6.4 
± 0.21 ng/ml vs. 9.3 ± 0.59 respectively). The IL-6 concentration of the medium 
was also significantly reduced to 1.5 ± 0.12 ng/ml. Insulin post treatment, 
DEX/ETX/INS, did not alter either TNF or IL-6 production in these cells. 
2. Primary Macrophage Cells 
Two primary macrophage cell types (peritoneal macrophages and Kupffer 
cells) were tested with the above described protocol to determine the effects on 
isolated cells that are approaching the in vivo setting. The timing and dosages 
administered are the same as described above except the dose of endotoxin was 
increased to 100 ng/ml as 1 ng/ml did not induce the production of TNF or IL-6 
in the peritoneal macrophages. 
The TNF and IL-6 production by rat peritoneal macrophages is described 
in Figs. 32 and 33, respectively. Saline treatment did not provoke TNF production 
in the peritoneal macrophages. There was however, basal production of IL-6 in 
the medium of 138.5 ± 29.5 pg/ml by these cells. ETX stimulated cells produced 
1.6 ± 0.22 ng/ml TNF and 467 ± 30.9 pg/ml of IL-6. The addition of insulin, 
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Fig. 30. TNF production by RAW 264. 7 macrophages . RAW 264. 7 macrophages were pretreated with 
dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) administration. One hour 
·after ETX, insulin, INS, ( 100 uU ) was added to the cells. Media was harvested 16 hours after ETX and analysed 
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Fig. 31. IL-6 production by RAW 264. 7 macrophages . RAW 264. 7 macrophages were pretreated with 
dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) administration. One hour 
after ETX, insulin, INS, ( 100 uU ) was added to the cells. Media was harvested 16 hours after ETX and analysed for 
IL-6 by ELISA. +designates the agents given. The absence of+ designates saline was given. * p < 0.05 
compares ETX saline and with DEX/ETX. 
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Fig. 32. TNF production by peritoneal macrophages. The cells were pretreated with dexamethasone, DEX, ( 100 
nM ) or saline 3 hours prior to endotoxin, ETX, ( 100 ng/ml ) administration. One hour after ETX, insulin, INS, ( 100 
· uU ) was added to the cells. Media was harvested 16 hours after ETX and analysed for TNF by ELISA. 
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Fig. 33. IL-6 production by peritoneal macrophages. The cells were pretreated with dexamethasone, DEX, 
( 100 nM ) or saline 3 hours prior to endotoxin, ETX, ( 100 ng/ml ) administration. One hour after ETX, insulin, INS, 
· ( 100 uU ) was added to the cells. Media was harvested 16 hours after ETX and analysed for IL-6 by 89 bioassay. 
+ designates the agents given. The absence of+ designates saline was given. * p < 0.05 compares ETX with 
saline. # p < 0.05 compares DEX/ETX with DEX/ETX/INS. 
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ETX/INS, did not significantly alter TNF or IL-6 production in these cells (1.41 ± 
0.12 ng/ml and 561.6 ± 42.3 pg/ml). DEX/ETX treatment completely suppressed 
both TNF and IL-6 production. Insulin administration to a DEX/ETX group 
I 
stimulated a modest but significant increase in TNF concentration (0.354 ± ng/ml). 
DEX/ETX/INS treatment in these cells completely restored IL-6 production (455.4 
± 33.9 pg/ml) such that there was no statistical difference from the ETX group. 
INS, DEX, or DEX/INS treatment did not alter TNF or IL-6 production. 
Fig. 34 and fig. 35 illustrate the response of Kupffer cells to hormonal 
modulation. Kupffer cells in this system did not constitutively produce TNF, 
however, IL-6 was constitutively produced at a level of 176.6 ± 22.15 pg/ml. 
Endotoxin stimulation (100 ng/ml) prompted a significant increase in TNF 
concentration (2.43 ± 0.326 ng/ml). Interleukin 6 was also significantly increased 
by endotoxin treatment (428.45 ± 19.4 pg/ml). As observed with the ANA1 cells, 
insulin post-treatment of endotoxin stimulated Kupffer cells resulted in a significant 
decrease, p<0.001 in TNF and IL-6 production, p<0.01, in comparison with ETX 
treatment. Dexamethasone pretreatment, DEX/ETX, significantly suppressed both 
TNF and IL-6 production to control values. Insulin post-treatment, DEX/ETX/INS 
resulted in a small increase in TNF production (0.675 ± 0.29 ng/ml) and a modest 
increase in IL-6 production (302.5 ± 21.3 pg/ml) in comparison to DEX/ETX 
treatment. DEX, DEX/INS and INS treatment groups were found to have TNF and 
IL-6 concentrations that were not significantly different from saline treated cells. 
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Fig. 34. TNF production by Kupffer cells. Kupffer cells were pretreated with dexamethasone, DEX, ( 100 nM ) or 
saline 3 hours prior to endotoxin, ETX, ( 100 ng/ml) administration. One hour after ETX, insulin, INS, ( 100 uU) 
· was added to the cells. Media was harvested 16 hours after ETX and analysed for TNF by ELISA. +designates 
the agents given. The absence of+ designates saline was given. * p < 0.05 compares ETX with saline and with 
ETX/INS. # p < 0.05 compares DEX/ETX with DEX/ETX/INS. 
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Fig. 35. IL-6 production by Kupffer cells. Kupffer cells were pretreated with dexamethasone, DEX, ( 100 nM ) or 
saline 3 hours prior to endotoxin, ETX, ( 100 ng/ml) administration. One hour after ETX, insulin, INS, ( 100 uU) 
was added to the cells. Media was harvested 16 hours after ETX and analysed for IL-6 by 89 bioassay. + 
designates the agents given. The absence of+ designates saline was given. * p < 0.05 compares ETX with 
ETX/INS. # p < 0.05 compares DEX/ETX with DEX/ETX/INS. ~ ~ 
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3. Mechanisms of Insulin Action on TNF and IL-6 In Vitro 
To investigate the possible mechanisms of insulin action on TNF and IL-6 
production several pharmacological agonists and antagonists of known second 
messenger pathways were added to the in vitro protocol described above. The 
ANA 1 cells and the peritoneal macrophages were chosen as the cell types to be 
tested because of their initial positive responses to the various treatment groups. 
Briefly, dexamethasone phosphate (100 nM) was added to the cells three hours 
prior to treatment with S. enteritidis endotoxin at 1 ng/ml for the ANA 1 cells or 100 
ng/ml for the peritoneal macrophages. Insulin (100 µU) and/or a pharmacological 
agent was added 1 hour post endotoxin. The medium was harvested 16 hours 
post endotoxin and analyzed for TNF and IL-6 concentrations. These treatments, 
with the exception of cycloheximide, did not alter cell viability or the rate of growth 
over the test period. The endotoxin contamination of all the pharmacological 
substances used was determined to be less than 0.1 ng/ml. 
.fil The Role of Protein Kinase C 
Table 10 depicts the effect of PMA on ANA 1 macrophages. PMA stimulated 
ANA1 cells to produce 1.20 ± 0.34 ng/ml of IL-6. ETX stimulated IL-6 significant 
increases in IL-6 medium concentration (6.58 ± 0. 72 ng/ml). ETX/PMA treatment 
did not cause a significant augmentation in IL-6 (5.62 ± 1.72 ng/ml). 
Dexamethasone pretreatment, DEX/ETX, severely depressed IL-6 production and 
the addition of PMA to the media, DEX/ETX/PMA, overcame the depression (3.28 
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Table 10--The Effect of PMA on IL-6 production in ANA1 macrophages. 
Groups IL-6 ( ng/ml ) 
saline ~ 0.001 
ETX 6.58 ± 0.72** 
PMA 1.20 ± 0.34* 
ETX/PMA 5.62 ± 1.7 
DEX/ETX ~ 0.001 
DEX ~ 0.001 
DEX/ETX/PMA. 3.28 ± 0.84** 
DEX/PMA ~ 0.001 
Cells were treated with dexamethasone , DEX, (100 nM) 3 hours prior to the 
addition of S. enteritidis endotoxin, ETX, (1 ng/ml). One hour later PMA (1 nM) 
was added to the cells. Media was harvested 16 hours after ETX stimulation and 
analysed for IL-6 by ELISA. 
*p<0.01 compares saline with PMA. 
**p<0.001 compares saline with ETX and also DEX/ETX with DEX/ETX/PMA. 
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± 0.84 ng/ml). Dexamethasone was also shown to depress PMA induced IL-6 
secretion. 
Since the data in table 1 O demonstrated that PMA and insulin were acting 
in a similar manner with respect to IL-6 production in ANA1 macrophages, H-7, 
an inhibitor of protein kinase C was added to the original protocol as a 
cotreatment with insulin to observe the effects. Table 11 illustrates the results 
from this experiment. H-7 cotreatment had no effect on the initial observations 
demonstrated in fig. 29. 
The effect PMA (1 nM) was also tested on peritoneal macrophages. Table 
12 summarizes the results of PMA treatment on TNF and IL-6 production. PMA 
alone was able to stimulate both TNF (0.98 ± 0.36 ng/ml) and IL-6 (362 ± 87 
pg/ml) secretion. ETX/PMA treatment significantly increased TNF but not IL-6 
secretion in comparison to ETX treatment. DEXIETX/PMA was shown to restore 
TNF secretion in comparison to DEX/ETX treatment, however, IL-6 was not 
statistically increased. As demonstrated with the ANA1 cells dexamethasone 
treatment was able to suppress PMA induced TNF secretion. 
Table 13 depicts the effect of H-7 cotreatment on the insulin-induced 
cytokine production of peritoneal macrophages. As previously shown in the ANA 1 
cells H-7 did not alter either TNF or IL-6 production. 
Ql The Role of Prostaglandins 
To determine if the modulation of prostaglandin production was involved 
144 
Table 11--The effect of H-7 on IL-6 production in ANA1 macrophages. 
Groups IL-6 (ng/ml) 
saline I H-7 :S 0.001 
ETX/H-7 5.31 ± 0.731 
ETX/INS/H-7 5.12 ± 0.92 
INS/H-7 :s: 0.001 
DEX/ETX/H-7 :S 0.001 
DEX/H-7 :S 0.001 
DEX/ETX/I NS/H-7 4.82 ± 0.631 
DEX/INS/H-7 :S 0.001 
Cells were treated with dexamethasone , DEX, ( 100 nM) 3 hours prior to the 
addition of S. enteritidis endotoxin, ETX, (1 ng/ml). One hour later insulin (100 
µU) and H-7 (1 pg/ml) was added to the cells. Media was harvested 16 hours 
after ETX stimulation and analysed for IL-6 by ELISA. 
Table 12--The effect of PMA on TNF and IL-6 production in peritoneal 
macrophages. 
Groups TNF (ng/ml) IL-6 (ng/ml) 
saline ~ 0.001 0.153 ± 0.076 
ETX 1.84 ± 0.713 0.643 ± 0.049 
PMA 0.98 ± 0.365 0.362 ± 0.087 
ETX/PMA 3.10 ± 0.75. 0.740 ± 0.140 
DEX/ETX ~ 0.001 0.142 ± 0.023 
DEX ~ 0.001 0.137 ± 0.011 
DEX/ETX/PMA 0.741 ± 0.12· 0.321 ± 0.13 
DEX/PMA ~ 0.001 0.254 ± 0.085 
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Cells were treated with dexamethasone , DEX, (100 nM) 3 hours prior to the 
addition of S. enteritidis endotoxin, ETX, (100 ng/ml). One hour later PMA (1 nM) 
was added to the cells. 
*p<0.05 compares ETX with ETX/PMA and DEX/ETX with DEX/ETX/PMA 
Table 13-- The effect of H-7 on TNF and IL-6 production in peritoneal 
macrophages. 
Groups TNF (ng/ml) IL-6 (ng/ml) 
saline I H-7 s: 0.001 0.122 ± 0.036 
ETX/H-7 1.63 ± 0.486 0.564 ± 0.031 
ETX/INS/H-7 1.30 ± 0.871 0.497 ± 0.92 
INS/H-7 s: 0.001 s: 0.001 
DEX/ETX/H-7 s: 0.001 s: 0.001 
DEX/H-7 s: 0.001 s: 0.001 
DEX/ETX/INS/H-7 0.410 ± 0.176 0.534 ± 0.043 
DEX/INS/H-7 s: 0.001 s: 0.001 
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Cells were treated with dexamethasone , DEX, (100 nM) 3 hours prior to the 
addition of S. enteritidis endotoxin, ETX, (100 ng/ml). One hour later insulin 
(100 µU) and H-7 (1 µg/ml) was added to the cells. Media was harvested 16 
hours after ETX stimulation and analysed for IL-6 by ELISA. 
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in the insulin-induced IL-6 synthesis by ANA1 cells, INDO (1 µM) was added to 
the cells with insulin. Fig. 36 portrays the effect of INDO in this system. INDO 
treatment stimulated the production of 4.43 ± 0.40 ng/ml of IL-6. ETX/INDO and 
ETX/INS/INDO treatment was not different from INDO alone. Dexamethasone 
suppressed INDO stimulated IL-6 production as well as the IL-6 concentration of 
the DEX/ETX/INDO group. The treatment combination DEX/ETX/INS/INDO was 
observed to increase IL-6 concentration (2.19 ± 0.235 ng/ml). 
Figs. 37 and 38 examine the effect of INDO on TNF and IL-6 production 
in the peritoneal macrophages. INDO treatment did not significantly alter TNF or 
IL-6 production in comparison to the original treatment groups that are depicted 
in fig. 32 and 33. 
fil The Effect of IGF-1 on Cvtokine Production 
The growth factor IGF-1 and its receptor are structurally homologous to 
insulin and the insulin receptor. Insulin at elevated physiological concentrations 
is able to bind to IGF-1 receptors. To determine if IGF-1 can induce similar 
responses in cytokine production as those observed with insulin treatment, 10 
ng/ml IGF-1 was substituted for insulin in the original treatment protocol. 
Fig. 39 summarizes the effect of IGF-1 treatment on TNF and IL-6 
production in ANA1 cells. IGF-1 alone did not stimulate secretion of either IL-6 or 
TNF. ETX/IGF-1 treatment dramatically increased both TNF and IL-6 production. 
This increase was significantly above that observed for ETX alone. 
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Fig. 36. The effect of indomethacin, INDO, on IL-6 production by ANA1 macrophages. ANA1 macrophages 
were pretreated with dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) 
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Fig. 37. The effect of indomethacin, INDO , on TNF production by peritoneal macrophages . The cells were 
. pretreated with dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) 
administration. One hour after ETX, insulin, INS, ( 100 uU ) and INDO ( 1 uM ) were added to the cells. Media was 
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Fig. 38. The effect of indomethacin, INDO, on IL-6 production by peritoneal macrophages. The cells were 
pretreated with dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) 
administration. One hour after ETX, insulin, INS, ( 100 uU) and INDO ( 1 uM) were added to the cells. Media was 
harvested 16 hours after ETX . + designates the agents given. The absence of + designates that saline was 
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Fig 39. TNF and IL-6 production by ANA1 macrophages. ANA1 macrophages were pretreated with 
dexamethasone, DEX, ( 100 nM) or saline 3 hours prior to endotoxin, ETX, ( 1 ng/ml) administration. One 
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Dexamethasone pretreatment of ANA 1 cells abolished IL-6 concentrations. Insulin 
post treatment, DEX/ETX/INS, was able to re-establish IL-6 production. This was 
not observed for DEX/ETX/IGF-1 treatment. 11-6 was not significantly increased 
above baseline values. 
IGF-1 was able to stimulate TNF and IL-6 production in peritoneal 
macrophages as shown in Fig. 40 and 41. The amounts were 0.613 ± 0.14 ng/ml 
and 345 ± 25.1 pg/ml respectively. The addition of ETX, in the ETX/IGF-1 group, 
significantly increased TNF concentration to 2.43 ± 0.353 ng/ml in comparison 
to ETX treatment which was 1.6 ± 0.224 ng/ml (data not shown). ETX/IGF-1 
treatment also dramatically elevated the medium IL-6 content (625 ± 45 pg/ml). 
The combination of ETX/IGF-1/INS resulted in a trend towards a decrease in TNF 
and IL-6 that was not statistically significant. Dexamethasone suppressed IGF-1-
induced TNF and IL-6 secretion. DEX/ETX/IGF-1 treatment re-established both 
TNF and IL-6 secretion. Both the TNF and IL-6 media concentrations of the 
DEX/ETX/INS/IGF-1 group exhibited a decrease, however, this was not statistically 
different from the DEX/ETX/IGF-1 group. 
Ql The Role of Serine Phosphatases 
Serine phosphatases have been implicated in the signal transduction 
pathways necessary for cytokine synthesis and secretion. The effect of the 
inhibitor of serine phosphatase activity, okadaic acid, OKA, on IL-6 production by 
ANA 1 cells and TNF and IL-6 production by peritoneal macrophages is displayed 
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Fig. 40. The effect of IGF-1, on TNF production by peritoneal macrophages. The cells were pretreated with 
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in fig. 42, fig. 43 and fig. 44. 
OKA incited secretion of IL-6 by ANA1 cells. The secretion was not further 
increased by the addition of ETX, in fact, IL-6 production was decreased. 
ETX/INS/OKA stimulated an increase in IL-6 production. Dexamethasone 
pretreatment suppressed OKA-induced IL-6 secretion. The treatment groups 
DEX/ETX/OKA and DEX/ETX/INS/OKA were not significantly different from 
DEX/OKA treatment. 
OKA treatment resulted in both TNF (1.22 ± 0.56 ng/ml) and IL-6 (391.8 
± 28.5 pg/ml) production by peritoneal macrophages (fig. 43 and 44). ETX/OKA 
stimulated a markedly enhanced secretion of TNF (4.32 ± 0.53 ng/ml). The IL-6 
content of the medium was also increased (587.3 ± 44.4 pg/ml) by ETX/OKA 
treatment. Dexamethasone was able to suppress OKA-induced TNF but not IL-6 
secretion. DEXIETX/OKA treatment resulted in a mild increase in TNF and no 
increase in IL-6. DEX/ETX/INS/OKA had opposite effects on TNF and IL-6 
production. TNF was severely suppressed whereas IL-6 was dramatically 
increased (492.5 ± 640 pg/ml). 
fil The Role of RNAase I 
RNAse I has been implicated as being responsible for the degradation of 
mRNA of cytokines with the UAUAU rich regions. These regions confer message 
instability and thus result in rapid message turnover. Cycloheximide has been 
shown to "superinduce" cytokine production by inhibiting the synthesis of RNAses 
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responsible for mRNA degradation. Figs. 45, 46 and 47 demonstrate the effect of 
cycloheximide addition to the treatment groups. Fig. 45 illustrates the effect of 
eve on IL-6 secretion by ANA1 cells. eve, surprisingly caused superinduction 
of IL-6 in the ETXJeve treatment group. Insulin addition to this group, 
ETX/eVe/INS also notably enhanced IL-6 secretion. Dexamethasone significantly 
suppressed IL-6 production in the DEXIETXJeve group in comparison to 
ETXJeve treatment. DEX/ETX/INS/eVe treatment did not alter IL-6 production 
above that observed with the DEX/ETX/eVe group. 
Figs. 46 and 47 demonstrate the effect of eve on TNF and IL-6 secretion 
in peritoneal macrophages. eve caused "superinduction" of TNF synthesis 
above that observed for ETX alone (4.43 ± 0.387 ng/ml vs. 1.61 ± 0.22 ng/ml). 
Insulin addition to this group abolished TNF synthesis. Surprisingly, 
DEX/ETX/INS/eve treatment elicited a profound increase in TNF concentration 
(5.47 ± 0.72 ng/ml) not observed with DEX/ETX/eve treatment. 
Fig. 47 illustrates the effect of eve on IL-6 production by peritoneal 
macrophages. Although there are significant differences when comparing the 
treatment groups to each other, in relationship to the results from the original 
treatment groups illustrated in fig. 33, eve severely inhibited IL-6 secretion. 
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A. In Vivo Projects 
CHAPTERV 
DISCUSSION 
1. The Effect of Exogenous Insulin Administration and Endogenous Insulin 
Secretion on Lethality and Glucose Homeostasis 
.fil Mortality Effects 
This study was initially designed to examine metabolic and mortality 
differences observed in response to endotoxin and to determine if insulin would 
alter dexamethasone protection of endotoxic lethality. This preliminary in vivo 
experiment was essential so that the effects of the various treatments could be 
observed in a conscious unrestrained model. The rats were fasted overnight to 
stabilize plasma insulin at low levels. Dexamethasone was administered at 0.33 
mg/kg. This dose was proven to protect rats against endotoxic lethality in a study 
by Yelich et al., 1987, (358). This dose also represents an analogous dose of 
methylprednisolone (MP) that has been used in clinical studies (47, 164) 
considering that MP is approximately one tenth the therapeutic strength of 
dexamethasone. In comparison to the clinically recommended therapeutic dose 
of dexamethasone (5 mg/kg) and the amount administered to animals in other 
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studies (18), the dose of dexamethasone used in this experiment is significantly 
reduced; The administration of dexamethasone three hours before endotoxin 
administration enabled the intraperitoneal injection to be effectively absorbed. 
Hinshaw et al., 1978, ( 164) have shown that glucocorticoid treatment can be 
protective if administered prior or even concurrently with endotoxin. 
The dose of endotoxin chosen for this experiment was 20 mg/kg. This 
amount of endotoxin was determined from pilot studies to be midrange lethal dose 
of 66% for this particular lot of endotoxin. In comparison to Buchanan's (51,52) 
experiments (1mg total) this is a much larger dose. In comparison to other 
species the rat is extremely resistant to endotoxic challenge. Although, there is 
no recorded effective lethal dose for man, the amount administered to human 
volunteers in clinical studies is usually in the nanogram range, resulting in 
physiological alterations such as increased fever, blood pressure and TNF 
production (116, 270). The preparation of endotoxin used in this study is the 
Boivin extraction with approximately 18% protein existing with the 
lipopolysaccharide coat. Raetz et al., 1991 (267) have suggested that the protein 
is important for the activation of macrophages with subsequent cytokine 
production and antigenic response by macrophages. 
The insulin dose used was chosen after examination of Buchanan's work. 
As illustrated in table 6, 0.5 U was as effective as 1 U and 0.25U yielded results 
no different from endotoxin alone. Insulin was administered one hour post 
endotoxin. During this time period after endotoxin administration plasma insulin 
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and plasma glucose concentrations usually increase. This response has been 
described as the "insulin resistant" hyperglycemic phase of endotoxicosis (112). 
Insulin was administered during this period to determine if the animal was truly 
resistant to the action of insulin in insulin dependent tissues. As illustrated in fig. 
15 the administration of insulin one hour after endotoxin, ETX/INS, increased 
mortality from 66% to 100%. This combination was extremely and consistently 
lethal with animals succumbing within 2 hour after insulin administration. This 
was not an unexpected finding as Buchanan and Filkins,1976, (51) previously 
demonstrated that endotoxin and insulin coadministration resulted in increased 
mortality in comparison to endotoxin alone. Mortality in his study was increased 
from 25% to 100% by insulin administration. 
The protective effects of dexamethasone pretreatment against endotoxic 
lethality have been well described (36,37, 164, 167). Dexamethasone therapy is 
believed to stabilize plasma glucose, blood pressure and modulate the 
inflammatory response during endotoxicosis (358). In this study dexamethasone 
effectively reduced mortality from 61 % to 6.25% . However, insulin administration 
to dexamethasone-treated endotoxic rats was able to reverse protection 
increasing mortality from 6.25 to 75 %. The bowel of the DEX/ETX/INS group at 
autopsy was noted to have significant areas of petechiae and focal necrosis and 
appeared deep purple in color in contrast to the pink color of the bowel of saline 
treated rats. These observations were similar to those of the ETX and the 
ETX/INS groups and are consistent with death due to endotoxicosis. The 
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appearance of the bowel of animals dying from insulin-induced hypoglycemia is 
distinct as the peritoneum and intestines exhibit areas of blanching and white 
strangulation. 
Tolbutamide, a sulfonylurea derivative used therapeutically for the 
stimulation of insulin secretion in Type II late onset diabetes was utilized in this 
study to determine if the increase in mortality was due specifically to exogenous 
insulin administration and also to determine if endogenously produced insulin 
would elicit the same response and reverse dexamethasone protection against 
endotoxicosis. Although tolbutamide alone did not result in any deaths, ETX!TOL 
mortality was 100%. Buchanan and Filkins, 1976, (51) demonstrated previously 
that the addition of tolbutamide to endotoxin animals treated with an LD20 resulted 
in increased mortality to 100%. As illustrated in our experiment, dexamethasone 
protection was also reversed by tolbutamide administration. However, mortality 
was only increased to the level of the ETX group. The amount of tolbutamide 
administered stimulated only a modest amount of insulin secretion from the 
pancreas and thus plasma concentrations of insulin were reduced. Since insulin, 
either from an exogenous or endogenous source, was able to alter mortality, the 
endotoxic rats were not truly unresponsive to insulin effects. 
These findings suggest that insulin is a key hormonal regulator during 
endotoxic shock. The ability of insulin to enhance endotoxin's ability to increase 
mortality and negate dexamethasone's protective effects cause concern if 
extrapolated to the clinical setting. Therapeutically administered substances which 
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increase endogenous insulin such as glucose, or total parenteral 
hyperalimentation could alter dexamethasone protection by initiating insulin 
secretion a competitive cascade with endogenous or exogenously administered 
glucocorticoids. Glucocorticoid therapy in two highly cited clinical trials (47, 166) 
has been shown to be ineffective, although in almost all nonhuman studies 
glucocorticoids have proven to be protective. The failure of the predicted outcome 
in the clinical trials has been attributed to severity of injury of the patients as well 
as to the time of administration of glucocorticoids (167). Bone et al., 1987 (47) 
and Hinshaw et al. 1985 (166) did not examine the effects of therapies such as 
hyperalimentation and dextrose administration and plasma insulin was not 
measured in these studies. 
Ql Plasma Metabolite Effects 
The early phase of a septic challenge is characterized by two distinct 
phases of glucose metabolism (107, 112). Initially a transient" insulin resistant" 
hyperglycemic phase occurs within two hours post endotoxin. This phase is 
termed "insulin resistant" because an abnormal increase in plasma insulin without 
a subsequent decrease in the already abnormally elevated plasma glucose level 
is observed (107). Insulin dependent tissues such as fat and muscle are unable 
to take up glucose in the presence of insulin due to the presence of alterations 
in glucose transporter activity (193). The exact mechanism of the impaired 
transporter activity has not been uncovered, however, endotoxin-stimulated 
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production of tumor necrosis factor has been implicated as a possible mediator 
(214,337). 
The hyperglycemic phase terminates abruptly and is followed by a rapid 
onset lethal hypoglycemic phase (107, 143). Gluconeogenesis by the liver is 
significantly impaired during sepsis and the glucose demand by non-insulin 
dependent tissues such as the brain and the cells of the immune system is 
elevated (193,223). Non-insulin dependent utilization of glucose is approximately 
70-85% of total body disposal (193,222). Other tissues responsible for this uptake 
during sepsis include liver, spleen, lung, ileum and skin. Insulin dependent tissues 
such as muscle have also increased glucose needs (222). Therefore, the 
peripheral glucose requirements exceed the glucose output by the liver and 
hypoglycemia occurs. 
Plasma glucose levels of the ETX/INS and of the ETX/TOL rats were 
significantly reducedin this study in comparison with the ETX treatment group. 
Since blood samples were obtained approximately 3 hours after endotoxin 
administration the plasma glucose concentration of the ETX treatment group 
would be expected to be slightly decreased as illustrated in fig. 16. The addition 
of the insulin or tolbutamide to the ETX groups during the hyperglycemic phase 
exacerbated the ETX induced hypoglycemia. 
Hepatic gluconeogenesis is significantly impaired during sepsis (36,37). 
The key enzyme responsible for gluconeogenesis, PEPCK, is upregulated under 
normal conditions by cortisol and glucagon and is dominantly suppressed by 
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insulin and phorbol esters (242,243,254). In sepsis, even though plasma cortisol 
and glucagon concentrations are elevated, PEPCK activity is impaired 
(11, 12,306). Mccallum and Hill, 1992, (161) have shown that PEPCK activity is 
inhibited both at the activity and the transcriptional level by the cytokines TNF and 
IL-6. Our data suggest that the addition of insulin or tolbutamide to endotoxic rats 
may have act to further impair PEPCK activity and decrease glucose output by the 
liver. 
Dexamethasone pretreatment resulted in a persistent hyperglycemia and 
has been shown to maintain plasma glucose at euglycemic to hyperglycemic 
levels for an extended period of time post endotoxin challenge (358). Both insulin 
and tolbutamide treatment of DEX/ETX rats negated the hyperglycemia and 
induced a profound hypoglycemia. This observation supports the role of insulin 
as a dominant regulator of plasma glucose homeostasis. 
During sepsis an increase in plasma lactate is considered to be a marker 
of metabolic distress (202,230). Endotoxin is thought to alter pyruvate 
dehydrogenase and mitochondrial activity resulting in uncontrolled lactate 
production (330). Van Lambalgen et al., 1988, (330) demonstrated in a canine 
model that endotoxin increases plasma lactate significantly within 30 minutes. 
Salleh et al. 1990, (279) also demonstrated that in cecal ligation and puncture 
models of sepsis plasma lactate levels increased 100% over those of sham 
controls.Fong et al., 1990, (116) found that although no significant increase in 
plasma lactate occurred iln human volunteers administered endotoxin an 
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increased efflux of lactate from skeletal muscle was observed. A recent report 
(202) suggests that macrophages are capable of utilizing lactate as a fuel during 
stress and that lactate transporters exist on the surface of these cells. 
Plasma lactate levels in saline treated rats was increased by endotoxin 
administration from 1.0 mmol/L to 3 mmol/L. The addition of insulin or tolbutamide 
resulted in an intense hyperlacticacidemia. Dexamethasone pretreatment reduced 
plasma lactate concentrations by possibly increasing the delivery of glucose or 
oxygen to the cells. Insulin administration increased plasma lactate concentrations 
of the DEX/ETX/INS and the DEXIETX/TOL groups by reducing the available 
glucose through the inhibition of gluconeogenesis. 
During the first hour after an endotoxin challenge plasma glucose increases 
rapidly with a simultaneous increase in plasma insulin concentration. There is also 
substantial evidence that the pancreas hypersecretes insulin in response to a 
glucose challenge during sepsis. Buchanan and Filkins, 1976, (52) demonstrated 
in rats that within 90 minutes after an injection of endotoxin, insulin increases to 
a maximum of 120 µU/ml, and then rapidly decreases .As depicted in our 
experiment, plasma insulin in the ETX group was elevated above that of the 
control rats. Other authors have noted similar elevations in plasma insulin 
concentrations after an LPS challenge or in cecal ligation and puncture models 
( 11, 12,279). Results of studies involving septic patients have shown an 
inconsistency with respect to the presence or absence of elevated plasma insulin 
concentrations (64, 116, 122). This discrepancy could be due to the administration 
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of dextrose or glucose to maintain plasma euglycemia which, in turn, alters the 
plasma insulin profile. 
Even with the administration of pharmacological levels of insulin to the rats 
in this study the peak insulin observed was approximately 120 µU/ml. This value 
is within the range of plasma insulin observed during endotoxin-stimulated insulin 
secretion. Tolbutamide did not increase plasma insulin levels as dramatically as 
anticipated, however, a significant increase in mortality was observed. These 
observations suggest that an increase in insulin turnover occurred in the endotoxic 
animals and that a very small concentration of insulin can exert a lethal effect. 
Tolbutamide may also produce effects unrelated to insulin secretion however, 
tolbutamide administration alone did not cause death. 
2. The Effect of Restoring Euglycemia on Mortality 
Although the observations from the bowel pathology did not indicate death 
as a result of hypoglycemia, the plasma glucose concentrations were so 
diminished that hypoglycemia was postulated as the cause of death of the 
treatment groups. If plasma glucose concentration could be re-established in 
these groups by the administration of dextrose, would the prognosis be altered ? 
The stabilization of euglycemic plasma glucose concentrations in these 
animals without significantly altering the model created a dilemma. The 
appropriate model would have been to surgically implant catheters and glucose 
clamp the animals at a stable plasma glucose concentration. However, the effects 
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from anaesthesia, surgery and recovery would alter the original model. Therefore, 
the administration of dextrose intraperitoneally was chosen. As illustrated in fig. 
16, plasma glucose was significantly increased by dextrose therapy in the 
ETX/INS and DEX/ETX/INS groups at the time of death without significant 
reductions in mortality. Surprisingly, the administration of dextrose to the ETX 
group resulted in 100% mortality. Buchanan and Filkins, 1976, (51) have shown 
that administration of glucose significantly increased mortality from 10 to 60 % if 
given one hour post endotoxin. Satomi et al. 1985, (284) also confirmed this 
observation in mice. The stimulation of insulin secretion by dextrose injection in 
these studies was postulated to cause the increased mortality. Therefore, from 
Satomi's studies and from our results, insulin administration to endotoxic rats did 
cause hypoglycemia and contributed to death, however, insulin may have 
stimulated other physiological or immunological pathways resulting in the demise 
of the animals. 
3. The Effect of PMA and H-7 on Mortality 
PKC activation has been implicated in the development of endotoxemia. 
PMA, an activator of PKC is known to stimulate the physiologic sequelae 
observed during sepsis, including macrophage differentiation and cytokine 
production (345,347). Inaba and Filkins, 1991, (177) demonstrated that endotoxin 
lethality could be exacerbated by the injection of PMA into rats. They also showed 
that inhibitors of PKC, such as H-7 or polymyxin B, attenuated insulin induced 
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hypoglycemia and the rise in insulin during IVGTT (178). 
PMA was used to in place of insulin and insulin was combined with H-7 to 
observe if the effect of insulin was by a PKC activation. As demonstrated in the 
Inaba study, endotoxin was extremely lethal when combined with PMA. 
Dexamethasone pretreatment was also unable to protect against PMA induced 
lethality, as was demonstrated with insulin. H-7 in combination with insulin did not 
alter the significant mortality due to insulin. Although, this finding suggests that 
PKC activation may not be involved, the effects of in vivo administration of H-7 
are complex. H-7 administration in vivo at the dosage used in this study also 
induces alterations in plasma glucose and blood pressure. Also H-7 is not an 
entirely specific inhibitor of PKC and it also affects PKA activity. 
B. Cvtokine Production In Vivo 
As the administration of dextrose did not alter mortality in the experiments 
discussed above, the effects of hormonal modulation of other responses was 
examined. Endotoxin stimulates the production of an assortment of biologically 
active mediators, such as prostaglandins, leukotrienes, hormones and 
immunological cytokines. The production of TNF by macrophages is a critical 
initial response to endotoxemia. Coincidently, the initial increase in plasma TNF 
occurs in parallel with plasma hyperglycemia and hyperinsulinemia (182, 185). 
TNF then disappears from the circulation as other cytokines such as ll-1 and IL-
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6, begin to appear (116, 185). The decline in plasma TNF levels also coincides 
with the onset of endotoxin-induced hypoglycemia . 
This study examined the insulin and dexamethasone modulation of TNF 
and IL-6 production in vivo using the treatment protocol described in the mortality 
experiments. In order to facilitate serial blood sampling the rats were anesthetized 
with pentobarbital. The administration of pentobarbital alters the sympathetic 
response and catecholamine production of anesthetized animals by inhibiting 
parasympathetic activity in the brain. Increased plasma catecholamines alter heart 
rate and metabolic responses by stimulation of beta adrenergic receptors. 
Plasma glucose and lactate concentrations in this study were slightly different to 
those observed in conscious animals possibly due to the effects of anesthesia. 
Plasma TNF was increased significantly 60 minutes after endotoxin 
administration. Peak plasma TNF levels occurred at 90 minutes, with a decline to 
near basal levels by 180 minutes post endotoxin. This time course and pattern 
of TNF production appears to be a consistent with many studies and has been 
described in several species (78, 182, 185, 271, 324,325). Insulin administration 
to the endotoxic rats did not alter the amount of TNF produced , however, the 
plasma TNF level was sustained in contrast to the declining plasma TNF of the 
endotoxic group. Since rats in the insulin post-treated endotoxic group died prior 
to the conclusion of the study, the trend to increasing or persisting TNF 
concentrations could not be measured. The effect of insulin on TNF production 
could be by either direct or indirect modulation of TNF. The insulin-endotoxic 
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group also exhibited profound hypoglycemia and lacticacidemia. Elevated plasma 
TNF concentrations have been previously correlated with significantly reduced 
plasma glucose levels. Satomi et al., 1985 (284) have demonstrated that the 
administration of glucose 30 minutes prior to or Xsimultaneousl,vith endotoxin 
reduced plasma TNF, however, glucose administered after endotoxin had no 
effect on TNF. 
The plasma IL-6 amounts in the endotoxin-insulin group was also 
significantly elevated at the 120 minute time point. Elevations of plasma IL-6 are 
known to occur approximately 2 to 4 hours after LPS stimulation (200,317). In 
comparison to the endotoxin group, the plasma IL-6 levels were markedly 
increased. The appearance of elevated plasma IL-6 concentrations has been 
associated with a fatal outcome in rats and in humans (60,307). Recently, Casey 
et al., 1993, (60) verified that in a population of septic patients who died, the only 
factor that correlated with a poor prognosis was elevated IL-6 levels. The effect 
of insulin could be theorized as due to either direct or indirect modulation of TNF 
and IL-6 production. From in vitro studies evidence exists that insulin and 
endotoxin alter TNF, IL-1 and IL-6 production by cells (34,84, 172). The indirect 
effect could be via the production of other cytokines such as IL-1 and IFNy. 
Interleukin 1 has been shown to increase insulin secretion by the pancreas (70), 
however, the in vivo effects of insulin on IL-1 production have not been 
investigated. IFNy synergizes with endotoxin to produce elevated amounts of 
TNF and IL-6 (85,212). Although IFNy was not measured in this study, insulin 
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may have altered this lymphocyte produced cytokine. Insulin is important for the 
upregulation of insulin receptors on T-lymphocytes and subsequent 
immunobiological activity. Helderman et al., 1992, (156) has demonstrated that 
insulin-stimulated macrophages produce a monocyte-derived insulin receptor 
factor (MIRRF) which increases insulin receptors on T-lymphocytes. 
Dexamethasone pretreatment significantly suppressed plasma TNF and 
IL-6. Waage, 1987, (339) has shown that maximal suppression of plasma TNF 
occurs if dexamethasone is administered 3 to 8 hours prior to endotoxin. 
Dexamethasone can also be administered simultaneously with endotoxin in vivo 
and effectively reduces TNF production, however, a delay of only 20 minutes after 
endotoxin will not prevent TNF production (167). Dexamethasone suppression of 
TNF production occurs at the posttranslational level (44,340) whereas 
dexamethasone suppression of IL-6 occurs at the transcriptional level (76). The 
effect of dexamethasone on TNF or IL-6 secretion has not been examined. Insulin 
administration to dexamethasone-endotoxic rats resulted in a restoration of 
plasma TNF concentrations, with no marked effect on plasma IL-6. The rise of 
plasma TNF occurred rapidly after insulin injection. This observation indicates 
that insulin can affect either posttranscriptional processing of TNF mRNA or the 
actual secretion of the TNF protein. 
TNF and IL-6 administration have been shown to cause hypoglycemia and 
death in experimental animals (93,337). A strong inverse correlation is observed 
in endotoxin treated mice when plasma TNF and glucose concentrations are 
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examined (284). The administration of a hypoglycemic dose of insulin to a group 
of saline treated rats was shown in this study to not alter plasma TNF or plasma 
IL-6 concentrations. 
C. Ex Vivo Studies 
Several authors have demonstrated that the liver is a vital organ for the 
maintenance of physiological stability during sepsis (39, 118, 134,333,341 ). The 
liver is responsible for the production of glucose as well as the removal, 
neutralization and processing of endotoxin (190,302). The subsequent 
presentation of endotoxin on the surface of antigen presenting cells results in the 
activation of the immune functions and cytokine production by the resident Kupffer 
cells (15,57,101,217). The hepatocytes and endothelial cells are also capable of 
producing cytokines in response to LPS (102, 169). The Kupffer cells however, 
are believed to be the primary producers of TNF, IL-6 and IL-1 in the liver (180). 
To investigate the role of the liver in cytokine production the isolated 
perfused liver (IPL) was used as a model for TNF and IL-6 production. The 
physiological and metabolic functions of the liver are regulated by elevated portal 
concentrations of insulin and glucocorticoids, therefore, the effects of these 
hormones were also examined. The IPL has been a model for examination of the 
various aspects of hepatic function for over 100 years (191,207,342,351). This 
model offers several advantages over in vivo and currently widely used in vitro 
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techniques. In comparison to in vivo studies the direct effects of a substance on 
liver function can be tested without interference from neural and hormonal factors 
secreted in response by other organs (139). Also, multiple samples of perfusate 
can be taken over time without impairing organ function (351). The advantage of 
this technique over in vitro studies is that the architecture and integrity of the 
environment of a specific cell population, for example the Kupffer cell is 
maintained (139,351). The discrepancies and variations in cytokine production 
observed in many studies may be a reflection of the matrix of cells regulating the 
production of cytokines by specific cells. 
In this experiment a recirculating system was chosen so that the 
accumulation of TNF and IL-6 could be measured. Initially we postulated that the 
high flow rates required to deliver adequate amounts of oxygen to the cells would 
wash out any TNF or IL-6 produced. By using this system the rates of production 
could also be measured. In many IPL systems RBCs are added to maintain 
oxygenation (207). We did not use RBCs because of possible interference in TNF 
and IL-6 production . Since TNF and IL-6 are labile proteins which have very short 
half-lives in plasma and from our experience with other protein such as insulin 
which adheres to the glassware and tubing, 5% albumin was chosen from pilot 
studies to be an appropriate amount to maintain stable detectable levels of TNF 
and IL-6. Figs. 23 and 24 indicate that both TNF and IL-6 were stable during the 
perfusion period. In order to achieve detectable levels within a perfusion volume 
of 100 ml, 70 and 20 ng of TNF and 50 ng of IL-6 were required. Only one 
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perfusion at each concentration of cytokine was performed due to the expense 
and availability of the cytokines. The TNF and IL-6 produced by the liver may 
have contributed to the lethality observed in the in vivo experiments. Therefore 
the livers were isolated from rats which had been administered dexamethasone, 
endotoxin and insulin according to the protocol as described previously in this 
dissertation. 
Fig. 25 illustrates the TNF production over 60 minutes with several 
treatments. This is the first study to demonstrate directly the ability of the liver to 
produce TNF. Therefore, observations from the literature to support these findings 
are taken from in vitro and in vivo studies. TNF production by the saline treated 
rats was not observed until after 50 minutes of the perfusion period. This result 
was unexpected. From earlier unpublished work in our laboratory the production 
of TNF at this time point has been consistent and repeatable. Initially this 
response was postulated to be due to contamination by endotoxin. However, 
Limulus testing determined that the perfusion apparatus was free of endotoxin. 
Surgical conditions as well were used to maintain sterility. The alterations in liver 
integrity due to the perfusion are usually not observed until 3 to 4 hours after 
perfusion. This study was only 60 minutes in duration and no alterations in liver 
flow or integrity were observed. Ghezzi , 1992, (134) has stated that TNF is 
required for normal liver regeneration and significant quantities of TNF are 
produced early in response to hepatectomy. A more probable cause for this 
increase in TNF production is due to the removal from its normal milieu of 
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hormones and growth factors which suppress TNF production. Without 
suppression by such hormones as corticsterone, TNF could be produced in an 
unregulated manner. As demonstrated in this study, exogenous dexamethasone 
treatment completely suppresses this response. 
ETX treatment in the rat caused a significant early increase in TNF 
production. Production was still increasing by the end of the experimental period. 
The approximate rate of TNF production was 0.711 pg/min/g of liver in almost a 
linear manner. Dexamethasone pretreatment of endotoxic rats was also shown 
to suppress liver TNF production. Many papers show, indirectly, that the liver is 
capable of producing TNF after endotoxin stimulation (101, 102, 134, 180); however, 
there is little direct evidence that the liver is an actual contributor to the circulating 
TNF pool (206). Byerly et al., 1989,(54) have shown that TNF message in the liver 
is expressed one hour after i.v. administration of E coli. Ulich et al.,1990, (324) 
and 1991, (325) have indicated that TNF mRNA increase occurs as early as 15 
minutes after endotoxin exposure and that this increase in mRNA can be 
suppressed by dexamethasone treatment. However, in studies using CAT reporter 
constructs in transgenic mice, Girior et al. 1991, (136) and 1992, (137) have 
shown that the liver does not produce TNF. This discrepancy could be due to the 
incomplete expression of the construct in the transgenic animal. Hunt et al., 1992, 
(169) have shown by in situ hybridization that hepatocytes and endothelial cells 
of mice produce TNF. Results of in vitro studies with isolated Kupffer cells have 
shown that endotoxin stimulates TNF production and that dexamethasone is a 
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powerful inhibitor of TNF and IL-6. Karck et al., 1992 (180) demonstrated that 100 
nM dexamethasone and PGE2 were both effective in reducing TNF production by 
85% and that dexamethasone could be administered up to 30 min. after LPS and 
still alter TNF production. 
Fig. 26 clearly demonstrates the effect of insulin on TNF in the isolated 
perfused liver. The initial TNFlevels of the ETX/INS were group significantly 
elevated in comparison to TNF levels in ETX alone; however, the rates of 
production were the same. Insulin posttreatment did not alter dexamethasone 
suppression of TNF production. This observation indicates that dexamethasone 
in vivo is extremely effective in reducing TNF production. The liver could be a 
target organ for glucocorticoid suppression of TNF production. From the earlier 
in vivo experiments it appears that the contribution of TNF to the circulating pool 
from insulin stimulation could be from another cell population that cannot be 
suppressed as effectively as those in the liver. As the initial TNF response in the 
ETX/INS group was elevated although the rates of production were parallel, 
perhaps another tissue source of TNF production was no longer contributing when 
the liver was isolated . 
Several authors have demonstrated that the liver is an important organ for 
the production of IL-6 (15,76,95,101,102,131,180,252). Endotoxin stimulated 
Kupffer cells, hepatocytes and endothelial cells are capable of producing IL-6. The 
production of IL-6 results in the of acute stimulation of acute phase protein 
synthesis by the liver, (26,56, 103,245,329) as well as the induction of fever and 
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the synthesis of ACTH from the pituitary (235). 
Interleukin 6 production by the IPL is illustrated in fig. 27. Initial IL-6 
production was suddenly curtailed at approximately 20 minutes into the perfusion. 
At this point in time the liver was continuing to produce TNF. TNF has been 
shown to be a potent stimulator of IL-6 production. The production of factors by 
the liver may account for the sudden decrease in IL-6 production liver. Stadler 
et al., 1993,(303) have recently demonstrated that nitric oxide production inhibited 
the production of IL-6 by isolated Kupffer cells. Dexamethasone pretreatment 
significantly inhibited IL-6 production by the endotoxic liver. Insulin did not alter 
the dexamethasone suppression. These findings indicate that the liver produces 
IL-6 and that glucocorticoids are dominant down regulators of synthesis. 
D. In Vitro Studies 
1. Cell Lines 
The use of isolated specific cell populations to investigate the mechanism 
of a particular physiological response has become an extensively used technique. 
Investigation of the effects and possible mechanisms of insulin and glucocorticoid 
regulation of TNF and IL-6 production at the in vitro level were examined in four 
different macrophage populations. Advocates of in vitro experimentation describe 
the primary advantage of cell culture techniques as reducing the number of 
confounding factors and removing biological variability associated with in vivo 
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studies. From these in vitro studies new questions at a different level of biological 
complexity were introduced. Initial experiments were undertaken in the ANA 1 
cells, a transformed macrophage cell population primarily due to the ease of 
growth and maintenance of these cells. ANA 1 cells also express on their cell 
surface several of the immunological receptors and antigens characteristic of 
peritoneal macrophages (75). Since the ANA1 cells have not been well described, 
another more widely used macrophage cell line (RAW 264.7) was also tested. 
The dose of endotoxin (1 ng/ml) was chosen from the results of preliminary 
dose-response studies to determine an effective amount that would stimulate TNF 
and IL-6 production. The administration of 100 nM dexamethasone was chosen 
from several reports as effective in suppressing TNF and IL-6 in several cell lines. 
U937 cells treated with 100 nM dexamethasone show a 90 % suppression of TNF 
and IL-6 production. The insulin amount was chosen from a study by Cavalot et 
al., 1992 (61). Insulin at 100 µU/ml is a physiological dose of insulin that was 
reported to alter lymphocyte chemotaxis. This dose is also similar to the plasma 
level of insulin achieved during endotoxicosis in the in vivo studies. 
Endotoxin stimulated significant production of TNF and IL-6 by the ANA1 
macrophages. In contrast to our in vivo and ex vivo results ETX/INS suppressed 
both TNF and IL-6 production. Doherty et al., 1992, (84) demonstrated that 
ETX/INS increased both TNF and IL-6 production by peritoneal macrophages. 
They employed serum free medium and a larger amount of both endotoxin and 
insulin. Possible differences between this study and the results of Doherty could 
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be due to unknown growth factors in the serum or concentration differences of 
hormones administered. This indicates the effects observed in vivo may not be 
direct effects of insulin and that other modulating substances are involved. 
Dexamethasone pretreatment of endotoxic ANA1 cells did not significantly 
suppress TNF production but completely abolished IL-6 production. Han et al., 
1991, (147, 148)) demonstrated that dexamethasone regulates TNF production 
by altering the rate of mRNA degradation. This observation suggests that the 
ANA1 cells process TNF mRNA differently. Insulin post treatment of DEX/ETX 
cells was effective in restoring IL-6 production. In many cell types such as 
fibroblasts and endothelial cells TNF production must precede IL-6 production. In 
ANA 1 cells IL-6 production appears to be independent of initial TNF synthesis. 
This uncoupled IL-6 production has also been observed in J77 4.1 macrophages 
and PD3881 macrophages (211). 
Endotoxin stimulated both TNF and IL-6 production by RAW 264.7 
macrophages. In comparison to the ANA 1 cells the RAW cells produced 
significantly more TNF and a lesser amount of IL-6. ETX/INS treatment did not 
alter TNF or IL-6 production although this treatment inhibited both TNF and IL-6 
production in ANA 1 macrophages. Dexamethasone was effective in suppressing 
the production of both TNF and IL-6 and insulin posttreatment did not alter the 
amount of either cytokine. These results indicate that two macrophage cell-lines 
under similar treatment conditions exhibit differential responses in cytokine 
production. Divergence in the observed response could be due to the specific 
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alterations in DNA due to the virus used to immortalize the cells. These changes 
in turn might alter the regulation of transcription and posttranscriptional processing 
of mRNA. Dissimilar populations of receptors for glucocorticoids or insulin could 
also explain the variations in cytokine production between the two cell lines. 
Salkowsky and Vogel, 1992, (280) demonstrated that glucocorticoid receptor 
populations in macrophages are upregulated by LPS, thus enhancing the 
suppressive ability of dexamethasone. The choice of a particular cell line for 
examination of TNF and IL-6 production will, therefore, determine the specific 
response; therefore, caution should be used in extrapolating the results to the in 
vivo scenario. 
2. Primary Macrophage Cells 
The effect of insulin and glucocorticoid modulation of cytokine production 
was also tested in vitro utilizing two primary cell populations, peritoneal 
macrophages and Kupffer cells. Since these cells were isolated directly from the 
rat peritoneal cavity and liver, TNF and IL-6 production by these cells should 
better reflect the in vivo and ex vivo production of the cytokines. 
Peritoneal macrophages responded to endotoxin stimulation by producing 
TNF and IL-6. In contrast to the established cell lines, TNF and IL-6 production 
by peritoneal macrophages was significantly less. ETX/INS treatment did not 
significantly alter TNF or IL-6 production although a trend of increased IL-6 
concentration was observed. The peritoneal cells could possibly be stimulated 
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maximally by this concentration of endotoxin and further stimulation by the 
addition of insulin would not result in further production of TNF. Both TNF and IL-
6 production was abolished by dexamethasone pretreatment. Glucocorticoid 
receptor populations are increased in peritoneal macrophages by LPS stimulation 
(280). Therefore dexamethasone treatment effectively suppresses TNF and IL-6 
production. 
Insulin post-treatment of the DEX/ETX group resulted in a mild increase in 
TNF and a more substantial augmentation of IL-6 production. Insulin receptors 
are present on the surface of peritoneal macrophages (29,30,364). However, 
since macrophages are considered non-insulin dependent cells , insulin is not 
required for glucose metabolism in these cells (223,224). The function of the 
insulin receptors on the surface of macrophages is unknown. The insulin receptor 
density can be reduced by certain stimuli such as infection by Propionium acne 
bacterium (29). The effect of endotoxin stimulation on insulin receptor 
concentration in macrophages has not been studied. The reversal of 
dexamethasone-suppressed TNF and IL-6 production by insulin has not been 
documented. Interferon y has been shown to reverse dexamethasone 
suppression of TNF production in human monocytes (205). 
Kupffer cells were extremely difficult to isolate and maintain in a cell culture 
environment . In comparison to the other cell types, Kupffer cells require a 
medium with high glucose and the addition of buffering agents for growth 
(35, 186,349). The recommended addition of dexamethasone and insulin required 
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for basal maintenance of these cells was not added to the media. The absence 
of these hormones may have affected the initial recovery of the cells following 
isolation. Kupffer cells in culture constitutively produced IL-6. This has also been 
observed by Feder et al., 1993 (101). Both hepatic endothelial cells and Kupffer 
cells were shown to spontaneously produce both IL-1 and IL-6 in a time 
dependent manner (101) with maximal levels attained after 10 hours in culture. 
Endotoxin addition stimulated an increase in TNF and IL-6 production. 
Insulin addition surprisingly, reduced TNF and IL-6 concentrations in the medium 
of endotoxin stimulated Kupffer cells. Rae et al., 1992, (265) described an 
increase in PGE2 binding to its receptor by insulin in P388D1 macrophages. 
PGE2 is a potent inhibitor of TNF production in several types of macrophages 
(56,57,345). The inhibition of TNF production by PGE2 in Kupffer cells has been 
described by Karck et al. 1988, (180). 
Dexamethasone posttreatment in our study significantly reduced TNF and 
IL-6 concentrations in the medium. Insulin induced only a weak recovery of TNF 
and IL-6 production in the LPS-DEX treated cells. 
The contrasting responses of peritoneal macrophages and Kupffer cells to 
hormonal modulation of cytokine production could be attributed to many factors. 
The density of insulin and glucocorticoid receptors might be different as well as 
alterations in receptor density as a result of endotoxin stimulation. Modulation by 
other factors such as PGE2 could be of differential importance to the cells. Since 
insulin is recommended for growth of Kupffer cells and liver sinusoidal 
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concentrations of insulin are normally higher than in plasma, Kupffer cells may 
have exhibit a modified response in terms of TNF and IL-6 production. The 
Kupffer cell is normally intimately associated with endothelial cells as well as other 
cells of the hepatic sinusoid (341). One can speculate that Kupffer cell responses 
are largely dictated by the other cells present. Peritoneal macrophages are 
probably more independent on stimuli from other cells. 
3. Mechanisms of Insulin Action on TNF and IL-6 In Vitro 
In order to elucidate the possible mechanisms of insulin and 
dexamethasone regulation of TNF and IL-6 production by macrophages, specific 
pharmacological agents which alter second messenger pathways were added to 
the cell culture medium and the effects on IL-6 production by ANA1 macrophages 
and TNF and IL-6 production by peritoneal macrophages were examined. 
Protein kinase C activation has been implicated as a possible second 
messenger system required for endotoxin stimulation of macrophage cytokine 
production as well as macrophage differentiation (320,345,347). PMA, an activator 
of PKC has has been reported in several other studies to stimulate IL-6 
production by macrophages (76, 220). ETX/PMA treatment did not further 
increase IL-6 production. This finding indicates that either maximal stimulation of 
IL-6 production had been obtained or that ETX treatment down regulated PKC, 
thus preventing maximal stimulation by PMA. As was demonstrated with insulin, 
PMA, was able to reestablish IL-6 production which was suppressed by 
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dexamethasone. Mengozzi et al., 1991, (220) demonstrated that PMA 
administration was more effective than IFNy in restoring IL-6 production in LPS 
tolerant mice . Insulin restoration of IL-6 production by ANA1 cells may be via 
PKC activation. 
Peritoneal macrophages were also stimulated to produce TNF and IL-6 by 
PMA. ETX/PMA stimulation increased TNF but not IL-6 production. As was 
demonstrated with ANA 1 cells, PMA was able to reverse the effect of 
dexamethasone suppression of TNF production. The action of PMA in this 
experiment is similar to that observed when macrophages are treated with IFNy. 
Dunham et al. 1990, (86) have shown that IFNy treatment of macrophages 
reverses the suppressive effects of both TGFp and glucocorticoids on TNF 
production. Leudecke and Cerami, 1990, (205) also concluded that INFy can 
restore TNF secretion inhibited by dexamethasone. Interferon y may exert its 
modulatory effects via PKC , however, this has not been established. Insulin could 
also be exerting its effects on cytokine production by a mechanism similar to that 
of IFN y. 
To determine if insulin was acting via a PKC mechanism, H-7, an inhibitor 
of PKC was added with insulin to the ANA 1 cells and the peritoneal macrophages. 
H-7 did not alter cytokine production by either cell type. These findings suggest 
that PKC activation is not involved in insulin activation of cytokine production. 
However, H-7 has been shown to exert a differential effect on TNF production 
based on the dose administered to the cells (66). The dose used in our study may 
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have not been effective in modulating the effect of insulin. 
lndomethacin inhibits the production of prostaglandins by inhibiting 
cycloxygenase activity. PGE2 , produced by macrophages via an autocrine 
mechanism, suppresses the production of TNF. By the inhibition of PGE2 
synthesis, indomethacin facilitates an unregulated increase in TNF production by 
macrophages. lndomethacin treatment was able to stimulate IL-6 synthesis by 
ANA1 macrophages. Callery et al. 1990, (56) have demonstrated that 
indomethacin treatment of Kupffer cells results in an increase in IL-6 production. 
In our study ETX/INDO treatment did not further increase IL-6 production, 
indicating that production at this dose was maximal. lndomethacin did alter 
ETX/INS induced inhibition of IL-6 production. Therefore, insulin in this treatment 
group possibly affected PGE2 binding. Dexamethasone was able to suppression 
the stimulation of IL-6 production by indomethacin. Dexamethasone also inhibits 
the production of phospholipase A2 which in turn decreases PGE2 synthesis. 
These results indicate that dexamethasone inhibits transcription of IL-6. 
Previous reports have shown that the inhibition of PGE2 by indomethacin 
increases TNF and IL-6 production in peritoneal macrophages (209,292). 
lndomethacin treatment of peritoneal macrophages in our experiment did not 
result in an alteration of TNF or IL-6 production. The ineffectiveness of 
indomethacin may have been due to the dose or preparation of indomethacin at 
the time of the study. The addition of PGE2 and the subsequent addition of 
indomethacin in our system would act as a positive control to test the 
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indomethacin preparation. 
Insulin and IGF-1 are structurally homologous peptides with distinct 
receptors that are structurally homologous (262,363). Insulin is also able to bind 
to IGF-1 receptors at elevated physiological concentrations (179,262,364). IGF-1 
acting as a growth factor for many cell types has been well documented (121, 
263). Recently, IGF-1 treatment of macrophages was demonstrated to result in an 
increase in superoxide production (125). 
In this study IGF-1 was added to ANA1 cells and TNF and IL-6 production 
were examined. In contrast to ETX/INS treatment , ETX/IGF-1 stimulated 
substantial increases in TNF and IL-6 production. Peritoneal macrophages also 
treated with ETX/IGF-1 produced substantial amounts of both TNF and IL-6. The 
intracellular signalling events for both IGF-1 and endotoxin remain unresolved. 
IGF-1 could possibly effect PKC. 
IGF-1 was unable to reestablish only IL-6 production in dexamethasone 
pretreated endotoxic ANA1 cells in contrast to insulin. However, IGF-1 was able 
to restore both TNF and IL-6 in DEXIETX peritoneal macrophages. Insulin was 
partially able to inhibit the IGF-1 augmentation of TNF and IL-6 production by the 
peritoneal cells. This effect could have been due to insulin occupation of IGF-1 
receptors that would result in a blunted response. 
Okadaic acid is a specific inhibitor of serine phosphatases (231,310). 
Phosphorylation of intracellular proteins is postulated to be an important step in 
the stimulation of TNF and IL-6 production (310). Phosphatases act to 
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dephosphorylate these proteins and, thus, prevent the continuous production of 
TNF and IL-6 (310). Okadaic acid addition to macrophages in culture results in 
augmented TNF production. This effect appears to be mediated at the 
posttranscriptional level (310). The effects of okadaic acid on IL-6 production 
remain undocumented. 
In this study okadaic acid was shown to stimulate IL-6 production by ANA1 
cells. ETX/OKA did not result in an amplified response in comparison to the ETX 
group. Possibly, the maximal amount of IL-6 that could be produced by these cells 
had been achieved. Although, ETX/OKA/INS did not cause a statistically 
significant increase in IL-6, again indicating maximal production was attained, 
okadaic acid was able to reestablish IL-6 production suppressed by ETX/INS 
treatment. Okadaic acid addition to the media was also shown to restore IL-6 
production in DEXIETX treated ANA 1 cells. 
Okadaic acid addition to endotoxin stimulated peritoneal macrophages 
resulted in increases in both TNF and IL-6. TNF, but not IL-6, production was 
found to be increased in the ETX/INS/OKA group. Recently, Begum et al., 1993 
(32) demonstrated that insulin regulates the activity of phosphatases A1 and Ai at 
the posttranslational level. Also, insulin altered the phosphorylation of 56 in 
HepG2 cells (260). Therefore, insulin may exert its effect on TNF production at 
the translational level. Okadaic acid was also able to overcome dexamethasone 
induced suppression of both TNF and IL-6 production. Insulin addition to the 
DEXIETX/OKA group resulted in a suppression of TNF and an increase in IL-6. 
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Cycloheximide has been used in in vivo and in in vitro experiments to 
superinduce the production of cytokines, primarily TNF (65,247). Cycloheximide 
prevents the synthesis of RNAse I which is responsible for the rapid degradation 
of accumulated TNF mRNA (44). The effect of superinduction appears to be 
specific for TNF , whereas, IL-6 mRNA is not directly affected (65,247). 
IL-6 production by ETX/CYC ANA1 cells was suppressed, indicating that 
cycloheximide affected IL-6 during transcription. However, in this study, 
cycloheximide addition to the medium superinduced the production of TNF by 
endotoxin stimulated peritoneal macrophages. Further superinduction was 
observed with the addition of cycloheximide to the DEX/ETX/INS group. 
Consequently, the mechanism by which insulin overcomes dexamethasone 
suppression of cytokine production could be by posttranslational modification. 
Insulin could affect the synthesis of RNAse I, and thereby stabilizing mRNA. 
Insulin addition to hepatocytes alters the rate of mRNA degradation (19). 
In summary, figs. 48, 49 and 50 depict the hypothesized influence of 
dexamethasone and insulin with respect to TNF and IL-6 production in the three 
models used in these studies. In vivo ,insulin, in the presence of endotoxin, could 
modulate the production of TNF and IL-6 directly. Also, indirect modulation of 
cytokine production could occur by insulin-stimulated production of MIRRF by 
macrophages. MIRRF could stimulate the production of IFNy by T cells. IFNy 
would then synergize with endotoxin and as well as reverse the dexamethasone 
supression of TNF and IL-6 synthesis. In the isolated perfused liver 
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dexamethasone appears to be a dominant regulator of TNF and IL-6 production 
as insulin did not stimulate TNF or IL-6 production. A factor, possibly NO, 
inhibited IL-6 production during the perfusion. In vitro dexamethasone was shown 
to suppress both TNF and IL-6 production. The supression could have occurred 
at the transcriptional or translational levels. Insulin may have restored cytokine 
production by altering the activity of RNAse I. 
CHAPTER VI 
SUMMARY AND CONCLUSIONS 
The major goal of this dissertation research was to examine the 
interactions between two humeral mediators, glucocorticoids and insulin, and to 
evaluate the consequence of both on cytokine production during endotoxin-
induced sepsis. Initially, the combined effects of insulin and dexamethasone were 
tested on mortality and metabolic parameters of sepsis in an in vivo conscious rat 
endotoxic model. The regulation of TNF and IL-6 production in vivo by insulin and 
dexamethasone was also explored. The use of the isolated perfused liver 
provided an opportunity whereby TNF and IL-6 from a specific organ could be 
measured. Lastly, the regulation of TNF and IL-6 production was examined in 
isolated macrophages. This in vitro system enabled the possible mechanisms of 
the hormonal interaction on TNF and IL-6 production to be explored. 
The following conclusions were derived from the data in these experiments: 
From the in vivo studies: 
1) Insulin from both exogenous and endogenous sources exacerbated 
endotoxin-induced mortality. Its presence induced a rapid demise associated with 
significant hypoglycemia and hyperlacticacidemia. 
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2) Dexamethasone pretreatment significantly reduced endotoxin-induced 
mortality and stabilized plasma lactate concentrations and euglycemia. 
3) Insulin from both endogenous and exogenous sources reversed the 
protective action of dexamethasone pretreatment and a profound hypoglycemia 
and hyperlacticaidemia was observed. 
4) Since the administration of insulin during the "insulin resistant" phase of 
the endotoxic time course resulted in an increase in mortality, these animals were 
responsive to the action of insulin. 
5) Although marked hypoglycemia was observed, the rats died with 
hypoglycemia as opposed to of hypoglycemia as the administration of dextrose 
did not significantly alter mortality. 
6) The phorbol ester, PMA , was also able to exacerbate endotoxic 
mortality similar to insulin. Dexamethasone protection was also negated by PMA 
administration. 
7) Since H-7, an inhibitor of PKC was unable to alter the mortality of the 
insulin-endotoxin and dexamethasone-endotoxin-insulin treated rats, PKC 
activation was not involved in insulin-induced mortality. 
8) Endotoxin administration in vivo stimulated the production of both TNF 
and IL-6. The administration of insulin did not alter the early pattern of cytokine 
production; however, it did cause a sustained increase in both TNF and IL-6 at 
120 minutes post endotoxin. 
9) Dexamethasone pretreatment blocked the elevation in circulating levels 
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of TNF and IL-6 in vivo. Insulin was able to reverse the suppression of TNF but 
not IL-6 in this model. 
10) The insulin treated endotoxic animals exhibited hypoglycemia over the 
time course of the experiment. Insulin-induced hypoglycemia alone did not 
stimulate TNF or IL-6 production in vivo, suggesting that hypoglycemia was 
responsible for TNF or IL-6 production by the endotoxic rats. 
From the isolated perfused liver: 
11) TNF production was not observed in saline control animals until 45 
minutes of the perfusion. Dexamethasone pretreatment blocked this increase in 
TNF production. This finding implicates glucocorticoids as stern regulators of 
cytokine production under basal conditions. 
12) Endotoxin stimulated both TNF and IL-6 production by the isolated 
perfused liver. 
13) The addition of insulin resulted in an initial significant increase in TNF 
production above that of endotoxin alone. Since that rate of production during the 
perfusion was parallel to that of endotoxic group, another source of TNF 
production outside the liver is affected by insulin coadministration. 
14) Dexamethasone was able to suppress both TNF and IL-6 production 
by the endotoxic liver. In this model insulin was unable to restore TNF or IL-6 
production. This finding suggests that glucocorticoids are possibly dominant 
regulators of cytokine production by the liver. 
201 
15) Since insulin altered TNF production in vivo but was ineffective in the 
isolated perfused liver, the liver may not be the site of cytokine production 
regulated by insulin. 
From the in vitro studies: 
16) Endotoxin stimulated TNF and IL-6 production by all four macrophage 
cell types tested. The transformed cell-lines, ANA 1 and RAW 264. 7 cells were 
generous producers of TNF and IL-6 in comparison to the primary cells, the 
peritoneal macrophages and the Kupffer cells. Differential effects were exhibited 
even been the two transformed lines. In three of the cell types, except the ANA1 
cells IL-6 production appears to be linked to the initial synthesis of TNF. 
17) Insulin added to endotoxin-stimulated macrophages also had differential 
effects dependent on the cell type used. Inhibition of TNF and IL-6 production was 
observed with the ANA 1 cells and the Kupffer cells. There was no stimulation or 
depression of TNF or IL-6 production by the RAW 264.7 or the peritoneal 
macrophages. 
18) Dexamethasone pretreatment significantly reduced TNF and IL-6 
production in all cells except the ANA 1 cells, where only IL-6 was significantly 
suppressed. 
19) Insulin administration to the dexamethasone-protected-endotoxic 
macrophages reversed TNF and IL-6 production by the primary cell lines and IL-6 
production by the ANA 1 cells. 
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20) Protein Kinase C activation was not involved in the insulin-induced 
effects on TNF and IL-6 production, as H-7 was unable to effect the cells 
production of either cytokine. PMA as observed in vivo mimicked the insulin 
response in these cells. 
21) Prostaglandin synthesis was also not responsible for the reversal of 
dexamethasone protection, however, indomethacin treatment was able to reverse 
the endotoxin-insulin induced inhibition of cytokines suggesting a role of insulin 
in modulating PGE2 induced TNF suppression. 
22) The effects observed by the substitution of IGF-1 for insulin suggest 
that although these peptides are structurally similar they exert differential effects 
on TNF and IL-6 production by macrophages. 
23) The second messenger pathway affected by insulin appears to involve 
the regulation of phosphatase activity. 
An overall conclusion that can be drawn from the results documented in 
this dissertation is that even though a similar treatment protocol was applied to 
three levels of experimentation the results obtained are very different and in some 
cases conflicting. The observations derived from in vitro and ex vivo examination 
alone cannot always be successfully extrapolated to the in vivo environment. 
Future experiments may involve examination of the role of interferon y or 
the activation of other second messenger pathways, such as tyrosine kinase 
phosphorylation, and the transcriptional and posttranscriptional regulatory 
activities initiated by insulin. Future results may provide valuable insight into 
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possible biological and pharmacological avenues which may be implemented as 
modulators of TNF and IL-6 production in the septic patient. However, Gram-
negative infection perturbs the behavior of every organ-system of the hospitalized 
septic syndrome patient. The research focus which examines the interactions 
between systems (eg. endocrine system and the immune system) as opposed 
to the intricacies of an individual system will probably provide the therapeutic and 
clinical modalities that will save lives. 
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